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p53 is a transcription factor with tumour suppressor properties, which is able to 
induce mitochondrial apoptosis independently of its transcriptional activity. 
Analogues of the spiro[imidazo[1,5-c] thiazole-3,3′-indoline] -2′,5,7(6H,7aH) -
trione, previously synthesized from my research group, as p53 modulators were 
synthesized during my PhD, aiming to explore new structural requirements at 
the thiazolidine domain to increase the antiproliferative activity and improve 
p53 modulation. Derivative 5-bromo-3′- (cyclohexane carbonyl) -1-methyl-
2oxospiro[indoline-3,2′-thiazolidine] (SM13) emerged as the most potent 
compound of all series, inhibiting, in vitro, 30% of p53−MDM2 interaction at 5 
μM and the cell growth of different human tumor cells at nanomolar 
concentrations. Docking studies confirmed the interactions of SM13 with the 
well-known Trp23 and Phe19 clefts, explaining the reasons for its binding 
affinity to MDM2. SM13 at 50 nM is capable of inducing the accumulation of 
p53 protein, inducing significant apoptotic cell death without affecting the cell 
cycle progression. Comparative studies using nutlin in the same cellular system 
confirmed the potential of SM13 as a tool for increasing understanding of the 
process involved in the nontranscriptional proapoptotic activities of p53. Thus, 
the effectiveness of this compound in tumors carrying a mutated form of the p53 
gene without transcriptional activity was verified.The effectiveness of SM13 in 
cancer cell lines carrying WT, mutated and null p53 gene were evaluatedi vitro. 
At the same time, in vivo studies were performed in BALB/c nude mice and the 
signal-dependent mitochondrial apoptosis was evaluated by western stain. 
SM13 reduced cell proliferation and induced apoptosis in the in vitro studies, 
suggesting that its effect is independent of p53 transcriptional activity. On the 
contrary, SM13 had no effect in a null p53 cell line. In vivo, SM13 induced 
tumor cell death in a dose dependent manner through the activation of death 
mitochondrial-dependent signaling in cells mutated p53. Overall these studies 
highlights the efficacy of SM13 as anticancer cancer to be used for the treatment 




A second part of my PhD was, instead, dedicated, to the synthesis of a series of 
highly functionalized DNTQ-based derivatives. Most of the synthesized 
compounds exerted, in vitro, a cytotoxic effect against several tumour cell lines 
greater than doxorubicin. In particular N-(4-chlorobenzyl)-4,9-dioxo-3-(2-
(piperidin-1-yl) acetamido)-2,3,4,9-tetrahydronaphtho[2,3-b]thiophene-3- 
carboxamide (compound 14), showed a reduced  cardiotoxicity, inducing, at the 
ame time, cell differentiation and was distributed mainly in the cytoplasm in the 
human glioblastoma LN229 cell line. Moreover, compound 14 reduced both 
cellular glucose uptake and serine/threonine kinase AKT expression, and 
triggered cell apoptosis. These findings suggest that highly functionalized 
DTNQ-based derivatives are promising pharmacological tools for the study of 
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1.1 Introduction: Carcinogenesis, an overview 
Cancer is the name given to a collection of related diseases, which have a 
common feature: their cells grow without stopping and spread into surrounding 
tissues. Cancer originates in our own cells, but several intrinsic and external 
factors can add to the cancer risk. Infections, diet, toxins, smoking, alcohol, 
obesity, environmental chemical pollutants, industrial effluents and some 
therapeutic drugs can act as a stimulus to induce and promote cancer 
development. Cancer research has generated a rich and complex body of 
knowledge crystallizing, so far, in two drastically different approaches to 
understanding the driving forces behind cancer onset and proliferation. These 
are the somatic mutation theory (SMT)1 and the tissue organization field theory 
(TOFT).2 The essence of SMT is that cancer is derived from a single somatic 
cell which has successively accumulated multiple DNA mutations, and that 
those mutations occur on gene controlling cell proliferation and cell cycle. Thus, 
according to SMT the neoplastic lesions that destroy normal tissue architecture 
are the results of DNA-level events. Conversely, according to TOFT, 
carcinogenesis is primarily a problem of tissue organization: carcinogenic 
agents (eg, environmental chemicals, inflammation, viruses) destroy the normal 
tissue architecture thus disrupting cell-to-cell signaling and compromising 
genomic integrity. Hence, in TOFT the DNA mutations are the effect, and not 
the cause, of the tissue-level events. However, a large grey zone of biological 
facts and clinical cases exists which poses the questions that are difficult to 
resolve from either of these view-points.3 Essentially, for a long time the 
theories conceptually close to SMT and TOFT were considered as two different 
facets (along with many others) of the complex phenomenon of carcinogenesis. 
Indeed, the cornerstone of SMT is the notion that carcinogenesis is triggered by 
a single aberrant cell which happened to acquire multiple DNA mutations, and 
that these mutations predominantly damage the genes responsible for the cell 
cycle and apoptosis. Cancer cells develop the ability to defy the mechanisms of 
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apoptosis, to outrick the immune system responsible for their elimination, and 
as a result, to obtain exclusive capabilities to survive, to proliferate, and to 
transfer deleterious mutations to progeny. (Figure 1) 
 
 
Figure 1. Intracellular Signaling Networks Regulate the Operations of the Cancer 
Cell: SMT theory. An elaborate integrated circuit operates within normal cells and is 
reprogrammed to regulate hallmark capabilities within cancer cells. Separate 
subcircuits, depicted here in differently colored fields, are specialized to orchestrate 
the various capabilities. At one level, this depiction is simplistic, as there is 
considerable crosstalk between such subcircuits. In addition, because each cancer 
cell is exposed to a complex mixture of signals from its microenvironment, each of 
these subcircuits is connected with signals originating from other cells in the tumor 
microenvironment 
 
 In direct opposition to these views, TOFT depicts carcinogenesis as general 
deterioration of the tissue microenvironment due to extracellular causes. This 
deterioration hinders normal cell-to-cell signaling thus making normal 
functioning of the intracellular machinery impossible and eventually leading it 
to the breaking point. In such a scenario, the deleterious mutations should be 
scattered all over the genome randomly and incoherently with little chance for 
clonal homogeneity. (Figure 2) 
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Figure 2. Carcinogenesis according to the TOFT. A single or multiple carcinogenic 
exposure acts disturbing the reciprocal biophysical and biomechanical 
communication between the parenchyma and the mesenchyme/stroma in a given 
morphogenic field. This results in miscues that manifest morphologically in both the 
stroma and the epithelium. The proliferation and motility restraints imposed by 
normal tissue architecture loosen and as a consequence, hyperplasia of the 
epithelium may occur. Further alteration of the reciprocal interactions between tissue 
compartments will induce metaplasia, dysplasia, and carcinoma. The stroma also 
may show alterations (desmoplasia, inflammatory cells) 
 
According to SMT, cancer progression is a unidirectional and mostly 
irreversible process; the disease cannot be cured unless the entire tumor mass is 
surgically removed, radiationally killed, or deprived of its aggressive nature by 
carefully targeted chemotherapeutic agent. Paramount importance of TOFT for 
cancer biology, for the practice of clinical oncology and for cancer prevention, 
dwells in the fact that according to this view carcinogenesis is not a 
unidirectional process; rather, it is curable and reversible.4 
Recently a new approach outlines a plausible scenery, in an attempted 
reconciling the two previous theories, in which a single event, insignificant on 
its own, may trigger a system-wide catastrophic restructuring. Such a scenery 
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may be envisioned and conceptualized within the framework of the so called 
self-organized criticality (SOC).5 Genetic regulatory network in an individual 
cell is an excellent example of a system permanently existing on the edge of 
chaos. Each transcription event, i.e., synthesis of a single mRNA molecule, 
requires participation of a large number of transcription factors (TFs) which 
essentially are the proteins expressed by other genes. In turn, these supporting 
proteins cannot come into existence unless their parent genes have complete 
teams of their own TFs coming from yet another set of genes. This tight 
interdependence of genes (gene-to-gene interactions) creates the situation when 
each gene may be expressed only with the support of many other genes, 
essentially of the entire network. Ideally, the system can only work in a perfectly 
synchronized manner, with each of thousands of parts being produced and 
delivered where needed in a timely manner. If, however, at least one part fails 
to arrive in time to its destination, the corresponding assembly line then comes 
to a stop, thus triggering the domino effect of secondary failures and ultimately 
driving the entire system to a complete halt. Comparatively simple and universal 
forces driving the living systems towards critical conditions are always present 
behind the scenes in all SOC phenomena. In very general terms, a hallmark of 
living entities is their ability to replicate and proliferate themselves. In a 
community of such entities, unstoppable proliferation will inevitably drive the 
community towards exhaustion of common resources, whatever these resources 
are, thus bringing the populations to the verge of extinction. SOC plays an 
important role in DNA damage and transition of cellular machinery into chaotic 
state. The first cellular factor to sustain the damage is the RNA Polymerase II 
during the transcription of an active gene; this damage leads to a stalled 
transcription fork. The stalled fork triggers DNA repair mechanisms by 
attracting a large number of proteins which, in turn, allosterically modify 
binding affinities of many other proteins. It may happen that the damage occurs 
in the so called “hub” proteins (such as p53 protein) which are capable of 
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modifying a large number of vital cellular functions simultaneously.6 A subtle 
balance always exists between the rates of damage and repair. Up to a certain 
level of mutagenic load, the repair mechanisms are capable of containing 
damage, thus maintaining a generally healthy cell population. However, the last 
straw effect may also occur when the cell, after an insult, remains unrepaired 
yet undestroyed, thus giving rise to a genetically aberrant sub-population. This 
last straw event is analogous to the last grain of sand in the sandpile avalanche 
because it fires up multiple, very complex, and mostly irreversible pathways. 
Such a massive complex response to a seemingly minor event is a hallmark of 
SOC. It would be an obvious misjudgment to regard any particular minor event 
as a cause of the system’s collapse. Rather, one may expect that a mutationally 
overloaded system would collapse anyway, whatever a minor event actually 
happens to be the trigger. In this context both the self-organized criticality and 
the somatic mutation theories match. (Figure 3) In particular, as observed by 
Nowell,7 cytogenetic studies have demonstrated that in many primary tumors 
all cells show the same abnormal karyotype; the immunoglobulin produced by 
plasma cell tumors has in almost every case the homogeneity characteristic of a 
single clone.  As an ultimate manifestation of this paradigm, direct evidence of 
a single catastrophic event triggering carcinogenesis has been presented by 
Stephens et al.8 The authors explain that the overwhelming majority of 
rearrangements leading the distinctive genomic structures, present in the 
different cancer types, occurs in a single catastrophic event. In this scenario, the 
chromosome or chromosomal region shatters into tens to hundreds of pieces, 
some (but not all) of which are then stitched together by the DNA repair 
machinery in a mosaic patchwork of genomic fragments. A cell suffering tens 
to hundreds of DNA breaks in a single cataclysmic event would be expected to 
undergo apoptosis.  
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Figure 3. Different representations of self-organized criticality theory. Sandpile 
paradigm: if additional sand grains are randomly added to a sand pile then inevitably 
an instance will occur when local steepness of the slope surpasses a certain critical 
threshold thus causing local failure of structural stability. The excess of material will 
cascade into adjacent areas of the pile causing their failure as well 
 
That a cell can survive such an insult and progress to become cancerous suggests 
that the extensive remodeling of the genome may confer significant selective 
advantage to that clone. Self-organized criticality confirms also one basilar 
point of the tissue organization field theory on the evolution of tissue, from a 
healthy state to a precancerous state and further to tumorigenesis, using some 
concepts of the somatic mutation theory. In particular, chronic systemic 
inflammation has been widely recognized to be among the leading factors in 
progression of healthy tissue towards precancerous and cancerous lesions. The 
specific mechanisms of such progression include sustained cell proliferation in 
an environment rich in inflammatory cells and molecular agents causing DNA 
damage.9 Excessive and pathologic inflammation causes DNA damage, 
genomic instability, epigenetic dysregulation, and alteration of intracellular 
signaling, all of which are involved in neoplastic transformation.10 It is 
important to realize that inflammation-triggered carcinogenesis cannot be 
reduced to just cell proliferation and conquering new tissue territories. A 
number of complex molecular mediators facilitate proliferation of genomic 
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damage, among which an important role belongs to inflammasomes, i.e., the 
multi-protein complexes that mediate immune response.11 
Another fondamental aspect of carcinogenesis is the DNA methylation. In 
normal tissue, gene methylation is mostly localized in the coding region whereas 
the promoter region remains mostly unmethylated. A different pattern is 
observed in neoplasia: the genome-wide hypomethylation is accompanied by 
localized hypermethylation. Evidence suggests that methylation is an important 
factor in carcinogenesis since genome-wide hypomethylation can trigger the 
chromosome instability and increase the mutation rates, playing an key role in 
different cancer types and probably at different stages of oncogenesis.12, 13 
Generally, abnormal patterns of methylation signify elevated cancer risk due to 
heightened susceptibility to cancer cell proliferation. According to Vendramini-
Costa and Carvalho,14 tumor initiation involves irreversible changes in DNA 
through activation of oncogenes or inactivation of tumor suppressor genes. 
Further development leads mutated cells to expansion through increased 
proliferation and suppression of cell death. In the process of invasion of adjacent 
tissues cancer cells may accumulate other mutations, thus exacerbating their 
phenotype. Again, the process is quite similar to the forest fire propagation, 
which accumulates additional strength while invading new territories. Last, the 
disruption of cell-to-cell communication is an important aspect characterizing 
precancerous tissue, and it is a central component of a bigger process of tissue 
disorganization.15 The viewpoint is that a community of cells is not simply a 
collection of units dwelling within certain architectural structures. With the 
destruction of signaling pathways, not only the normal regulation of individual 
cellular processes is damaged, but also a blow is dealt, so to speak, to the mental 
capabilities of the community as a whole. Its collective memory is wiped out or 
distorted, customary division of labor between subpopulations is shifted 
towards aberrant modalities, and community-wide self-defense mechanisms are 
weakened or broken. These processes in turn cause a shift in expression profiles 
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and metabolic dynamics, eventually penetrating to the level of DNA and causing 
multiple mutations. The mechanisms of tumor initiation play a prominent role 
in carcinogenesis, and a single catastrophic event indeed can make a 
fundamental impact on all subsequent events. However, not every event that 
may be seen as catastrophic on the level of individual cell would necessarily 
lead to carcinogenesis. Vast majority of those events would fade and disappear 
without traces. This is because the immune system remains on guard of tissue 
homeostasis. When tissue homeostasis is perturbed, sentinel macrophages and 
mast cells release cytokines, chemokines, reactive oxygen species (ROS), and 
other bioactive mediators that induce mobilization of additional leukocytes.16 
This means that the mutant cell capable of starting the domino-effect of 
subsequent failures should be able to overcome the tissue’s natural defenses; 
this may happen only if the tissue is already preconditioned for failure and 
resides on the verge of systemic collapse. All these findings provide just a 
glimpse of extremely complex and tangled transition of healthy tissue towards 
precancerous state. Obviously, even a complete knowledge of each and every 
process contributing to this transition does not automatically lead to 
understanding the process as a whole. Resorting to the sandpile analogy, it 
would be as difficult as understanding the phenomenon of avalanche from 
observations of each sand grain trajectory. This is why systemic approaches are 
not simply helpful, they are absolutely necessary and unavoidable for 
synthesizing existing biomolecular knowledge into a coherent picture of 
carcinogenesis. Thus, recognition of the widespread applicability of  concepts, 
outlined here, will increasingly affect the development of new strategies to treat 
human cancer.
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1.2 Cell cycle regulation  
With advancements on the basic mechanisms of oncogenesis, we have gained a 
better understanding of the role that the cell cycle regulation plays in malignant 
transformation and in the development of resistance to chemotherapy, laying 
the bases for development of a new class of anticancer therapeutics in clinical 
development.17 
The fondamental task of the cell cycle is to ensure that DNA is faithfully 
replicated once during S phase and that identical chromosomal copies are 
distributed equally to two daughter cells during M phase.18 The machinery for 
DNA replication and chromosome segregation is insulated from interruption by 
extracellular signals, and its essential and autonomous nature implies that 
damage to the pivotal components would be highly debilitating, if not fatal, to 
cells. Therefore, genes commanding these processes should not be frequent 
targets of mutation, deletion, or amplification in cancer. Oncogenic processes 
exert their greatest effect by targeting particular regulators of GI phase 
progression.19 During the G, phase, cells respond to extracellular signals by 
either advancing toward another division or withdrawing from the cycle into a 
resting state (Go).20 Unlike transit through the S, G2, and M phases, G 
progression normally relies on stimulation by mitogens and can be blocked by 
antiproliferative cytokines. Cancer cells abandon these controls and tend to 
remain in cycle, and because cell cycle exit can facilitate maturation and 
terminal differentiation, these processes are subverted as well.21 The decision to 
divide occurs as cells pass a restriction point late in GI, after which they become 
refractory to extracellular growth regulatory signals and instead commit to the 
autonomous program that carries them through to division. An appreciation of 
restriction point control is central to our understanding of how and why cancer 
cells continuously cycle. The cell cycle is a critical regulator of the processes of 
cell proliferation and growth as well as of cell division after DNA damage. It 
governs the transition from quiescence (G0) to cell proliferation, and through 
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its checkpoints, ensures the fidelity of the genetic transcript. It is the mechanism 
by which cells reproduce, and is typically divided into four phases. The periods 
associated with DNA synthesis (S phase) and mitosis (M phase) are separated 
by gaps of varying length called G1 and G2 (Figure 4). Progression of a cell 
through the cell cycle is promoted by a number of CDKs which, when 
complexed with specific regulatory proteins called cyclins, drive the cell 
forward through the cell cycle. There exist corresponding cell cycle inhibitory 
proteins (CDK inhibitors [CDKIs]) that serve as negative regulators of the cell 
cycle and stop the cell from proceeding to the next phase of the cell cycle (Figure 
3). The INK4 (for inhibitor of cdk4) class of CDKIs, notably p16lnk4a, 
p15lnk4b, p18lnk4c, and p191nk4 days, bind and inhibit cyclin D–associated 
kinases (CDK2, -4, and -6). The kinase inhibitor protein (KIP) group of CDK 
inhibitors, p21waf1, p27kip1, and p57kip2, negatively regulate cyclin E/CDK2 
and cyclin A/CDK2 complexes.22 
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Figure 4. The cell cycle 
 
The pattern of cyclin expression varies with a cell’s progression through the cell 
cycle, and this specific cyclin expression pattern defines the relative position of 
the cell within the cell cycle.23 At least nine structurally related CDKs (CDK1- 
CDK9) have been identified, though not all have clearly defined cell cycle 
regulatory roles. A considerable number of cyclins have been identified to date 
(cyclin A–cyclin T). CDK/cyclin complexes themselves become activated by 
phosphorylation at specific sites on the CDKby cdk7/cyclin H, also referred to 
as CDK-activating kinase (CAK).24 Cyclin D isoforms (cyclin D1-D3) interact 
with CDK2, -4, and -6 and drive a cell’s progression through G1. The 
association of cyclin E with CDK2 is active at the G1/S transition and directs 
entry into S phase. S phase progression is directed by the cyclin A/CDK2 
complex, and the complex of cyclin A with CDK1 (also known as cdc2) is 
important in G2. CDK1/cyclin B is necessary for mitosis to occur. The cell 
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responds to mitogenic stimuli and decides to advance through the various phases 
of the cell cycle only during a limited phase of its cycle. In fact, the cell needs 
stimulation only during the first two-thirds of its G1 phase where it may decide 
to continue its advanceand complete its cell cycle. This point is termed 
‘restriction point’ (R point); it is a central event in normal cellular proliferation 
control. It has been demonstrated that pRb is the molecular device that serves 
as the R point switch. pRb is hypophosphorylated in resting G0 cells, is 
increasingly phosphorylated during progression through G1 and is maintained 
in a hyperphosphorylated state until late mitosis. pRb phosphorylation seems to 
be related to mitogenic signals, which converge on the cell cycle machinery, 
represented by the cyclin D1/cdk4 (cdk6) complex in the early and mid-G1, and 
composed of cyclin E/cdk2 in late G1. 
 
1.2.1 The cancer and the cell cycle  
In physiological conditions, activation of CDK/Cyclin kinases is tightly 
controlled both spatially and temporally. However, CDK/Cyclins are 
dysregulated in several human cancers, which wreaks havoc in the coordinated 
cycle of cell growth and proliferation and contributes to the uncontrolled 
proliferation characteristic of cancer cells.25 In fact, together with mutations in 
proto-oncogenes, mutations leading to hyperactivation of CDK activity have 
been reportedly found in human cancer genomes, and confer selective growth 
advantage to cells, whilst mutations that inactivate checkpoint regulators, 
tumour suppressor genes or CKIs result in loss of cell cycle inhibition.26 
CDK/Cyclin hyperactivation may result from one of several causes, including 
gene amplification and protein overexpression of either the CDK or cyclin 
subunit, alternative splicing and expression of truncated cyclin variants, 
untimely expression and mislocalization, or constitutive activation of 
CDK/Cyclins by preventing their inactivation through binding to INK or 
KIP/CIP inhibitors.27 A representative panel of mutations which occur in CDKs 
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and Cyclins may be found in the catalogue of Cosmic Mutations in Cancer 
which integrates all mutations identified through sequencing of human cancer 
tissue samples. (Figure 5) 
 
 
Figure 5. CDK/Cyclins and Cancer. (A) Schematic representation of normal cell 
growth and division regulated by cyclin-dependent kinases. Hyperactivation of these 
kinases contributes to development of cancer cell proliferation; (B) CDK4/cyclin D in 
cancers: Among all the CDK/cyclins, the complex CDK4/cyclin D is the one which 
presents most aberrations in cancers. Hyperactive CDK4/cyclin D is found in several 
human cancers associated with the R24C mutation of CDK4 which prevents the fixation 
of the endogenous inhibitor p16INK4A, mutation of p16INK4a itself or CDK4 or cyclin 
D amplification; (C) CDK5/p25 in cancers. 
 
A second class of growth-deregulating mutations comprises those that target the 
principal late-G1 cell-cycle checkpoint regulated by pRB. Loss of pocket 
protein functions may induce cell cycle deregulation and lead to a malignant 
phenotype. Defects in this pathway, which may be universal in human cancers, 
include deletion of the RBgene itself and deregulation of the CDKs that 
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phosphorylate and functionally inactivate pRB, either through direct over-
activation of CDKs or through genetic loss of their inhibitors.28 Another 
frequent proliferative lesion that has the effect of deregulating the cell cycle is 
uncontrolled expression of Myc.29 Myc expression is tightly controlled by 
mitogen availability in normal cells, but it is usually expressed in a deregulated 
or elevated manner in tumor cells.30,31 Myc seems to be a strategic controller of 
cell proliferation that acts pleiotropically to coordinate both cell growth  and 
concomitant progression through the cell cycle.32 The presence in individual 
tumors of multiple mutations that affect each of the pathways discussed above 
suggests that each pathway contributes a discrete type of proliferative function 
to the neoplastic phenotype. But precisely what such functions are and how and 
why they interact, remains unknown. In addition to driving aberrant cell 
division, mutations in the various proliferative control pathways have a 
profound impact on other cell functions. For example, many of the proliferative 
lesions in tumor cells also contribute to the inhibition of differentiation, thereby 
preventing the elimination of progeny cells from the proliferative compartment 
of many types of tissue. pRB, for example, is essential in differentiation of 
several tissue types through interactions with factors such as the helix–loop–
helix proteins MyoD26 33 and Id2. Loss or inhibition of pRB function prevents 
normal differentiation, a contribution to tumor development distinct from the 
direct deregulation of cell-cycle progression. Deregulated Myc expression also 
inhibits differentiation, in part by activation of Id2 expression.34 
 
1.3 Apoptosis  
Apoptosis, or programmed cell death (Figure 6), is a normal component of the 
development and health of multicellular organisms. Apoptosis occurs during the 
normal development of multicellular organisms and continues throughout adult 
life. The combination of apoptosis and cell proliferation is responsible for 
shaping tissues and organs in developing embryos. Cells die in response to a 
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variety of stimuli and during apoptosis they do so in a controlled, regulated 
fashion.  
There are a number of mechanisms through which apoptosis can be induced in 
cells. The sensitivity of cells to any of these stimuli can vary depending on a 
number of factors such as the expression of pro- and anti-apoptotic proteins (eg. 
the Bcl-2 proteins or the Inhibitor of Apoptosis Proteins), the severity of the 
stimulus and the stage of the cell cycle. Some of the major stimuli that can 
induce apoptosis include virus infection, cell stress and DNA damage. In some 
cases the apoptotic stimuli comprise extrinsic signals such as the binding of 
death inducing ligands to cell surface receptors called death receptors. These 
ligands can either be soluble factors or can be expressed on the surface of cells 
such as cytotoxic T lymphocytes. The latter occurs when T-cells recognize 
damaged or virus infected cells and initiate apoptosis in order to prevent 
damaged cells from becoming neoplastic (cancerous) or virus-infected cells 
from spreading the infection. Apoptosis can also be induced by cytotoxic T-
lymphocytes using the enzyme granzyme. In other cases apoptosis can be 
initiated following intrinsic signals that are produced following cellular stress. 
Cellular stress may occur from exposure to radiation or chemicals or to viral 
infection. It might also be a consequence of growth factor deprivation or 
oxidative stress caused by free radicals. In general intrinsic signals initiate 
apoptosis via the involvement of the mitochondria. The relative ratios of the 
various bcl-2 proteins can often determine how much cellular stress is necessary 
to induce apoptosis.  
Upon receiving specific signals instructing the cells to undergo apoptosis a 
number of distinctive changes occur in the cell. A family of proteins known as 
caspases is typically activated in the early stages of apoptosis. These proteins 
breakdown or cleave key cellular components that are required for normal 
cellular function including structural proteins in the cytoskeleton and nuclear 
proteins such as DNA repair enzymes. The caspases can also activate other 
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degradative enzymes such as DNases, which begin to cleave the DNA in the 
nucleus. This makes apoptosis distinct from another form of cell death called 
necrosis in which uncontrolled cell death leads to lysis of cells, inflammatory 
responses and, potentially, to serious health problems. Apoptosis, by contrast, 
is a process in which cells play an active role in their own death (which is why 
apoptosis is often referred to as cell suicide). 
 
 
Figure 6. Apoptosis 
 
1.3.1 Connecting apoptosis and proliferation in cancer 
The central engines of apoptosis are the caspases, cascades of cysteine aspartyl 
proteases that implement cell death by cleaving a variety of intracellular 
substrates that trigger cell dissolution. Caspases are synthesized as latent 
zymogens that are activated by proteolytic cleavage: typically through the action 
of upstream apical caspases. An activation pathway (extrinsic pathway) is 
mediated by transmembrane death receptors of the CD95 (Apo-1 or 
Fas)/TRAIL/tumor-necrosis factor (TNF) receptor 1 family, whose ligation 
triggers recruitment and assembly of multiprotein complexes that activate  
apical caspase 8.35 The other principal apoptotic death-signaling pathway 
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involves the mitochondrion (intrinsic pathway), which acts as an integrating 
sensor of multiple death insults by releasing cytochrome c into the cytosol where 
it triggers caspase activation. The mitochondrial pathway is thought to be the 
principal target of survival signaling pathways, which act by stabilizing 
mitochondrial function and integrity and suppressing release of cytochrome c.36 
Once cytochrome c has been released from the mitochondrion, it orchestrates 
assembly of an intracellular apoptosome complex that recruits apical caspase 9 
via the adaptor protein Apaf-1.37 The anti-apoptotic oncoproteins Bcl-2 and Bcl-
xL, which exert their principal effects through stabilization of the 
mitochondrion, are overexpressed in several tumor types and recent analyses 
have indicated that loss of Apaf-1 is a relatively frequent event in malignant 
melanoma that presumably confers resistance to apoptosis.38 A particularly 
potent driving force for the suppression of apoptosis in tumor cells is the coupled 
relationship between cell proliferation and cell death, a phenomenon 
exemplified by the Myc protein. In addition to its well documented growth-
promoting property, Myc was found to be a powerful inducer of apoptosis, 
especially under conditions of stress, genotoxic damage or depleted survival 
factors.39 Consideration of such observations led to the proposal that the innate 
apoptotic potential of Myc serves as an inbuilt foil to its oncogenic capacity 
(Figure 7). 
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Figure 7. Activation of growth-deregulating lesions triggers ‘sentinel’  
 
In this example, the oncoprotein Myc is shown activating a p53 damage sentinel 
through the ARF/MDM-2 pathway, thereby sensitizing the cell to any DNA 
damage. Myc also promotes release of holocytochrome c from the 
mitochondrion into the cytosol where it triggers apoptosis. Release of 
holocytochrome c is inhibited by paracrine ‘survival’ signals that are typically 
restricted both in supply and location. Clonal outgrowth driven by relentless 
Myc expression outstrips survival factor availability, triggering the ‘trophic 
sentinel’ to kill the cell. Another common pathway through which a wide variety 
of proliferative signals influence the apoptotic program is through induction of 
ARF, an alternate product of the INK4a locus, one of whose functions is to 
trigger upregulation of p53 through its inhibitory action on MDM-2.40 Another 
potent selective pressure in cancers to suppress apoptosis arises from the fact 
that programmed cell death is the typical response of somatic cells to many 
forms of stress and damage; in particular damage to cell DNA (a fact exploited 
by most classical cancer therapeutics). Stress-associated signals that activate 
apoptosis include many of those encountered by the incipient tumor cell, 
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including hypoxia and nutrient deprivation, as well as DNA damage arising 
from telomere erosion, defective repair, oncogene deregulation and therapy. The 
p53 protein is important in transducing such diverse signals into tumor-
suppressive apoptotic or growth-arresting responses, which implies that there is 
strong selection for tumor cells to loose p53 function.41 Importantly, differing 
p53-activating stresses tend to arise at different stages of carcinogenic 
progression. For example, oncogene deregulation occurs early, as it is a 
prerequisite for clonal expansion, whereas hypoxia is significant only after the 
tumor reaches macroscopic size. Consequently, p53 exerts a tumor-suppressive 
role at multiple stages of carcinogenic progression, (Figure 8) offering an 




Figure 8. Many stress signals encountered during tumor progression activate p53, 
resulting in apoptosis or growth arrest 
 
Loss either of the ability to activate p53 or of p53 function itself has 
considerable impact on the ‘success’ of the carcinogenic process, as it increases 
the chances of a tumor cell surviving progressively adverse conditions. Inability 
to activate p53 in response to stress signals encountered early during tumor 
development, such as deregulated proliferation, may to be sufficient to allow 
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the formation of preneoplastic lesions. However, lesions that suppress activation 
of p53 in response to such oncogene-associated stress signals do not necessarily 
block activation of p53 by subsequent events encountered during malignant 
progression, such as DNA damage. Consequently, additional alterations in 
pathways that activate or respond to p53, or loss of p53 by direct mutation of 
the gene itself, may be selected during progression to more malignant cancers. 
 
1.4 Molecular targeting of cell proliferation and apoptosis 
Because deregulated proliferation and inhibition of apoptosis lie at the heart of 
all tumor development, they present two obvious targets for therapeutic 
intervention in all cancers. Clearly there are numerous mechanisms through 
which these two defects can occur, and the success of targeted therapy will 
depend to a large part on the molecular fingerprinting of individual tumours.42 
Although most existing cancer drugs are anti-mitotic, they act not by targeting 
the specific lesions responsible for deregulated tumor growth, but by crudely 
interfering with the basic machinery of DNA synthesis and cell division. 
Moreover, we now know that the surprising selectivity of such crude agents 
results largely from the increased sensitivity to apoptosis afforded to tumor cells 
by their oncogenic lesions. Drugs designed to specifically inhibit growth-
deregulating lesions are currently being tested in clinical trials, and include 
inhibitors of RTKs, Ras, downstream signaling kinases such as the mitogen-
activate protein kinase and Akt pathway, and CDKs. At first glance, targeted 
inhibition of growth-deregulating lesions in cancer would be seem to have 
limited therapeutic efficacy, as they would at best be cytostatic. However, 
unexpected therapeutic bonuses may emerge from such an approach because 
growth deregulation induces a plethora of downstream activities in affected cells 
and their adjacent tissues. Therapeutic inhibition of the offending oncoprotein 
in tumors arising from cell lineages where terminal differentiation has been 
blocked could be sufficient to trigger a resumption of that differentiation 
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program, permanently expelling the tumor cell from the proliferating 
compartment.43 
The second obvious strategy for cancer therapy is to target the lesions that 
suppress apoptosis in tumor cells. The potent proapoptotic effects of growth-
deregulating mutations mean that tumors are peculiarly dependent upon their 
particular suite of antiapoptotic mutations for continued survival. Thus, 
although apoptosis in tumor cells is sufficiently suppressed to below a critical 
threshold to enable them to survive, they remain acutely sensitized to apoptosis. 
In most, if not all, cancer, this ability to survive results in part from inhibition 
of the p53 pathway, either by inactivating mutations in p53 itself, perturbation 
of the signaling pathways that allow activation of p53 in response to stress, or 
defects in the downstream mediators of p53-induced apoptosis. Reintroduction 
of p53 function is sufficient to induce apoptosis in many tumor cells, and several 
mechanisms to reactivate p53 are being considered as therapeutic strategies. 
These include introduction of wild-type p53 into tumors expressing a mutant 
protein, or inhibition of negative regulators of p53, such as MDM-2, in those 
tumors that retain wild-type p53.41 Regardless of efficiency in cell killing, the 
success of repairing the apoptotic response in tumor cells depends on the extent 
to which such therapies confine death to the cancer cells, and allow survival of 
normal tissue. Many conventional chemotherapies induce significant toxicity, 
particularly in tissues that normally maintain a proliferative compartment, such 
as gut epithelium and the hematopoietic system. This DNA damage-induced 
toxicity is mediated in part through p53, leading to the suggestion that inhibition 
of p53 in these normal tissues may protect against drug-induced toxicity, 
thereby improving the tolerance of conventional cancer therapies. However, 
implicit in the development of drugs that target specific lesions responsible for 
tumor cell growth is the prediction that these approaches will show significantly 
more specificity for tumor cell killing than conventional therapies. Although 
activation of apoptotic pathways can lead to the death of untransformed cells, a 
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process that is essential in normal development, a fundamental difference exists 
between tumor cells and their normal counterparts, as normal cells neither have 
to sustain the pro-apoptotic onslaught that is inherent in deregulated 
proliferation, nor survive away from their usual environment in the absence of 
requisite survival signals. Repair or replacement of a single apoptotic signal, be 
it reactivation of p53 or removal of a survival signal, could well prove too much 
for a tumor cell already burdened with a heavy apoptotic load. By contrast, the 
same perturbation may scarcely ruffle the equilibrium of a normal cell, safely 
buffered in its appropriate soma and enjoying the full gamut of trophic support 
that ensures normal cell survival. 
 
1.5 p53: molecular target 
p53, (53KD) also known as tumor protein 53 (TP53),is a transcription factor 
that regulates the cell cycle and apoptosis, in case of cellular insults, and hence 
functions as a tumor suppressor. p53 contains a natively unfolded amino-
terminal transactivation domain (TAD), which can be further subdivided into 
the subdomains TAD1 and TAD2, followed by a proline-rich region (PRR). The 
structured DNA-binding and tetramerization domains (OD) are connected 
through a flexible linker region. (Figure 9) Similarly to the TAD region, the 
regulatory domain at the extreme carboxyl terminus (CTD) is also intrinsically 
disordered.44 The vertical bars, shown in Figure 9, indicate the relative 
missense-mutation frequency in human cancer for each residue based on the 
TP53 Mutation Database of the International Agency for Research on Cancer45, 
showing that most cancer mutations are located in the DNA-binding domain. 
The structure of the DNA-binding domain (PDB code 1TSR) is shown (Figure 
9) as a ribbon representation and colored with a rainbow gradient from the 
amino terminus (blue) to the carboxyl terminus (red).  
 
 
Chapter I: The cancer and p53 “guardian of the genome” 
- 24 - 
 
 
Figure 9. Domain structure of p53 
 
p53 has been described as "the guardian of the genome", "the guardian angel 
gene", or the "master watchman", referring to its role in conserving stability by 
preventing genome mutation.  The transcription factor p53 responds to diverse 
cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, 
senescence, DNA repair, or changes in metabolism.46 In addition, p53 appears 
to induce apoptosis through nontranscriptional cytoplasmic processes.47 In 
unstressed cells, p53 is kept inactive essentially through the actions of the 
ubiquitin ligase MDM2, which ftinhibits p53 transcriptional activity and 
ubiquitinates p53 to promote its degradation.47 Numerous posttranslational 
modifications modulate p53 activity, most notably phosphorylation and 
acetylation. Several less abundant p53 isoforms also modulate p53 activity. 
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Activity of p53 is ubiquitously lost in human cancer either by mutation of the 
p53 gene itself or by loss of cell signaling upstream or downstream of p53.  
 
1.5.1 The role of p53 in normal cells 
Activation of p53 can result in a number of cellular responses, and it is possible 
that different responses are induced by different stress signals. There is evidence 
that p53 can play a part in determining which response is induced through 
differential activation of target-gene expression. Although the importance of 
these responses to tumor suppression is clear, previously unanticipated 
contributions of these responses to other aspects of human health and disease 
are being uncovered. The role of p53 in tumor suppression, development and 
ageing is likely to depend on which cellular response is activated and on the 
context in which the activation occurs. p53 is an intensively studied protein, its 
fame stemming mainly from its clear role as a tumor suppressor in humans and 
other mammals.48 Loss or mutation of p53 is strongly associated with an 
increased susceptibility to cancer, and most functions of p53 have been 
considered in the light of how p53 might protect from malignant progression.49 
Some p53-null mice can develop normally 50 an observation that has been taken 
to rule out major functions for p53 in normal physiology. But recent studies are 
questioning whether p53 is truly such a single-minded protein, and other 
functions of p53 that might be profoundly important during normal life are being 
uncovered. These include roles for p53 in regulating longevity and ageing, 
glycolytic pathways that might determine endurance and overall fitness, and 
apoptotic responses during ischemic and other types of stress. Evidence for 
genetic variations in the activity of the p53 pathway in humans gives these ideas 
extra relevance.51 One of the major mechanisms by which p53 functions is as a 
transcription factor that both positively and negatively regulates the expression 
of a large and disparate group of responsive genes (Figure 7).52 Although some 
of these p53- responsive genes have an important role in mediating cell-cycle 
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arrest, senescence and apoptosis (the best understood activities of p53), it is now 
evident that the ability of p53 to influence gene expression has wider reaching 
effects. Numerous studies have identified p53-regulated genes that could have 
a role in a number of different and sometimes unexpected responses.53 Although 
some of these still need to be fully validated, there is now clear evidence for a 
role of p53 in the regulation of glycolysis,54 and autophagy,55 the repair of 
genotoxic damage,56 cell survival and regulation of oxidative stress,57 invasion 
and motility,58 cellular senescence,59 angiogenesis,60 differentiation,61 and bone 
remodeling.62 The cellular pathways in which p53 is involved, are schematically 
represented in Figure 10. In these aspects, its worthy to analyze there is any 
cancer cells are expressing wild type p53, and if they are expressing, its role in 
cancer cells has to be studied before clinical use of p53 mediated gene therapy 
as an anticancer therapy. 
 
Figure 10. Activation and functions of p53 
 
1.5.2 The role of p53 in cancers cells 
In the two decades since its original discovery, p53 has found a singularly 
prominent place in our understanding of human cancer. Although the 
biochemistry of p53 has been worked out in some detail, our knowledge of the 
biologic consequences of p53 dysfunction is still quite rudimentary. 
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p53 dysfunction in cancer cells are mainly due to its mutation (50%), epigenetic 
modulation at expressional level and low persistence of p53 protein level due to 
its enhanced turnover. Most p53 mutations found in human cancers are not null 
mutations but rather encode mutant version of the p53 protein that may have 
unwanted activities such as a gain-of-function or be dominant negative 
inhibitors of wt p53 activity. In this regard, it will be important to determine 
how best to harness the complex properties of p53’s ability to induce cellular 
growth arrest and cell death to generate novel, effective approaches to cancer 
therapy. Furthermore, a clearer appreciation of the direct interaction epigenetic 
factors with p53 will lead to development of strategies to inhibit tumor initiation 
and progression. DNA damage was the first type of stress found to activate p53 
and, based on this, p53 has been widely regarded as “the guardian of the 
genome”.63 Extensive characterization of the signaling routes that connect DNA 
damage with p53 have identified a cascade of Ser/Thr kinases that includes 
ATM, ATR, Chk1 and Chk2, which phosphorylate p53.64 This signaling 
cascade is permanently activated in human cancer, suggesting that the cancerous 
state is intrinsically associated to the generation of DNA damage .65,66 The 
constitutive DNA damage present in cancer cells is thought to emanate 
primarily from the strong generation of reactive oxygen species,67 as well as, 
from the aberrant firing of DNA replication origins.68 Recent characterization 
of mice genetically manipulated with a knocked-in p53 that cannot be 
phosphorylated at two of the main residues targeted by ATM/ATR/Chk1/Chk2, 
namely, Ser18 and Ser23 (Ser15 and Ser20 in human p53), indicates an 
important role of these phosphorylation sites in some, but not all, the DNA 
damage induced and p53-dependent responses.69 In agreement with this, mice 
carrying p53 S18A/S23A alleles are tumor prone,70 although this phenotype is 
considerably milder than in the case of p53-null mice.71  These data suggest that 
the activation of p53 in response to DNA damage occurs through multiple 
pathways, which in addition to the well-established kinase cascade of 
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ATM/ATR/Chk1/Chk2, probably include other kinases such as p38, 
JNK/SAPK and c-Abl (Figure 11).72 Regarding human cancer, the available 
information gathered from the analysis of epigenetic aberrations indicates that 
the aforementioned DNA damage signaling kinases are not, in general, 
significant targets of genetic and epi-genetic inactivation.73 The only exception 
to this is found in hematological malignancies, which present a high incidence 
of mutations in ATM (13–40% depending on the particular type of 
malignancy).74 In line with this, a recent large-scale sequencing effort of 210 
diverse human cancers has identified ATM among the three most frequently 
mutated kinases (5% incidence).75 Based on the above genetic evidence, it can 
be concluded that DNA damage is conveyed to p53 through multiple redundant 
pathways in which many transducers participate, but none of them plays a 
critical role and, therefore, alteration of a single component does not have a 
significant impact on p53 function. 
 
Figure 11. p53 is at the center of a complex network of biological interactions that 
translates stress signals into cell cycle arrest or apoptosis 
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According, upstream signaling to p53 increases its level and activates its 
function as a transcription factor in response to a wide variety of stresses, 
whereas downstream components execute the appropriate cellular response (see 
below). The principal sensors seem to be MDM2 and MDM4 and their 
interaction with p53.76 In non-stressed conditions these proteins bind p53, 
ubiquitylate it and target it for degradation by the proteasome. In stressed 
conditions the function of the MDM2–MDM4 complex is blocked by 
phosphorylation, protein-binding events and/or enhanced degradation. Hence, 
phosphorylation of MDM4 is essential for the p53 response to ionizing 
radiation, and the response to oncogene activation depends on the binding of 
ARF to MDM2. Many p53-activating small molecules function by causing the 
release of ribosomal proteins from the nucleolus to the nucleoplasm, where they 
bind to MDM2 and MDM4 and inhibit their function. Molecules that activate 
wild-type p53 in tumors by disrupting MDM2 activity can compensate for any 
missing upstream components of the p53 pathway. However, defective 
downstream p53 signaling might substantially decrease their effectiveness. 
Therefore, the ability to identify tumors in which downstream p53 signaling is 
unaffected is important. The development of strategies to ensure that the desired 
p53 response is initiated when it is reactivated might be necessary and could 
require the judicious use of drug combinations. 
 
1.6 p53 network: co-activators and associated proteins 
The interaction between p53 and transcriptional co-activators also influences its 
affinity for promoters. It is therefore plausible that the specific co-factors 
expressed in a particular cellular context determine the repertoire of p53-target 
genes induced, and consequently whether the cell undergoes growth arrest or 
apoptosis, or even a particular apoptotic pathway, may be subject to the 
availability of co-activators.76 Once the p53 protein is activated, it initiates a 
transcriptional program that reflects the nature of the stress signal, the protein 
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modifications and proteins associated with the p53 protein. The p53 protein 
binds to a specific DNA sequence, termed the p53- responsive element (RE),77 
and induces the expression of downstream genes. An algorithm that identifies 
p53-responsive genes in the human and mouse genome has been utilized to 
detect a number of new genes regulated by the p53 protein.78 The genes in this 
p53 network mainly initiate one of three programs that result in cell cycle arrest, 
DNA repair or apoptosis. The exact criteria that influence p53 to stimulate cell 
cycle arrest or apoptosis are only partially understood and are the subject of 
intense study. Several general factors that influence this decision include p53 
expression levels, the type of stress signal, the cell type and the cellular context 
at the time of exposure to stress. Several intriguing observations have recently 
provided insight into the apparent intricacies of such cell fate determination. 
The examples described below involve the binding of p53 to its canonical 
binding sequence in target genes. Note, however, that p53 can also activate 
target genes through a non-canonical sequence. The first such example is in the 
p53-induced gene 3 (PIG3), which has been implicated in the accumulation of 
reactive oxygen species and apoptosis induction. PIG3 can be induced by p53 
through a microsatellite sequence within its untranslated region. Another 
recently described example is the gene encoding the pro-apoptotic phosphatase 
PAC1, which is induced through binding of p53 to a novel palindromic binding 
site. This might represent a new mechanism for transcriptional regulation of 
apoptotic genes by p53, which differs from that already described (see below). 
Exacting discrimination between p53 arrest and apoptotic functions has been 
critical to the identification of the importance ofthe latter in tumor suppression. 
 
1.6.1 p53 and the DNA repair 
Soon after having established TP53 as the most frequently altered gene in 
human tumors in the 1990s,79 p53 was understood as a major component of the 
DNA damage response pathway. After the introduction of DNA injuries the 
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level of p53 protein rises, which in turn induces a transient cell cycle arrest or 
apoptotic cell death. DNA damage activates p53 through post-translational 
modifications by specific kinases, such as the strand break sensor ataxia 
telangiectasia mutated protein (Atm), by acetyltransferases like CREB-binding 
protein (Cbp)/p300, and by the poly (ADPribose) polymerase 1 (Parp-1), which 
prevent proteolysis via the Arf-mouse double minute 2 (MDM2) pathway and/or 
enhance binding of p53 to consensus sequences within the genome.80 Initially, 
investigations on a direct participation of p53 in DNA repair were spurred by a 
number of biochemical observations. Thus, the C-terminal 30 amino acids of 
p53 were shown to recognize several DNA damage-related structures, such as 
DNA ends, gaps, and insertion/deletion mismatches. p53 was also demonstrated 
to catalyze reannealing of short stretches of single- and double-stranded DNA 
and to promote strand exchange between them . Further, p53 binds to three-
stranded heteroduplex joints and four-stranded Holliday junction DNA 
structures with localization specifically at the junction, suggesting that p53 
directly participates in recombinational repair.81 Moreover, several groups 
demonstrated a Mg-dependent 3’–5’exonuclease activity intrinsic to p53. 
Noticeably, the same central region within p53, where tumorigenic mutations 
are clustered, recognizes DNA sequence specifically, is required for junction 
specific binding of heteroduplex joints and is necessary and sufficient for the 
3’–5’ exonuclease activity on DNA.82 In addition to p53’s biochemical 
activities, numerous reports on physical and functional protein interactions 
further strengthened the proposal of a direct role of p53 in nucleotide excision 
repair (NER), base excision repair (BER), and double-strand break (DSB) 
repair.83 
 
1.6.2 p53 and the growth arrest 
p21WAF1/CIP1 is known to be a p53-downstream gene, and has been suggested 
to mediate p53-induced growth arrest triggered by DNA damage. The p21 
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protein is a cyclin-dependent kinase inhibitor that associates with a class of 
CDKs and inhibits their kinase activities. This will facilitate the accumulation 
of hypophosphorylated form of pRB that in turn associates with E2F inhibiting 
its transcriptional activity, leading to cell cycle arrest. As long as pRb is bound 
to E2F, the cell is prevented from entering into S phase. This G1 arrest affords 
the cell time to repair the DNA damage. Should repair be unsuccessful, P53 
levels drop and CDK-cyclin protein kinase activity resumes, leading to entry 
into S phase. In the event that the DNA is not repair, p53 triggers apoptosis.84 
 
1.6.3 p53 and the apoptosis 
Pivotal to the tumor-suppressor activity of p53 is its ability to activate apoptosis 
via multiple different pathways. Since the most-studied function of p53 is its 
role as a transcription factor that can activate transcription of an ever-increasing 
number of target genes, its transcriptional activation of pro-apoptotic genes, as 
well as its transcriptional repression of anti-apoptotic genes, has been widely 
analyzed.85 However, although a large number of genes regulated by p53 during 
induction of apoptosis are known no single target gene has been identified 
whose altered expression alone can sufficiently explain p53 mediated 
transcription dependent apoptosis, and whose genetic deficiency phenocopies 
p53 deficiency in vivo. As an additional mode of p53’s pro-apoptotic activity, 
recent studies have placed non transcriptional pro- apoptotic activities of p53 at 
the center of an active debate that aims to establish a comprehensive 
understanding of p53- mediated apoptosis.86 
 
1.6.3.1 p53 role in transcription dependent apoptosis 
The past twenty-five years have seen intensive and varied investigations to 
better understand the functions that p53 uses to mediate apoptosis. The first 
indication of the role of p53 in apoptosis was obtained using the M1 mouse 
myeloid leukemia cell line lacking endogenous p53. Using M1 cells stably 
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transfected with a temperature-sensitive mutant that acquires the conformation 
of wild-type p53 at permissive temperature (32°C), it was observed that upon 
downshift to the permissive temperature, the transfectants underwent rapid loss 
of viability with the characteristics of apoptosis.87 Several mechanisms have 
been implicated in p53-mediated apoptosis. One is p53 activation to up-
regulation of pro-apoptotic Bax and down-regulation of pro-survival Bcl-2.88 
More recently its determined that p53-mediated apoptosis of M1 cells involves 
rapid activation of the pro-apoptotic Fas/CD95 death pathway-via up-regulation 
of membrane bound Fas and the intrinsic mitochondrial pathway, which results 
in activation of caspases 8, 9 and 10. (Figure 12) Either Fas blocking antibody 
or inhibition of the apical caspases 8 and 10, were each almost as effective as 
IL-6 in abrogating p53 mediated apoptosis. These observations argue that p53 
regulation of the bcl-2 members Bax and BcI-2, associated with the intrinsic 
mitochondrial apoptotic pathway, is ancillary to the extrinsic Fas/CD95 
apoptotic pathway in mediating p53 induced apoptosis of M1 myeloid leukemia 
cells.89 
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Figure 12. p53 mediated apoptosis 
 
In other cell types up-regulation IGF-BP3 90 which sequesters the cell survival 
factor insulin-like growth factor-1 has been associated with p53 mediated 
apoptosis. The gene encoding for the cathepsin-D protease, PAG-608 which 
encodes a nuclear zinc finger protein and the human homolog of the 
Drosophilasina gene have also been implicated as mediators of p53 induced 
apoptosis in various cell types. Furthermore, a series of p53-induced genes (PIG 
genes) were documented to encode proteins that respond to oxidative stress, 
suggesting that p53-mediated apoptosis involves activation of redox- 
controlling targets followed by increase in ROS, oxidative damage to 
mitochondria and caspase activation. Along this research line it was recently 
observed that p53 suppresses Nrf2-dependent transcription of antioxidant 
response genes, presumably to prevent the generation of antioxidants that could 
hinder induction of apoptosis.91 Clearly established is p53’s role as a nuclear 
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transcription factor with the ability to activate, or repress, the expression of 
many genes. A number of p53 transcriptional targets, such as the p53-induced 
genes BAX, PUMA, NOXA, and the p53-repressed genes BCL2 and 
SURVIVIN, represent genes with the potential to promote or inhibit apoptosis, 
respectively, in stressed cells. Puma and Noxa are thought to indirectly induce 
mitochondrial outer membrane permeabilization (MOMP), known to be 
induced by the activation of Bax and Bak, via interfering with Bax and Bac 
interaction with prosurvival Bcl-2 family members.  Interestingly, it was 
observed that Puma and Noxa differentially contribute to the regulation of p53-
mediated apoptotic pathways. In normal cells, Puma was found to induce 
mitochondrial outer membrane permeabilization via an ER-dependent pathway; 
however, upon E1A oncoprotein expression, cells also became susceptible to 
mitochondrial outer membrane permeabilization induction by Noxa via an ER-
independent pathway. In several instances, transcriptional activation by p53 was 
observed to be dispensable for p53-dependent apoptosis, since mutants p53 
which fail to activate transcription could still induce apoptosis.92 In addition, 
p53-dependent apoptosis could occur in the presence of inhibitors of 
transcription and translation.93 In recent years it has become clear that p53 also 
harbors a direct proapoptotic function at the mitochondria via engaging in 
protein-protein interactions with anti- and pro-apoptotic Bcl2 family members, 
including BclXL and Bak. 94 It has been reported, certain transcriptionally 
inactive mutants of p53 can still induce apoptosis when over expressed in tumor 
cells. Also, in response to some stresses, such as hypoxia, p53 induces apoptosis 
but does not function as a transactivator. Intriguingly has been demonstrated 
that during p53-dependent apoptosis a fraction cellular p53 protein localizes to 
mitochondria and induces cytochrome c release; however, this is not observed 
during p53-mediated cell cycle arrest.95 Additional support for the concept that 
p53 has a cytoplasmic role in apoptosis induction resulted from functional 
analysis of polymorphic variants of p53 (within exon 4 of the p53 gene, a 
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common single-nucleotide polymorphism (SNP) at codon 72 leads to the 
incorporation of either an arginine (R72) or a proline (P72) at this position of 
the protein. When explored the potential mechanisms underlying the observed 
functional difference between the two p53 variants, made the initially surprising 
discovery that the greater apoptotic potential of the R72 form correlated with its 
much better ability to traffic to mitochondria. Based on these data, therefore 
concluded that the enhanced apoptosis-inducing activity of the R72 protein 
related, at least in part, to its greater mitochondrial localization. An analysis of 
whole cell or mitochondrial extracts by immune precipitation-western blot 
analysis, demonstrated the R72 form of p53 binds better to the mitochondrial 
death-effectors protein BAK than does the P72 variant, correlating with the 
difference in apoptotic potential of the two p53 variants. In healthy cells, Bak 
resides at mitochondria as an inactive monomer. In response to various death 
stimuli, it undergoes an activating allosteric conformational change that 
promotes homo-oligomerization. This leads to formation of a pore in the outer 
mitochondrial membrane, and allows the release of cytochrome c and other 
caspase cascade (Figure 4). Recently, like BAK, the BCL2 family members 
BAX and BCL-XL have also been implicated in mitochondrial apoptosis 
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2.1 Aim of the study 
The ability of p53 to respond to stress signals by triggering cell-cycle arrest and 
cell death by apoptosis is crucial to inhibit tumor development and for the 
response to anticancer therapy.49,97,98 Inactivation of p53 by mutation occurs in 
about half of all human tumors. Tumors that retain wild-type p53 often acquire 
an alternative mechanism for its inactivation, largely through deregulation of 
MDM2 (murin double minute-2) protein. Negative regulation of p53 activity 
and stability is enhanced in many human tumors and effectively impairs the 
activities of the p53 pathway. Therefore, recovery of p53 activity in cancer cells 
by antagonizing MDM2 has been proposed as a novel approach for treating 
cancer and validated in vitro by macromolecular studies. MDM2 and p53 are 
part of an auto-regulatory feedback loop (Figure 13).99,100 MDM2 is 
transcriptionally activated by p53 and MDM2, in turn, inhibits p53 activity in 
several ways. MDM2 binds to the p53 transactivation domain and there by 
inhibits p53-mediated transactivation MDM2 also contains a signal sequence 
that is similar to the and, after binding to p53, it induces its nuclear export 
nuclear export signal of various viral proteins. As p53 is a transcription factor, 
it needs to be in the nucleus to be able to access the DNA; its transport to the 
cytoplasm by MDM2 prevents this. Finally, MDM2 is an ubiquitin ligase, so is 
able to target p53 for degradation by the proteasome. In normal cellular 
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Figure 13. Regulation of p53 by MDM2. p53 and MDM2 form an auto-regulatory 
feedback loop. p53 stimulates the expression of MDM2; MDM2 inhibits p53 activity 
because it blocks its transcriptional activity, favours its nuclear export and stimulates 
its degradation. Different cellular signals, such as DNA-damage or oncogene 
activation, induce p53 activation. DNA damage favours p53 phosphorylation, 
preventing its association with MDM2. Activated oncogenes activate the ARF protein, 
which prevents the MDM2-mediated degradation of p53. Similarly, inhibitors of the 
p53–MDM2 interaction should activate p53 tumour-suppressor activity in tumour cells 
that express wild-type p53. These compounds, because they bind to MDM2, could also 
affect the p53independent activities of MDM2 
 
The activation of p53 tumour suppressor activity therefore depends on its 
association with MDM2. Several pathways activate p53 via the control of its 
interaction with MDM2. For example, DNA damage induces the 
phosphorylation of different p53 residues (Ser15, Thr18 or Ser20), which 
prevents them from binding to MDM2. Alternatively, the activation of 
oncogenes such as c-MYC or RAS prevents MDM2-mediated degradation of 
p53 via expression of ARF,102 which, after binding to MDM2, abolishes 
MDM2-mediated degradation of p53. Overexpression of the MDM2 protein 
should have negative consequences for the cell, because it diminishes its ability 
to activate the p53 pathway under stress conditions. 
The analysis of more than 3,000 tumour samples shows that MDM2 is amplified 
in 7% of these tissues. The highest frequency of MDM2 amplification is 
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observed in soft-tissue tumours, osteosarcomas and oesophageal carcinomas. 
Furthermore, many reports describe the overexpression of MDM2 in different 
types of tumour.103 The presence of high levels of MDM2 in these tumours 
might be an important element for their survival, because it decreases their 
ability to activate p53.104,105 The design of compounds that prevent the 
interaction between p53 and MDM2 is therefore an attractive strategy for 
activating p53 tumour-suppressor activity in tumours. The structures of p53 and 
MDM2 have been determined by X-RAY CRYSTALLOGRAPHY,106 p5315-29 
binds into a large cleft that is present at the surface of MDM2 (Figure 14A). The 
residues 19–25 form an α-helix and residues 17, 18 and 26–29 take a more 
extended conformation. Thr18 is particularly important for the stability of the 
helix and the regulation of the p53–MDM2 interaction by phosphorylation.107 
A detailed structural analysis of the interface between p53 and MDM2 reveals 
many factors that must be considered when aiming to inhibit this interaction. 
Only one of the two partners (MDM2) has a structurally well-defined binding 
site. The inhibitors should therefore aim to mimic the other partner (p53). One 
of the two interfaces (p53) is formed by only one segment of contiguous 
aminoacids, allowing the design of peptidic inhibitors (p53 mimics). Three 
residues — Phe19, Trp23 and Leu26 (Figure 14B) — contribute to a large extent 
to the interaction and consequently to the binding energy of the p53 peptides. 
The inhibitors of the p53–MDM2 interaction will have to contain mimics of 
these amino acids. There are only three hydrogen bonds connecting p53 to 
MDM2, and at least the most buried one will have to be preserved to ensure 
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Figure 14. Structure of the p53–MDM2 complex. (A): the surface of MDM225–109 is in 
white and the backbone of p53 is in green. Two different views of the complex are 
presented, and the amino (N) and carboxyl (C) termini of the p53 peptide are indicated. 
(B): The p5317–29 backbone is in grey and the side chains of Phe19, Trp23 and Leu26 
are represented. The surface of MDM2 25-109 is in yellow 
 
According to these findings, and as part of my PhD program aimed to identify 
small-molecules endowed with antitumor activity, different series of 
compounds were designed as potential p53 modulators.  
Specifically, my research work has been focused on two different projects: 
 1) the synthesis of small molecules designed as modulators of apoptosis, 
mediated by p53; 
 2) the design and synthesis of DTNQ derivatives as antitumour agents 
potentially involved in the p53-MDM2 interaction.  
Finally, the aim of this study was to identify of suitable leads allowing further 
understanding about the molecular complexity of p53 network, thus improving 
the antitumor therapeutic arsenal
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3.1 Background and design 
Several low molecular weight inhibitors, have been identified and reported, so, 
Vassilev et al.109 identified the first group of molecules that target the MDM2-
p53 interaction (Figure 15). These imidazoline derivatives, defined as Nutlins, 
specifically bind and dissociate MDM2 from p53, leading to extensive p53 
activation and induction of a full-blown p53 response, which can trigger tumor 
shrinkage. The derivative Nutlin-3 is currently undergoing phase I clinical 
evaluation against advanced solid tumors and hematological malignancies.  
 
 
 Figure 15. Structures of different inhibitors of p53-MDM2 interaction  
 
The benzodiazepines 110 and the spirooxindole-based compounds 111 are other 
classes of small molecules that have been found to target the p53−MDM2 
interaction. These results led to the preclinical development of TDP665759 and 
MI-319, which disrupt the binding of MDM2 to p53 in vitro and suppress the 
growth of tumor cells both in vitro and in vivo. Both compounds limit tumor 
growth without causing major toxicity in the surrounding tissue. Although these  
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products induce high levels of p53, they are unable to activate the apoptotic 
cascade; other small-molecules inhibitors include chromenotriazolopyrimidines 
(1) 112 and oxoindoles (2).113 Most of the inhibitors we have described above 
share a common structural motifs, such as a rigid heterocyclic scaffold highly 
functionalized with appropriate aryl/alkyl groups, which are supposed to mimic 
the critical p53 residues binding MDM2 [Paragraph 2.1]. My research group has 
previously reported a series of spiro(oxindole-3,3′-thiazolidine)-based 
derivatives potentially able to mimic at least two critical p53 residues that bind 
MDM2.114 Compounds (3R,7aR)-6-(4-Chlorobenzyl)-1H-spiro[imidazo[1,5-
c]thiazole-3,3-indoline]-2’,5,7(6H,7aH)-trione (ISA27) and (3R,7aR)-5’-
methyl-6-(3,4,5-trimethoxybenzyl) -1H-spiro[imidazo[1,5-c]thiazole-3,3 
indoline] 2’,5,7 (6H,7aH) -trione (ISA36) inhibited cell growth of different 
human tumor cells at micromolar concentrations. In particular ISA27 induced 
apoptotic cell death after 24h of treatment at cytotoxic concentrations but did 
not alter the normal course of cell cycle. ISA27 also induced a time-dependent 
increment of p53 expression, indicating that the activity profiles of the 
compound might be regulated by this protein. More concretely, NMR studies 
(1H proton) performed on compounds ISA27 and ISA36 demonstrated the 
ability of these compounds to block p53−MDM2 interaction.114 Encouraged by 
the results obtained and aiming to improve the pharmacological profile of these 
compounds, new inhibitors of p53-MDM2 interaction were designed by 
structural modifications of ISA27. We considered of interest to manipulate the 
spiro (oxindole-3,3′-thiazolidine) nucleus of ISA27, by opening of imidazole 
ring, with the aim of altering its conformational properties. The opening of this 
ring would allow us to obtain more flexible structures (Figure 16, series 1 and 
2) with a potential third point of diversification through the 4'-carboxyl group 
of the thiazolidine moiety. This ring could allow the aromatic and/or alkyl side 
chains to assume more appropriate orientations to interact with the binding site.  
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Figure 16. Design of new series 1 and 2. Dashed lines define hypothetical interaction 
subsites 
 
Therefore, during the first year of my PhD programme I have been involved in 
the synthesis of two small libraries of compounds, both series retain the ester 
group at position C-4', while the oxoindole moiety carries either a weak 
releasing (CH3) or a withdrawing (Br) electron groups (R). Series 1 contains a 
substituted phenyl, benzyl, or a cyclohexyl side chains on the N-3' (R2), while 
these groups were positioned on N-1 in the series 2 (R1). 
 
3.2 Chemistry  
3.2.1 Chemistry 1st series  
The new (2'S,4'R) -ethyl 3'-substituted-2-oxospiro [indoline-3,2' thiazolidine]- 
4'-carboxylate derivatives (13a-f, 13l-n) were prepared applying the synthetic 
route shown in Scheme 1.115 Starting spirooxoindolethiazolidine skeletons (7-
12) were constructed by condensation between the isatin derivatives (1-6) and 
L-cysteine ethyl ester in EtOH. These derivatives were obtained with 80-90%  
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yields, as (2'R)/(2'S) epimeric mixtures ranging from 60/40 to 40/60 ratios as 
my research group previously described.114,116 
The 3'-acyl derivatives were obtained by reaction of compounds 7-12 with the 
corresponding 2-(4-chlorophenyl) acetyl, 4-chlorobenzoyl, 4-methylbenzoyl, 
benzoyl, or cyclohexanecarbonyl chlorides in THF using TEA as base. 
 
Scheme 1. Synthesis of 2-Oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate 
derivatives (Series 1 and 2) 
 
 
Reagents and conditions: (i): L-CysOEt, NaHCO3 in ETOH; (ii): R2
- TEA, in THF, 2 h, room temp.  
(See Table 1 for the correspondence between number of final products and substituent R, R1, and R2) 
 
In these conditions, all final products (13a-f and 13h-q) were obtained as single 
diastereomers in 32-58% overall yields. These stereoselectivities in the 
acylation reactions of thiazolidine derivatives have been previously observed by 
my research group116 and other authors117 and can be explained by the fact that  
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thiazolidines undergo rapid ring opening and closure reactions. This favors the 
formation of thermodynamically more stable diastereoisomers. Moreover, the 
reaction of intermediates 7-9 (R1=H) with 4-Cl-benzoyl chloride also gave the 
1-substituted derivatives 14a-c with 8-12% yields.  
In the synthesis of the 3-cyclohexylcarboxy derivatives 13n-q, two isomers 
were obtained in a 11/1 to 6/1 ratio (estimated by H-NMR), which differs for 
the cis/trans configuration at the N3'-COC6H11 amide bond.
118 (Figure 17) 
 
 
Figure 17. 1H NMR spectrum of compound 13n (SM13) 
 
The major isomer (cis) in these mixtures was identified on the basis of the ROE 
observed in the ROESY spectrum of 13n between the H-1″ of the 
cyclohexanecarbonyl group and the H-4' of the thiazolidine (Figure18), 
Cis/trans isomerization about amide bond was evidenced by 2D NMR. 
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Figure 18. ROE interaction observed between H-4' and H-1″ in the ROESY spectrum 
of compound 13n (SM13) 
 
In fact, interconversion was demonstrated by an exchange cross-peak between 
the H-4' hydrogen signals of the two isomers.100 (Figure 19).  
 
 
Figure 19. Roesy spectrum of compound 13n. Red arrow indicates the chemical 
exchange peak between H-4’ signals of the two isomers of 13n (same sign as the 
diagonal peaks). Blue arrow indicates the ROE interaction between H-4’ and H-1’’ of 
the major isomer (opposite sign as the diagonal peaks) 
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Changes in the condition of reactions that involve an increase of the reaction 
time (from 2 h to 12 or 24 h) do not significantly modify the above-described 
results, while increase of temperature resulted in a general decrease of reaction 
yields. However, with the use of microwave (Scheme 2),100 the reaction of 
intermediate 9 with 4-chlorobenzoyl chloride led to a mixture of two 
diastereoisomers (2'S,4'R)-13f and (2'R,4'R)-13g and the 1-substituted 
derivative 14c in 33%, 15%, and 9% yields, respectively. In the same conditions 
and using cyclohexanecarbonyl chloride as acylation agent, we observed the 
formation of only a diastereoisomer (2'S,4'R)-13q (42%), the 1-
cyclohexacarbonyl derivative 14d (25%), and a minor product with structure of 
2-oxo-5'H-spiro[indoline-3,2'-thiazole]-4'-ethyloxycarbonyl 15d with a 15% 
yield. 
 
Scheme 2. Reaction of ethyl 5-bromo-2-oxospiro [indoline-3,2' thiazolidine]-4'-
carboxylate with 4-chlorobenzoyl and cyclohexanecarbonyl chlorides 
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3.2.2 Chemistry 2nd series  
The 1-(4-chlorobenzoyl)-2-oxospiro[indoline-3,2'-thiazolidine] derivatives 
(14a-c) were prepared using an alternative synthetic route as shown in Scheme 
3.100 Treatment of isatins 1-3 with 4-chlorobenzoyl chloride in DCM and TEA 
gave the corresponding intermediates 16-18 which were condensed with 
cysteine ethyl ester in EtOH. In this condition, compounds 14a-c were obtained 
as single (2'S,4'R) diastereoisomer in 47% yields according to their 1D and 2D 
NMR spectra. In addition, working with the 5-substituted intermediates 17 and 
18, we also observed the formation of thiazoline derivatives 15b and 15c with 
8% yields.  
Scheme 3. Synthesis of (2'S,4'R) -ethyl 2-oxospiro[indoline-3,2'-thiazolidine]-4'-
carboxylate derivatives (14) and ethyl 2-oxo 5'H-spiro[indoline-3,2'-thiazole]-4'-
carboxylate derivatives (15) 
 




COCl, TEA in THF, 2h, room temp.; (ii): L-Cys-OEt, NaHCO
3
 in EtOH 
 
Moreover, the reaction of 1-3 with cyclohexanecarbonyl chloride did not lead 
to the desired 1-(cyclohexylcarbonyl) derivative, recovering the starting 
materials. Poor reactivity of cyclohexane carbonyl chloride could be explained,  
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if compared to 4-chlorobenzoyl chloride, by considering a higher steric 
hindrance of the first. Modifications of reaction conditions including changes of 
solvent, increase of temperature, or use of microwaves led to the same negative 
results.100 
 
3.3 Biological effects of the spiro-oxo-indole-thiazolidine synthesized  
3.3.1 Antiproliferative activity 
The synthesized compounds were examined, in the Department of Molecular 
and Cell Biology of the University of Naples “Federico II”, for their 
antiproliferative activity against two tumor cell lines: the human breast 
adenocarcinoma MCF-7 and human colon carcinoma HT-29 at 24 h. The 
obtained IC50 values are summarized in Table 1.
100 ISA27, considered our hit 
compound, showed a similar micromolar antiproliferative activity against the 
two tumoral cell lines used in the assay. The opening derivatives 13a, 13b, and 
13c showed an elevated activity with IC50 values in the micromolar range 
against MCF-7 and submicromolar against HT29 cell lines. Exchange of the 4-
chlorobenzyl group for 4-chlorophenyl gave compounds 13d-f, more active 
against MCF-7 cells, while 13f was 6-fold more active against the HT29 cell 
line. The activity data for compounds 13a-f and 13h-j (IC50 from 0.08 to >4.0 
µM) indicated that the nature of the substituents on the oxoindole moiety 
markedly affects the antiproliferative activity profile of these compounds. 
Contrary to what was observed in the precedent series (ISA27)99 presence of an 
electron-with drawing group, such as the bromide group, at position C-5 of the 
indole system caused an increase of the activity of the corresponding analogues 
13c, 13f, and 13j in both cell lines but particularly on HT29 cell. 
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Table 1. Antiproliferative activity of spiro[indoline-3,2'-thiazolidine] (13 and 14) and 
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We observed that the configuration at the 2' carbon has a notable influence on 
the cytotoxic activity on this cell line. In fact, (2'R,4'R) 13g was 18-fold less 
potent than its diastereoisomer (2'S,4'R)-13f on HT29 cells and 3-fold less 
potent on the MCF7 cell line. The introduction of a methyl group at N-1 
improved the activity of compounds 13h-j compared to the non methylated 
analogues (13d-f), especially on the colon cell line. The most potent compound 
of this subseries, 13j, gave IC50 values of 520 and 80 nM in MCF-7 and HT29 
cell lines, respectively. Modifications of 13j at the N-3' position produced 
different effects: the introduction of 4-Cl-benzoyl group increased (2-fold) the 
antiproliferative activity of analogue 13k on MCF-7 cells and reduced (4-fold) 
its activity on HT29 cells. A similar behavior was observed with compound 13l, 
which contains a phenyl group at the N-3' position. The introduction of a 4-CH3-
phenyl or a cyclohexyl group led to compounds 13m and 13n, which showed 
an antiproliferative activity in the nanomolar range (IC50 < 100 nM, for both cell 
lines). In particular, 13n was 14-fold more potent than its analogue 13j on MCF-
7 cells. Further modifications of this compound involving substitution or loss of 
the bromine atom at the C5 (compounds 13o and 13p), lack of the CH3 group at 
N1 (compound 13q), and ethyl ester hydrolysis to carboxylic acid (13r) all 
resulted in a loss of activity in the resulting compounds. These derivatives were 
less potent than 13n against MCF-7 (from 5- to 60-fold) and HT29 (from 8- to 
28-fold) cell lines. Furthermore, switching the 4-Cl-benzoyl or 
cyclohexylcarbonyl groups from position N3' to position N1 led to contrasting 
results. 4-chlorobenzoyl derivative 14c showed cytotoxic activity in the 
nanomolar range on both cell lines (IC50 of 150 and 20 nM) and was ~6-fold 
more potent than its regioisomer 13f. Derivative 14a was also 2- to 3-fold more 
potent than its regioisomer 13d, while compound 14b containing a CH3 group 
at C-5 position showed a slight decrease of activity on MCF-7 cells compared 
to its analogue 13e. In contrast compound 14b was 4-fold more potent than 13e 
Chapter III: Design, synthesis, results and discussion of potential p53 modulators 
(series 1 and series 2) 
- 55 - 
 
against HT29 cells. Surprisingly, the same change of the position for cyclohexyl 
carbonyl group (13q versus 14d) led to a considerable decrease in activity. In 
fact, 14d was 10-fold less potent than its regioisomer 13q on MCF-7 cells. 
Finally, the presence of a more planar thiazoline ring in the structure produced 
different effects: derivative 15b retained the cytotoxic activity of its thiazolidine 
analogue 14b, while compound 15c was 6- and 10-fold less active than 14c on 
both cell lines. In contrast, compound 15d showed a slight increase of activity 
(~1.5-fold) on both cell lines compared to 14d. Considering the interesting data 
of cytotoxicity for the most active compound, 13n or SM13, was also analyzed 
against a panel of human tumor cell lines, including PC3 (prostate), U937 
(leukemia), Calu (lung), HEPG2 (liver), and C643 (anaplastic thyroid) human 
cell lines (Table 2). Doxorubicin and nutlin-3 were used as reference cytotoxic 
agents. Data on the MCF-7cell line are also reported in Table 2. In all tested 
cells lines, SM13 showed marked cytotoxic potency with IC50 in the range 0.07-
0.55 µM, while nutlin-3 was much less effective in our panel, in accordance 
with some data found in the literature.119 SM13 was 18-fold more potent than 
doxorubicin on the Calu cell line and was equipotent to doxorubicin in PC3 and 
U937 cell lines. Table 2 also shows that SM13 inhibited the cellular growth of 
a human gingival fibroblast (HGF) normal cell line at low micromolar 
concentration. This cytotoxicity was similar to that shown by nutlin-3 on the 
same line and was 4 times less than that caused by doxorubicin. These data seem 
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Table 2. Antiproliferative activity of 13n (SM13) on multiple uman tumor cell lines and 
one normal cell line 
 
 
3.3.2 Modulation of p53-MDM2 interaction in vitro  
To test the effective ability of SM13 to inhibit p53−MDM2 interaction, we 
performed an in vitro binding assay using ImmunoSet p53/MDM2 complex 
ELISA (Figure 20). Nutlin-3 and compound 3were also evaluated as references. 
In this assay and for all compounds, the minimum effective concentration was 
determined at 5 µM. At this concentration, the percentage inhibition was 19% 
for nutlin-3 and 25% for 3, while compound SM13 has proved to be more 
effective inhibiting 30% of p53MDM2 interaction.100 
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Figure 20. Binding assay using ImmunoSet
TM
 p53/MDM2 complex ELISA set. Data 
was presented as % of inhibition referred to control (only standards) using 5 µM of 
Nutlin-3, ISA27 and SM13 
 
3.3.3 Modulation of p53-MDM2 interaction in cell 
In order to confirm the ability of SM13 to inhibit the MDM2-p53 interaction in 
cell, the expression levels of these two proteins were evaluated by western blot 
after 24, 48, and 72h of SM13 treatment and after 24h with nutlin-3. Compound 
concentrations close to their IC50 on the MCF-7 cell line were used in this assay 
(i.e.50 nM for SM13 and 3 µM for nutlin-3). In these conditions, SM13 induced 
the accumulation of p53 and MDM2 proteins, (Figure 21A, 21B). To determine 
whether SM13 was able to prevent MDM2-p53interaction, p53 expression 
levels were measured after MDM2 immunoprecipitation (Figure 21C, 21D). 
Cells were treated with SM13 for 24, 48, and 7h or with nutlin-3 for 24 h, 
MDM2 was immunoprecipitated. The samples underwent western blot to 
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Figure 21. (A) MCF-7 cells were treated with 50 nM SM13 for 24, 48, and 72 h or 3 
μM nutlin-3 for 24 h. Total cell lysates were analyzed by Western blotting for p53 and 
MDM2 with specific antibodies. (C) A similar experiment was performed for p53 after 
MDM2 immunoprecipitation. (B, D) Immunoblots were quantified by ImageQuant 
densitometric analysis. Protein expression levels were measured in arbitrary 
densitometric units, and data show the mean values ± SEM calculated from relative 
protein expression levels determined in three separate experiments 
 
Treatment with SM13 reduced the MDM2-p53 interaction as evidenced by a 
significant decrease in the p53 levels bound to MDM2 at 24 and 48 h. Nutlin-3 
seems to be inactive in this immunoprecipitation assay. We can hypothesize that 
nutlin acts more quickly than SM13; its unresponsiveness to the test may be due 
to a recombination of p53 and MDM2 within 24 h. Interestingly, this 
recombination is also observed for SM13 after 72 h.100 
 
3.3.4 Cell-cycle progression 
To investigate the effect in the reduction of tumor cell survival mediated by 
SM13, MCF-7 cell cycle was analyzed after 24, 48, and 72 h of treatment; again, 
nutlin-3 was used for comparison. Nutlin-3 (3 µM) induced cell cycle arrest, as 
shown by G0/G1 phase block and in accordance with literature data.94 SM13  
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(50 nM) did not significantly affect cell cycle. Indeed, SM13 treated cells 
showed the same distribution in G1, S, and G2/M phases of untreated cell at 24, 
48, and 72 h (Figure 22A, 22B, and 22C). When the same experiment was 
performed with increasing concentration of SM13 (500 nM, 1 µM, 5 µM), no 




Figure 22. Effects of SM13 on cell cycle progression analyzed for DNA content by 
FACS in breast cancer MCF-7 cells untreated or treated with 50 nM of SM13 or 3 µM 
nutlin-3 at (A) 24, (B) 48, and (C) 72 h and (D) MCF-7 cells untreated or treated with 
50, 500, 1000, and 5000 nM 4n at 24 h. The distribution and percentage of cells in G1, 
S, and G2/M phases of the cell cycle are indicated. Data points are mean values ± SEM. 
Significance is assumed at (*) p < 0.05, (**) 0.01 < p < 0.05, (***) p < 0.01 
 
3.3.5 Apoptotic cell-death  
To study if the mechanism of cell death induced by SM13 influence apoptosis, 
cell death with preliminary, qualitative assessment of apoptosis by subG1 
analysis was evaluated. The treatment with SM13 (50 nM) showed a strong 
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increase of the subG1 peak, which rose in a time dependent manner (Figure 23). 
Nutlin-3 (3 µM) also induced a significant increase of cell death.  
 
 
Figure 23. Representative subG1 populations calculated from FACS histograms. 
MCF-7 cells were incubated with 50 nM 4n or with 3 µM nutlin3 for 24, 48, and 72 h. 
Data are expressed as the percentage of subG1 cells 
 
However, the subG1 peak may consist of apoptotic and necrotic cells. To 
discriminate between the two possibilities, an annexin V binding assay was 
performed. SM13 and nutlin-3 induced a significant increase of cell fraction in 
early apoptosis (Figure 24). In particular, the apoptotic cell percentage increased 
from 4% of untreated cells to 10% and 12% of cells after 48 and 72 h of SM13 
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Figure 24. The cells were analyzed by FACS for the occurrence of apoptosis (FITC-
annexin binding). Values represent the mean ± SEM. Significance is assumed at (*) p 
< 0.05, (**) 0.01 < p < 0.05, (***) p < 0.01 
 
So it has been evidenced that, although p53 plays a pivotal role in regulating 
cell cycle and apoptosis, treatment of MCF-7 cells with SM13 or nutlin-3 has a 
different impact on both mechanisms Indeed, whereas nutlin-3 determined a cell 
cycle arrest, SM13 induced apoptotic cell death. To investigate the cell death 
mechanism induced by SM13, the p53 dependent apoptotic pathway was 
analyzed by Western blot. The analysis of the expression levels of p53 and p53 
transcriptional targets, such as p21 and p27, showed a progressive increase of 
these proteins during the treatment with SM13 in a time dependent manner 
(Figure 25). However, these increases do not seem to be sufficient to induce cell 
cycle arrest. On the contrary, nutlin-3 showed a greater accumulation of p21 
than 4n at 24, 48, and 72 h, inducing cell cycle arrest (Figure 25A and 25B). 
The cells committed to die via p53 dependent apoptosis typically follow the 
mitochondrial pathway, although p53 can also modulate cell death through 
death receptors. p53 has been reported to trigger apoptosis by modulation of 
gene transcription of Bcl-2 family members and by physical interaction with 
these proteins. 
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Figure 25. (A) MCF-7 cells were treated with 50 nM SM13 or 3 µM nutlin for the 
indicated time intervals. Total cell lysates were analyzed by Western blotting for 
phosphotyrosine p53, p21, p27, Bcl-xL/S, cytocrome c, and caspase-3 with specific 
antibodies. (B) Immunoblots were quantified by ImageQuant densitometric analysis. 
Protein expression levels were measured in arbitrary densitometric units, and data 
show the mean values ± SEM calculated from relative protein expression levels 
determined in three separate experiments: (*) p < 0.05 vs protein expression levels in 
untreatedcontrol cells. 
 
Western blot results indicated that SM13 and nutlin regulate Bcl-2 members, 
reducing the antiapoptotic Bcl-xL protein and increasing the pro apoptotic Bcl-
xS protein, although the two drugs affect BclxL/S expression at different times. 
The induction of 4n-mediated apoptosis was confirmed by the release of 
cytochrome c from mitochondria to the cytosol, which increased at various time 
intervals and became particularly evident at 72 h of drug treatment. Also nutlin-
3 affects cytochrome c release at 48 h even if at lower levels compared to SM13. 
One of the final effectors of the apoptotic process is caspase-3, which is 
activated by extrinsic and intrinsic or mitochondrial pathways. The cleavage of 
caspase-3 is a clear indicator of apoptosis; hence, we analyzed the p53 fragment 
with a specific antibody. Western blot analysis revealed that both SM13 and 
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nutlin-3 induced an accumulation of the cleavage product of caspase-3. All these 
findings suggest that in the MCF-7 breast cancer cell line, cell cycle arrest is the 
main molecular mechanism mediated by nutlin-3. On the contrary, 50 nM of 
SM13 did not block cell cycle progression but rather it induced apoptosis.100 
 
3.4 Molecular modeling studies  
To study the exact binding mode and to better rationalize the reasons behind the 
activity of our indoline-3,2'-thiazolidines, in the Departement of Pharmacy of 
the University of Naples “Federico II”, molecular docking studies were carried 
on SM13 which is the most potent antiproliferative agent in this series (Figure 
26). In particular, in the binding pose predicted for SM13 the ligand is inserted 
into the MDM2 binding site so that the 3-cyclohexylcarboxylic substituent is 
buried in the so-called Trp23 pocket, making favorable van der Waals contacts 
with Ile61, Val75, Phe86, Phe91, and Ile99 side chains. On the other hand, the 
MDM2 Phe19 subpocket is occupied by the ligand ethyl ester chain that is able 
to make direct contacts with Ile61 and Met62 side chains. The presence of this  
interaction could partially explain why hydrolysis of the ethyl ester chain to the 
corresponding carboxylic acid results in the loss of activity [Table 1;Paragraph 
3.3.1].  
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Figure 26. Predicted binding mode for SM13 in the MDM2 binding site. The ligand is 
represented as pink stick, while the protein is represented as blue sticks and ribbons 
and transparent white surface. 
 
On the other hand, reduction of membrane penetration cannot be ruled out. 
Interestingly, the Leu26 cleft does not seem to be completely filled by the 5-
bromo-2-oxindole nucleus that instead forms additional hydrophobic 
interactions with Leu54 through its N-1methyl substituent. This latter 
hydrophobic interaction could explain why 13d−f are generally less active than 
their methylated analogues 13h−j. In this position, edge−face π−π interaction 
with the Phe55 residue is also established in a shallow and rather liphophilic  
portion of the MDM2 protein in which the 5-bromine atom fills the crevice  
between Phe55, Met62, and Gln59. Indeed, the interaction with the Phe55 
residue has already been detected through X-ray studies for other structurally 
unrelated ligands in a very recent work by Olson’s group.120 Interestingly, the 
ligand N3′-COC6H11 amide bond adopts a cis configuration as already suggested 
by ROESY experiments.100 [Figure 19] 
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4.1 Chemistry 
Reagents, starting materials, and solvents were purchased from commercial 
suppliers and used as received. Analytical TLC was performed on plates coated 
with a 0.25 mm layer of silica gel 60 F254 Merck and preparative TLC on 20 
cm × 20 cm glass plates coated with a 0.5 mm layer of silica gel PF254 Merck. 
Silica gel 60 (300-400 mesh, Merck) was used for flash chromatography. 
Melting points were determined by a Kofler apparatus and are uncorrected. 
Optical rotations were measured on an Atago Polax 2-L polarimeter. 1H NMR 
and 13C NMR spectra were recorded with a Varian-400 spectrometer, operating 
at 400 and 100 MHz, respectively. Chemical shifts are reported in d values 
(ppm) relative to internal Me4Si, and J values are reported in hertz (Hz). ROESY
 
experiment was recorded at 25°C in the phase-sensitive mode using the method 
from States. Data block sizes were 2048 addresses in t2 and 512 equidistant t1 
values. Before Fourier transformation, the time domain data matrices were 
multiplied by shifted sin 2 functions in both dimensions. A mixing time of 500 
ms was used. ESIMS experiments were performed on an ApplieBiosystem API 
2000 triple-quadrupole spectrometer. Starting spiro(oxoindolethiazolidine) 
ethyl ester derivatives (7-12) were synthesized as described in refs 100 and 102. 
As an example, here we described the synthesis of (3RS,4'R)-ethyl 5-bromo-1-
methyl-2-oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate (12). Combustion 
microanalyses were performed on a Carlo Erba CNH 1106 analyzer, and all 
reported values are within 0.4% of calculated values. These elemental analyses 
confirmed >95% purity. 
 
Synthesis of (3RS,4'R) -Ethyl 5-Bromo-1-methyl-2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxylate. (12)  
NaHCO3 (1.0 g, 12 mmol) and 5-bromo-1-methyl isatin (6, 2.4 g, 10 mmol) were 
added to a solution of L-Cys-OEt (2.3 g, 12 mmol) in ethanol (100 mL), and the 
suspension was stirred at room temperature for 12 h. Then the suspension was 
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filtered, and the filtrate was concentrated. Spiro(oxoindolethiazolidine) ethyl 
ester residue was dissolved in DCM and washed with water (3 × 50 mL). The 
combined organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated. A 5:1diastereoisomeric mixture of the title’s compound was 
obtained as an oil with 73% yield. 
1H NMR (400 MHz, CDCl3)  1.36 (3H, m, CH3), 3.10 and 3.12 (3H, s, CH3), 
3.31 and 3.43 (1H, m, H-5'a), 3.71 and 3.93 (1H, m, H-5'b), 4.25 (4H, m, CH2), 
4.46 and 4.66 (2H, m, H-4'), 6.69 and 6.75 (1H, d, J = 8.0 Hz, H-7), 7.48 (1H, 
d, H-6), 7.60 and 7.71 (1H, s, H-4’). The compound was used in the next reaction 
without further purification. 
 
General Procedure for the Synthesis of the (2'R or 2'S,4'R) - Ethyl 3'-
Substituted-2-Oxospiro[indoline-3,2'-thiazolidine] 4'carboxylate Derivatives. 
(13a-q)  
To a solution of (2'R,4'R)- and (2'S,4'R)-ethyl 2-oxospiro[indoline-3,2'-
thiazolidine]-4'-carboxylate derivatives (7-12, 200 mg, 5 mmol) in dry THF (50 
mL) was added a solution of corresponding 4-chlorobenzoyl or 4-
methylbenzoyl or 4-chlorophenylacethyl or cyclohexanecarbonyl chlorides (5.5 
mmol) in THF (10 mL) and TEA (10 mmol). The reaction mixture was stirred 
at room temperature for 2 h, and water was then added. The organic solution 
was washed with water (3 × 100 mL), dried over Na2SO4, and evaporated in 
vacuo. Flash chromatography on silica gel, using ethyl acetate/n-hexane as 




Overall yield 43%. []25 D -7.1° (c 0.1, MeOH). 
1H NMR (400 MHz, CDCl3) 
1.40 (t, 3H, CH3); 3.44 (d, 1H, J = 12.0 Hz, H-5'a); 3.63 (s, 2H, CH2); 3.95 (dd, 
1H, J = 6.0 and 11.6 Hz, H-5'b); 4.39 (q, 2H, CH 5.08 (d, 1H, J = 6.0, H-4'); 
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6.76 (d, 1H, J = 8.4 Hz, H-7); 7.04 (t, 1H,H-6); 7.15 (d, 2H, J = 8.0 Hz, aryl); 
7.24 (t, 1H, J = 7.9 Hz, H-5); 7.28 (d, 2H, aryl); 7.43 (s, 1H, NH); 7.47 (d, 1H, 
H-4). 13C NMR (100 MHz, CDCl3) d 14.5 (CH3), 34.6 (C-5'), 41.4 (CH2), 62.5 
(CH), 64.3 (C 4'), 73.9 (C-2'), 109.3, 115.8, 123.5, 128.0, 128.9, 130.2, 134.4, 
136.2, and 143.1 (aryl), 170.1, 173.9, and 178.0 (C=O). ESIMS m/z calcd for 




Overall yield 39%. []25 D -13.6° (c 0.25, MeOH). 
1H NMR (400 MHz,CDCl3) 
δ 1.42 (t, 3H, CH3); 2.04 (s, 3H, CH3); 3.37 (d, 1H, J = 12.4 Hz, H-5’a); 3.61 (s, 
2H, CH2); 3.98 (dd, 1H, J = 6.0 and 11.6 Hz, H-5’b); 4.43 (q, 2H, CH2); 5.04 
(d, 1H, J = 6.0, H-4’); 6.70 ( d, 1H, J = 8.0 Hz, H-7); 7.08 (d, 1H, H-6); 7.19 (d, 
2H, J = 8.0 Hz, aryl); 7.31 (d, 2H, aryl); 7.40 (s, 1H, H-4); 7.79 (s, 1H, NH). 13C 
NMR (100 MHz,CDCl3) δ 14.2 (CH3), 21.7 (CH3), 34.8 (C-5’), 41.6 (CH2), 62.3 
(CH2), 64.7 (C-4’), 74.2 (C-2’), 109.8, 123.2, 128.5, 129.6, 130.7, 133.0, 137.4, 
and 142.8 (aryl), 170.6, 173.4, and 178.3 (C=O). ESIMS m/z calcd for 




Overall yield 37%. []25 D -29.1° (c 0.4, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.43 (t, 3H, CH3); 3.42 (d, 1H, J = 12.6 Hz, H-5’a); 3.65 (s, 2H, CH2); 4.01 (dd, 
1H, J = 6.0 and 12.0 Hz, H-5’b); 4.45 (q, 2H, CH2); 5.00 (d, 1H, J = 6.0, H-4’); 
6.73 ( d, 1H, J = 7.6 Hz, H-7); 7.23 (d, 2H, J = 8.0 Hz, aryl); 7.31 (d, 2H, aryl); 
7.48 (d, 1H, H-6); 7.95 (s, 1H, H-4); 8.04 (s, 1H, NH).  13C NMR (100 MHz, 
CDCl3) δ 14.3 (CH3), 21.9 (CH3), 34.6 (C-5’), 41.5 (CH2), 62.4 (CH2), 64.9 (C-
4’), 74.4 (C-2’), 109.5, 116.2, 123.4, 128.2, 129.0, 131.1, 132.5, 133.3, 137.2, 
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and 143.2 (aryl), 170.2, 173.5, and 178.9 (C=O). ESIMS m/z calcd for 




Overall yield 49%. []25 D -16.3° (c 0.1, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.36 (t, 3H, CH3); 3.40 (d, 1H, J = 11.6 Hz,  H-5’a); 3.95 (dd, 1H, J = 6.0 and 
11.6 Hz,  H-5’b); 4.38 (q, 2H, CH2); 4.87 (d, 1H, J = 6.0 Hz,  H-4’); 6.77 (d, 
1H, J = 8.0 Hz, H-7); 7.05 (t, 1H, J = 7.6 Hz, H-6);  7.20 ( t, 1H, H-5); 7.33 (d, 
2H, aryl, J = 7.6 Hz); 7.44 (d, 2H, aryl); 7.73 (d, 1H, H-4); 8.54 (s, 1H, NH).  
13C NMR (100 MHz,CDCl3) δ 14.5 (CH3), 34.5 (C-5’), 62.8 (CH2), 66.8 (C-4’), 
72.4 (C-2’), 110.7, 123.2, 125.5, 126,3, 128.4, 129.0, 130.3, 134.3, 137.1, and 
141.2 (aryl), 168.4, 170.6, and 177.1 (C=O).  ESIMS m/z calcd for 




Overall yield 58%. []25 D -5.7° (c 0.1, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.38 (t, 3H, CH3); 2.34 (s, 3H, CH3); 3.34 (d, 1H, J = 11.6 Hz,  H-5’a); 3.98 (dd, 
1H, J = 6.0 and 11.6 Hz,  H-5’b); 4.38 (q, 2H, CH2); 4.85 (d, 1H, J = 6.0 Hz, H-
4’); 6.72 (d, 1H, J = 8.0 Hz, H-7); 7.03 (d, 1H, H-6);  7.33 (d, 2H, J = 8.0 Hz, 
aryl); 7.44 (d, 2H, aryl); 7.54 (s, 1H, H-4); 8.06 (s, 1H, NH). 13C NMR (100 
MHz,CDCl3) δ: 14.5 (CH3), 21.5 (CH3), 34.5 (C-5’), 62.7 (CH2), 66.7 (C-4’), 
72.5 (C-2’), 110.2, 126.1, 128.4, 129.0, 130.8, 133.6, 136.2, and 138.4 (aryl), 
167.6, 170.1, and 176.2 (C=O).  ESIMS m/z calcd for. per C21H19ClN2O4S, 
430.08; found, 430.08. 
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Overall yield 46%. 1[]25 D -9.8° (c 0.24, MeOH). H NMR (400 MHz,CDCl3) δ 
1.40 (t, 3H, CH3); 3.35 (d, 1H, J = 12.0 Hz,  H-5’a); 3.89 (dd, 1H, J = 6.0 and 
11.8 Hz,  H-5’b); 4.42 (q, 2H, CH2); 4.84 (d, 1H, J = 6.0 Hz,  H-4’); 7.36-7.50 
(m, 5H, H-7, aryl); 7.78-7.81 (m, 2H, H-6, H-4); 8.04 (s, 1H, NH).  13C NMR 
(100 MHz,CDCl3) δ 14.5 (CH3), 35.3 (C-5’), 63.1 (CH2), 66.7 (C-4’), 72.3 (C-
2’), 116.8, 118.8, 128.4, 128.6, 128.7, 129.2, 131.2, 139.3, and 140.9 (aryl), 
168.7, 170.1, and 173.6 (C=O).  ESIMS m/z calcd for. per C20H16Br ClN2O4S, 




Overall yield 15%. []25 D -6.9° (c 0.11, MeOH).  
1H NMR (400 MHz,CDCl3) 
δ 1.24 (t, 3H, CH3); 3.61-3.62 (m, 2H, H-5’a, H-5’b); 4.25 (q, 2H, CH2); 5.43 
(t, 1H, J = 9.6 Hz,  H-4’); 7.45 (d, 2H, J = 8.4 Hz, aryl); 7.61 (d, 1H, J = 9.2 Hz, 
H-7); 7.79 (s, 1H, H-4); 8.05 (d, 2H, aryl); 8.90 (d, 1H, H-6); 9.51 (s, 1H, NH).  
13C NMR (100 MHz,CDCl3) δ 14.4 (CH3), 34.0 (C-5’), 62.4 (CH2), 66.9 (C-2’), 
78.8 (C-4’), 115.2, 122.2, 129.1, 129.6, 133.4, 134.7, 135.9, and 138.5 (aryl), 
165.4, 170.0, and 172.5 (C=O).  ESIMS m/z calcd for. per C20H16Br ClN2O4S, 




Overall yield 56%. []25 D -8.9° (c 0.2, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.36 (t, 3H, CH3); 3.29 (s, 3H, CH3); 3.38 (d, 1H, J = 11.6 Hz,  H-5’a); 3.97 (dd, 
1H, J = 6.0 and 11.6 Hz,  H-5’b); 4.38 (q, 2H, CH2); 4.85 (d, 1H, J = 5.6 Hz, H-
4’); 6.84 (d, 1H, J = 8.0 Hz, H-7); 7.10 (t, 1H, J = 8.0 Hz, H-6);  7.31-7.38 (m, 
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3H, H-5, aryl); 7.41 (d, 2H, aryl); 7.76 (d, 1H, J = 7.6 Hz,  H-4); 8.51 (s, 1H, 
NH).  13C NMR (100 MHz,CDCl3) δ 14.5 (CH3), 26.1 (CH3), 34.5 (C-5’), 62.8 
(CH2), 66.7 (C-4’), 72.5 (C-2’), 108.5, 123.4, 125.2, 128.4, 129.0, 130.4, 134.1, 
137.3, and 141.4 (aryl), 168.1, 170.7, and 177.2 (C=O). ESIMS m/z calcd for 




Overall yield 41%. []25 D -15.2° (c 0.4, MeOH).
1H NMR (400 MHz,CDCl3) δ 
1.37 (t, 3H, CH3); 2.35 (s, 3H, CH3); 3.33 (d, 1H, J = 12.0 Hz, H-5’a); 3.49 (s, 
3H, CH3); 4.00 (dd, 1H, J = 5.8 and 12.0 Hz, H-5’b); 4.38 (q, 2H, CH2); 4.85 
(d, 1H, J = 5.8 Hz, H-4’); 6.76 (d, 1H, J = 7.8 Hz, H-7); 7.12 (d, 1H, H-6);  7.33 
(d, 2H, J = 7.6 Hz, aryl); 7.41 (d, 2H, aryl); 7.56 (s, 1H, H-4). 13C NMR (100 
MHz, CDCl3) δ 14.5 (CH3), 22.9 (CH3), 29.8 (CH3), 34.5 (C-5’), 62.8 (CH2), 
66.7 (C-4’), 72.5 (C-2’), 108.5, 123.4, 125.2, 128.4, 129.0, 130.4, 134.1, 137.3, 
and 141.4 (aryl), 168.1, 170.7, and 177.2 (C=O).  ESIMS m/z calcd for 
C22H21ClN2O4S, 446.09; found, 446.11. 
 
(2’S,4'R)-ethyl-5-bromo-3'-(4-chlorobenzoyl)-1-methyl-2-oxospiro[indoline-
3,2'- thiazolidine]-4'-carboxylate. (13j) 
Overall yield 54%. []25 D -21.2° (c 0.4, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.48 (t, 3H, CH3); 3.32 (d, 1H, J = 12.4 Hz, H-5’a); 3.48 (s, 1H, CH3); 3.94-3.99 
(m, 1H, H-5’b); 4.40 (q, 2H, CH2); 4.87 (d, 1H, J = 6.2 Hz, H-4’); 7.38-7.47 ( 
m, 4H, aryl); 7.52 (d, 1H, J = 8.0 Hz, H-6); 7.79-7.83 (m, 2H, aryl).  13C NMR 
(100 MHz,CDCl3) δ 14.7 (CH3), 25.1 (CH3), 35.3 (C-5’), 63.2 (CH2), 66.7 (C-
4’), 72.8 (C-2’), 116.9, 128.7, 128.9, 129.0, 129.1, 131.4, 133.5, 137.9, 139.1 
(aryl), 168.5, 169.4, and 175.4 (C=O). ESIMS m/z calcd for C21H18BrClN2O4S, 
507.99; found, 508.04. 
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Overall yield  38%. []25 D -26.3° (c 0.4, MeOH). 
1H NMR (400 MHz,CDCl3) 
δ 1.41 (t, 3H, CH3); 3.20 (s, 3H, CH3); 3.47 (d, 1H, J = 12.0 Hz, H-5’a); 3.63 (s, 
2H, CH2); 3.94 (dd, 1H, J = 6.0 and 11.6 Hz, H-5’b); 4.38 (q, 2H, CH2); 5.06 
(d, 1H, J = 6.0, H-4’); 6.66 ( d, 1H, J = 8.4 Hz, H-7); 7.10 (d, 2H, J = 8.0 Hz, 
aryl); 7.27 (d, 2H, aryl); 7.39 (d, 1H, H-6); 7.60 (s, 1H, H-4). 13C NMR (100 
MHz,CDCl3) δ 14.5 (CH3), 27.0 (CH3), 34.1 (C-5’), 41.7 (CH2),  63.1 (CH2), 
64.5 (C-4’), 75.7 (C-2’), 110.1, 115.8, 127.8, 128.9, 129.2, 130.6, 132.9, 133.1, 
and 142.8 (aryl), 170.3, 174.3, and 177.8 (C=O). ESIMS m/z calcd for 
C22H20BrClN2O4S, 522.00; found 522.06. 
 
(2’S,4'R)-ethyl- 5-bromo-3'-benzoyl-1-methyl-2- oxospiro [indoline-3,2' 
thiazolidine]-4'-carboxylate. (13l) 
Overall yield 32%. []25 D -16.9° (c 0.5, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.45 (t, 3H, CH3); 3.29(s, 3H, CH3); 3.36 (d, 1H, J = 12.4 Hz, H-5’a); 3.96-4.01 
(m, 1H, H-5’b); 4.37 (q, 2H, CH2); 4.91 (d, 1H, J = 6.2 Hz, H-4’); 6.73 (d, 1H, 
J = 8.0 Hz, H-7); 7.38-7.51 ( m, 6H, H-6 and aryl); 7.91 (s, 1H, H-4). 13C NMR 
(100 MHz,CDCl3) δ 14.5 (CH3), 25.6 (CH3), 35.4 (C-5’), 63.1 (CH2), 66.9 (C-
4’), 73.1 (C-2’), 118.4, 127.5, 127.3, 128.2, 129.4, 133.5, 137.7, 139.2 (aryl), 





Overall yield 37%. []25 D -14.2° (c 0.3, MeOH).
1H NMR (400 MHz,CDCl3) δ 
1.40 (t, 3H, CH3); 2.35 (s, 3H, CH3);  3.28 (s, 3H, CH3);  3.32 (d, 1H, J = 11.6 
Hz, H-5’a); 3.95 (dd, 1H, J’ = 6.0 and 11.6 Hz H-5’b,); 4.39 (q, 2H, CH2); 4.91 
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(d, 1H, J = 5.6 Hz,  H-4’); 6.71 (d, 1H, J = 8.4 Hz,  H-7); 7.14 ( d, 2H, J = 7.6 
Hz, aryl); 7.34 (d, 2H, aryl); 7.45 (d, 1H, H-6); 7.91 (s, 1H, H-4). 13C NMR (100 
MHz,CDCl3) δ 14.5 (CH3), 21.6 (CH3), 27.0 (CH2), 34.8 (C-5’), 62.8 (CH2), 
66.8 (C-4’), 72.5 (C-2’), 109.9, 115.9, 126.9, 128.3, 128.4, 129.4, 133.0, 141.3, 
and 143.0 (aryl), 169.4, 170.6, and 175.2 (C=O). ESIMS m/z calcd for 




Overall yield  49%. []25 D -37.3° (c 0.8, MeOH). (A) : 
1H NMR (400 
MHz,CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.41 (t, 3H, CH3); 1.64-1.78 (m, 6H, 
CH2); 2.17 (t, 1H, CH);  3.20 (s, 3H, CH3); 3.47 (d, 1H, J = 12.0 Hz, H-5’a); 
3.97 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.41 (q, 2H, CH2); 5.13 (d, 1H, J = 
5.6 Hz, H-4’); 6.67 (d, 1H, J = 8.4 Hz, H-7); 7.39 (d, 1H, H-6); 7.57 (s, 1H, H-
4). 13C NMR (100 MHz,CDCl3) δ 14.4 (CH3), 25.8 (CH2), 26.7 (CH3), 30.2 
(CH2), 34.1 (C-5’), 44.1 (CH),  62.9 (CH2), 64.1 (C-4’), 75.7 (C-2’), 110.0, 
115.8, 127.6, 128.9, and 132.7 (aryl); 170.3, 174.3, and 177.8 (C=O);  (B) : 1H 
NMR (400 MHz,CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.41 (t, 3H, CH3); 1.64-1.78 
(m, 6H, CH2); 2.17 (t, 1H, CH);  3.26 (s, 3H, CH3); 3.34 (d, 1H, J = 12.0 Hz, H-
5’a); 3.92 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.37 (q, 2H, CH2); 5.52 (d, 
1H, J = 5.2 Hz, H-4’); 6.77 (d, 1H, J = 8.4 Hz, H-7); 7.49 (d, 1H, H-6); 7.56 (s, 
1H, H-4). 13C NMR (100 MHz,CDCl3) δ 14.4 (CH3), 25.8 (CH2), 26.9 (CH3), 
29.3 (CH2), 33.9 (C-5’), 43.8 (CH), 62.2 (CH2), 64.7 (C-4’), 75.7 (C-2’), 110.2, 
115.9, 127.9, 129.0, and 132.7 (aryl); 170.1, 174.5, and 177.6 (C=O). ESIMS 
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Overall yield 47%. []25 D -23.1° (c 0.5, MeOH). (A): 
1H NMR (400 
MHz,CDCl3) δ  1.15-1.26 (m, 4H, CH2); 1.40 (t, 3H, CH3); 1.63-1.73 (m, 6H, 
CH2); 2.17 (t, 1H, CH); 2.30 (s, 3H, CH3); 3.21 (s, 3H, CH3); 3.45 (d, 1H, J = 
12.0 Hz, H-5’a); 4.00 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.40 (q, 2H, CH2); 
5.13 (d, 1H, J = 5.6 Hz, H-4’); 6.67 (d, 1H, J = 8.0 Hz, H-7); 7.06 (d, 1H, H-6); 
7.26 (s, 1H, H-4). 13C NMR (100 MHz,CDCl3) δ 14.5 (CH3), 21.4 (CH3), 25.7 
(CH2), 26.9 (CH3), 29.2 (CH2), 33.8 (C-5’), 44.2 (CH),  62.7 (CH2), 64.2 (C-4’), 
75.7 (C-2’), 108.3, 125.0, 126.5, 130.3, 132.7 and 143.0 (aryl); 170.5, 174.2, 
and 177.8 (C=O); (B): 1H NMR (400 MHz,CDCl3) δ  1.15-1.26 (m, 4H, CH2); 
1.40 (t, 3H, CH3); 1.63-1.73 (m, 6H, CH2); 2.17 (t, 1H, CH); 2.35 (s, 3H, CH3); 
3.25 (s, 3H, CH3); 3.30 (d, 1H, J = 12.0 Hz, H-5’a); 3.94 (dd, 1H, J’ = 6.0 and 
11.6 Hz, H-5’b,); 4.36 (q, 2H, CH2); 5.52 (d, 1H, J = 6.0 Hz, H-4’); 6.78 (d, 1H, 
J = 8.0 Hz, H-7); 7.18 (d, 1H, H-6); 7.64 (s, 1H, H-4). 13C NMR (100 
MHz,CDCl3)  δ  14.5 (CH3), 21.1 (CH3), 25.4 (CH2), 25.8 (CH3), 29.6 (CH2), 
32.2 (C-5’), 43.8 (CH), 62.0 (CH2), 64.4 (C-4’), 75.8 (C-2’), 108.8, 126.4, 
131.2, 132.9 and 143.2 (aryl); 170.7, 174.4, and 177.8 (C=O). ESIMS m/z calcd 




Overall yield 45%. []25 D -20.0° (c 0.4, MeOH). (A): 
1H NMR (400 
MHz,CDCl3) δ 1.13-1.24 (m, 4H, CH2); 1.39 (t, 3H, CH3); 1.62-1.79 (m, 6H, 
CH2); 2.19 (t, 1H, CH);  3.23 (s, 3H, CH3); 3.45 (d, 1H, J = 12.0 Hz, H-5’a); 
3.99 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.38 (q, 2H, CH2); 5.13 (d, 1H, J = 
5.6 Hz, H-4’); 6.79 (d, 1H, J = 8.4 Hz, H-7); 7.02 (t, 1H, H-6); 7.27 (t, 1H, H-
5); 7.46 (d, 1H, H-4).  13C NMR (100 MHz,CDCl3) δ  14.5 (CH3), 25.7 (CH2), 
26.8 (CH3), 29.2 (CH2), 33.8 (C-5’), 44.1 (CH),  62.7 (CH2), 64.2 (C-4’), 75.9 
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(C-2’), 108.5, 123.2, 124.2, 126.1, 129.9, 131.0, and 143.5 (aryl); 170.5, 174.2, 
and 177.8 (C=O); (B): 1H NMR (400 MHz,CDCl3)  δ 1.13-1.24 (m, 4H, CH2); 
1.39 (t, 3H, CH3); 1.62-1.79 (m, 6H, CH2); 2.19 (t, 1H, CH);  3.28 (s, 3H, CH3); 
3.40 (d, 1H, J = 12.0 Hz, H-5’a); 3.95 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 
4.31 (q, 2H, CH2); 5.51 (d, 1H, J = 6.4 Hz, H-4’); 6.89 (d, 1H, J = 8.4 Hz, H-7); 
7.14 (t, 1H, H-6); 7.38 (t, 1H, H-5); 7.46 (d, 1H, H-4). 13C NMR (100 
MHz,CDCl3) δ 14.5 (CH3), 25.7 (CH2), 27.0 (CH3), 29.3 (CH2), 32.1 (C-5’), 
42.9 (CH), 62.1 (CH2), 65.3 (C-4’), 75.9 (C-2’), 109.0, 122.8, 125.1, 127.2, 
128.2, 131.0, and 143.7 (aryl); 170.6, 174.0, and 177.6 (C=O).  ESIMS m/z 




Overall yield  42%. []25 D -27.0° (c 0.5, MeOH). 
1H NMR (400 MHz,CDCl3) 
δ 1.15-1.22 (m, 4H, CH2); 1.41 (t, 3H, CH3); 1.64-1.78 (m, 6H, CH2); 1.96 (t, 
1H, CH);  3.43 (d, 1H, J = 12.0 Hz, H-5’a); 3.97 (dd, 1H, J = 6.0 and 11.6 Hz, 
H-5’b); 4.30 (q, 2H, CH2); 4.63 (d, 1H, J = 6.0 Hz, H-4’,); 7.49 (d, 1H, J = 8.4 
Hz, H-7’); 7.68 (s, 1H, H-4’); 8.10 (d, 1H, H-6’). 13C NMR (100 MHz,CDCl3) 
δ 14.4 (CH3), 25.8 (CH2), 29.3 (CH2),  39.0 (C-1), 44.9  (CH), 62.6 (CH2), 65.0 
(C-2), 75.7 (C-4), 118.8, 127.3, 128.0, 134.1, and 139.4 (aryl), 172.0, 175.9, and 
177.4 (C=O). ESIMS m/z calcd for C20H23BrN2O4S, 466.06; found, 466.12. 
 
(2’S,4'R), (2’R,4’R)-5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylic acid. (13r) 
Overall yield 37%. 1H NMR (400 MHz,CDCl3) () δ 1.14-1.38 (m, 6H, CH2); 
1.58-1.79 (m, 4H, CH2); 2.27 (t, 1H, CH);  3.19 (s, 3H, CH3); 3.54 (t, 1H, H-
5’a); 3.88-3.91 (m, 1H, H-5’b); 5.11 (d, 1H, J = 6.8 Hz, H-4’); 6.64 (d, 1H, J = 
8.0 Hz, H-7); 7.34 (d, 1H, H-6); 7.65 (s, 1H, H-4).   () δ 1.14-1.38 (m, 6H, 
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CH2); 1.58-1.79 (m, 4H, CH2); 2.27 (t, 1H, CH); 3.22 (s, 3H, CH3); 3.54 (t, 1H, 
H-5’a); 3.81-3.85 (m, 1H, H-5’b); 5.37 (d, 1H, J = 5.6 Hz, H-4’); 6.74 (d, 1H, J 
= 8.0 Hz, H-7); 7.47 (d, 1H, H-6); 8.00 (s, 1H, H-4). 13C NMR (100 
MHz,CDCl3) () δ 25.6 (CH2), 26.3 (CH2), 27.1 (CH2), 29.4 (CH2), 34.5 (C-
5’), 43.3 (CH),  64.9 (C-4’), 71.4 (C-2’), 109.9, 115.6, 127.7, 129.2, 132.5 and 
142.6 (aryl); 174.7, 175.3, and 176.9 (C=O). () δ 25.9 (CH2), 26.9 (CH2), 28.9 
(CH2), 29.9 (CH2), 32.6 (C-5’), 43.7 (CH), 58.7 (C-4’), 69.8 (C-2’), 110.4, 
116.7, 129.5, 129.9, 133.6 and 141.2 (aryl); 174.5, 175.2, and 176.7 (C=O). 
ESIMS m/z calcd for C18H19BrN2O4S, 438.02; found, 438.10. 
 
General Procedure for the Synthesis of the (2’S, 4'R)-ethyl  1-Substituted-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivatives. (14a-c)  
To a solution of indol-2,3-dione derivatives (1-3, 300 mg, 1.5 mmol) in 
dichloromethane was added 4-chlorobenzoyl chloride ( 1.8 mmol) and TEA (1.8 
mmol). The reaction mixture was stirred at room temperature for 1 h and water 
was then added.  The organic solution was washed with water (3x 100 mL), 
dried over Na2SO4, and evaporated in vacuo. Flash chromatography on silica 
gel, using ethyl acetate/n-hexane as eluent, overall yielded the correspondent 
derivatives 16-18. 1-substituted isatine 16-18 (150 mg, ~ 0,5 mmol) derivatives 
were dissolved in ethanol and cysteine ethyl ester and NaHCO3 were added (0, 
65 mmol). The mixture was stirred at room temperature for 12 h, then ethanol 
was filtrated and the surnatant was evaporated in vacuo. The crude was 
dissolved in dicholoromethane and washed with water (3 x 100 mL), the organic 
phase was dried over Na2SO4, and evaporated in vacuo. Flash chromatography 
on silica gel, using ethyl acetate/n-hexane as eluent, yielded the correspondent 
final derivatives 14a-c as solid compounds. 
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Overall yield 32%. []25 D +2.29° (c 0.5, MeOH). 
1H NMR (400 MHz,CDCl3) 
δ 1.32 (t, 3H, CH3); 3.34 (d, 2H, J = 5.6 Hz, H-5’); 4.27 (q, 2H, CH2); 5.01 (dd, 
1H, J = 5.5 and 13.0 Hz, H-4’); 7.08 (t, 1H, J = 7.6 Hz, H-6) 7.43 (d, 2H, J = 
8.4 Hz, aryl); 7.59 (t, 1H, H-5); 7.81 (d, 1H, J = 7.6 Hz, H-7);  7.87 (d, 2H, aryl); 
8.34 (d, 1H, J = 7.6 Hz, H-4). 13C NMR (100 MHz,CDCl3) δ 14.4 (CH3), 40.8 
(C-5’), 52.3 (C-4’), 62.8 (CH2), 71.8 (C-2’), 120.9, 123.0, 129.1, 129.4, 131.7, 
134.9, 137.5, 139.6, and 142.3 (aryl), 166.0, 172.1, and 190.6 (C=O). ESIMS 




Overall yield 28%. []25 D +3.21° (c 0.5, MeOH).
1H NMR (400 MHz,CDCl3) δ 
1.31 (t, 3H, CH3); 2.27 (s, 3H, CH3);  3.34 (d, 2H, J = 5.2 Hz, H-5’); 4.28 (q, 
2H, CH2); 5.02 (d, 1H, J = 6.0 Hz, H-4’); 7.36-7.44 ( m, 3H, H-7, aryl); 7.72 
(m, 3H, H-6, aryl); 8.11 (s, 1H, H-4). 13C NMR (100 MHz,CDCl3) δ 14.3 (CH3), 
21.0 (CH3), 40.7 (C-5’), 52.8 (C-4’), 62.5 (CH2), 72.3 (C-2’), 120.8, 128.8, 
128.9, 129.1, 129.3, 131.7, 132.0, 134.8, 138.4, and 140.5 (aryl), 166.2, 169.3, 




Overall yield  36%. []25 D +2.2° (c 0.4, MeOH). 
1H NMR (400 MHz,CDCl3) δ 
1.31 (t, 3H, CH3); 3.68 (d, 2H, J = 5.2 Hz, H-5’); 4.25 (q, 2H, CH2); 5.03 (dd, 
1H, J = 5.2 and 12.0 Hz, H-4’); 7.12 (d, 1H, J = 7.6 Hz, NH); 7.37-7.43 ( m, 
3H, H-7, H-6, H4); 7.72 (d, 2H, J = 8.0 Hz, aryl); 7.86 (m, 2H, aryl).  13C NMR 
(100 MHz,CDCl3) δ 14.3 (CH3), 30.9 (C-5’), 53.3 (C-4’), 62.5 (CH2), 72.3 (C-
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2’), 128.8, 128.9, 129.1, 129.3, 131.7, 132.0, 134.8, 138.4, and 140.7 (aryl), 
166.3, 170.3, and 190.2 (C=O). ESIMS m/z calcd for C20H16BrClN2O4S, 
493.97; found, 494.05. 
 
 (2’S,4’R)- ethyl 5-bromo-1-(cyclohexanecarbonyl)-2-oxospiro[indoline-3,2’-
thiazolidine]-4’-carboxylate. (14d) 
Overall yield 25%. []25 D -1.8° (c 0.1, MeOH). 
1H NMR (400 MHz,CDCl3) δ  
1.35 (t, 3H, CH3); 1.39-1.48 (m, 4H, CH2); 1.73-1.97 (m, 7H, CH2 and CH); 
3.23 (d, 1H, NH); 3.46 (dd, 1H, J’ = 5.2,  J” = 10.8 Hz, H-5’a); 3.93 (dd, 1H, 
J’ = 7.6, J” = 10.8 Hz, H-5’b,); 4.31 (q, 2H, CH2); 4.63 (t, 1H, H-4’); 7.49 (d, 
1H, J = 8.8 Hz, H-7); 7.67 (s, 1H, H-4); 8.10 (d, 1H, H-6). 13C NMR (100 
MHz,CDCl3) δ 14.4 (CH3), 25.8 (CH2), 26.0 (CH2), 29.2 (CH2),  39.1 (C-5’), 
45.0 (CH),  62.5 (CH2), 65.0 (C-4’), 75.8 (C-2’), 118.8, 127.3, 128.0, 134.1 and 
139.4 (aryl); 172.0, 175.9 and 177.4 (C=O). ESIMS m/z calcd for 




Overall yield  11%.1H NMR (400 MHz,CDCl3) δ 1.36 (t, 3H, CH3);  3.49 (s, 
3H, CH3); 4.39 (q, 2H, CH2);  4.59 (dd, 2H, J’ = 16.4 Hz, J” = 14.0 Hz, H-5); 
7.26 (s, 1H, H-4); 7.32 ( d, 1H, J = 8.0 Hz, H-7); 7.41-7.49 (m, 3H, aryl and H-
6); 7.69 (d, 2H, J = 8.0 Hz, aryl). 13C NMR (100 MHz, CDCl3) δ 29.9 (CH3), 
45.5 (C-1), 53.8 (CH3), 74.8 (C-2), 115.7, 126.3, 128.9, 130.3, 131.0, 131.6 and 
155.4 (aryl), 172.7, 176.9, and 179.3 (C=O). ESIMS m/z calcd for 
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Overall yield  8%. 1H NMR (400 MHz,CDCl3) δ  1.35 (t, 3H, CH3);  4.29-4.36 
(m, 4H, CH2 and H-5); 7.47-7.53 (m, 3H, aryl and H-7’); 7.63-7.70 (m, 3H, aryl 
and H-4’); 8.14 (d, 1H, J = 8.0 Hz, H-6’). 13C NMR (100 MHz,CDCl3) δ 14.8 
(CH3), 44.8 (C-1), 62.9 (CH2), 74.1 (C-2), 115.7, 119.3, 125.8, 127.7, 128.4, 
129.9, 133.5, 139.3 and 156.6 (aryl), 173.1, 175.9, and 178.2 (C=O). ESIMS 




Overall yield 12%. 1H NMR (400 MHz,CDCl3) δ 1.18-1.26 (m, 4H, CH2); 1.39 
(t, 3H, CH3); 1.48-1.53 (m, 2H, CH2); 1.62-1.70 (m, 4H, CH2); 1.96 (t, 1H, CH);  
4.42 (q, 2H, CH2); 4.64 (dd, 2H, J’ = 12.0 Hz, J” < 1Hz, H-5); 7.52 (d, 1H, J = 
8.0 Hz, H-7’); 7.58 (s, 1H, H-4’); 8.12 (d, 1H, H-6’). 13C NMR (100 
MHz,CDCl3) δ 14.8 (CH3), 25.6 (CH2), 30.1 (CH2),  44.4 (C-1), 45.6 (CH), 62.8 
(CH2), 74.4 (C-2), 118.2, 127.9, 128.6, 133.7, 139.5 and 156.3 (aryl), 172.6, 




Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), 
trypsin−EDTA solution (1×), penicillin and streptomycin, and phosphate 
buffered saline (PBS) were from Cambrex Biosciences. 3 (4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium iodide (PI), Triton X-
100, sodium citrate, and formamide were purchased from Sigma (Milan, Italy). 
Rabbit polyclonal anti-caspase-3, anti-MDM2, anti-Bcl-xS/L, mouse 
monoclonal anti-actin, anti-p53, anti p21, anti p27, and anti cytochrome c were 
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purchased from Santa Cruz Biotechnology (DBA; Milan, Italy). ECL reagent 
was obtained from Amersham Pharmacia Biotech, U.K. 
 
4.2.1 Cell culture  
Human prostate cancer (PC3), human histiocytic lymphoma (U937), human 
lung adenocarcinoma (Calu), human hepatoma (HepG2), human anaplastic 
thyroid carcinoma (C643), and human breast cancer (MCF-7) cell lines and 
human primary gingival fibroblasts were grown at 37 °C in Dulbecco’s modified 
Eagle medium containing 10 mM glucose (DMEMHG) supplemented with 10% 
fetal calf serum and 100 units/mL each of penicillin and streptomycin and 2 
mmol/L glutamine. In each experiment, cells were placed in fresh medium, 
cultured in the presence of synthesized compounds (from 0.1 to 25 mM), and 
followed for further analyses. 
 
4.2.2 Cell viability assay 
Cell viability was determined using the 3[4,5- dimethylthiazol-2,5-diphenyl-
2H-tetrazolium bromide (MTT) colorimetric assay. The test is based on the 
ability of mitochondrial dehydrogenase to convert, in viable cells, the yellow 
MTT reagent (Sigma Chemical Co., St. Louis, MO) into a soluble blue formazan 
dye. Cells were seeded into 96-well plates to a density of 105 cells/100 µL well. 
After 24 h of growth to allow attachment to the wells, compounds were added 
at various concentrations (from 0.1 to 25 M). After 24 or 48 h of growth and 
after removal of the culture medium, 100 µL/well medium containing 1 mg/mL 
MTT was added. Microplates were further incubated at 37 °C for 2 h in the dark. 
The solution was then gently aspirated from each well, and the formazan 
crystals within the cells were dissolved with 100 µL of DMSO. Optical densities 
were read at 550 nm using a Multiskan Spectrum Thermo Electron Corporation 
reader. Results were expressed as percentage relative to vehicle-treated control 
(0.5% DMSO was added to untreated cells). IC50 (concentration eliciting 50% 
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inhibition) values were determined by linear and polynomial regression. 
Experiments were performed in triplicate. 
 
4.2.3 In vitro inhibition of p53-MDM2 interaction assay  
We performed an in vitro binding assay using ImmunoSet p53/MDM2 complex 
ELISA set (Enzo Life Sciences). The assay was performed according to the 
manufacturer’s directions. Briefly, 96-multiwell was coated with p53 capture 
antibody and left overnight at room temperature. Then coating solution was 
removed and an amount of 200 µL of blocking buffer was added to each wells. 
The plate wasincubated for 1 h at room temperature. Blocking buffer was then 
removed, and an amount of 100 µL of p53/MDM2 standards was added to wells 
(except blank) in the presence of 5 µM indicated inhibitors. The plate was 
incubated for 1 h at room temperature on a plate shaker. Each well was washed 
4 times with 200 µL of wash buffer, and an amount of 100 µL of MDM2 
detection antibody was added to wells (except blank) for 1 h at room 
temperature. The plate was washed again, and an amount of 100 µL of SA-HRP 
conjugated antibody was added to the wells (except blank). The plate was 
incubated for 30 min at room temperature on a plate shaker. The wells were 
washed again, and an amount of 100 µL of TMB (3,3',5,5'tetramethylbenzidine) 
was added to each well for 30 min at room temperature. To stop reaction, an 
amount of 100 µL of 1 N HCl was added to the wells. After the plate reader was 
blanked against the substrate, optical density was read at 450 nm. Data were 
presented as % of inhibition referenced to control (only standards). 
 
4.2.4 Cell cycle analysis 
Cells (1 × 105) were harvested when subconfluent, fixed in 70% ethanol for 1 h 
at -20 °C, rehydrated in PBS, and the pellet was resuspended in 300 µL of PBS 
containing 250 µg/mL RNaseA and 10 µg/mL propidium iodide for 30 min in 
the dark. Samples were acquired with a CYAN flow cytometer (DAKO 
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Corporation, San Jose, CA, U.S.). The cell cycle distribution, expressed as 
percentage of cells in the G0/G1, S, and G2/M phases, was calculated using 
SUMMIT software. 
 
4.2.5 Annexin V assay 
Cells were plated at 1 × 105 in six-well plates and washed with 1× PBS and then 
with annexin V binding buffer. After centrifugation at 2000 rpm for 5 min, the 
cells were resuspended in 100 µL of annexin V binding buffer and incubated 
with 5 µLof FITC annexin V (BioLegend) and 2 µL of 500 µg/mL propidium 
iodide for 15 min at 25 °C in the dark. Finally, an amount of 400 µL of  annexin 
V binding buffer was added to each test tube. Samples were acquired with a 
CYAN flow cytometer (DAKO Corporation, San Jose, CA, U.S.) and analyzed 
using SUMMIT software. 
 
4.2.6 Western blotting and immunoprecipitation analysis 
MCF-7 cells were plated in Petri dishes (1 × 106 cells) in normal culture 
conditions and incubated with or without 4n and nutlin. At the indicated times, 
cells were lysed using an ice cold lysis buffer (50 M Tris, 150 mM NaCl, 10 
mM EDTA, 1% Triton) supplemented with a mixture of protease inhibitors 
containing antipain, bestatin, chymostatin, leupeptin, pepstatin, 
phosphoramidon, Pefabloc, EDTA, and aprotinin (Boehringer, Mannheim, 
Germany). Equivalent amounts of protein were loaded on 8-12% sodium 
dodecyl sulfate (SDS)-polyacrylamide gels and electrophoresed followed by 
blotting onto nitrocellulose membranes (Bio-Rad, Germany). After blotting 
with 5% (w/v) fat-free milk powder and 0.1% Tween 20 in TBS, the membrane 
was incubated overnight at 4°C with specific antibodies at the concentrations 
indicated by the manufacter’s protocol (Santa Cruz Biotechnology). The 
antibody was diluted in Tris-buffered saline/ Tween 20 and 5% milk powder. 
Following incubation with horseradish peroxidase conjugated secondary 
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antibodies, bands were detected by enhanced chemiluminescence (ECL kit, 
Amersham, Germany). Each filter was then probed with mouse monoclonal 
anti-actin antibody. Level of expression of detected bands was quantified by 
NIH ImageJ 1.40 after normalization with ß-actin. For immunoprecipitation, 
cells were lysed in immunoprecipitation buffer (0.05 mol/L Tris-HCl (pH 8.0), 
0.005 mol/L EDTA, 0.15 mol/L NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycolate, 0.1% SDS, 0.01 mol/L NaF, 0.005 mol/L EGTA, 0.01 mol/L 
sodium pyrophosphate, and 0.001 mol/L phenylmethylsulfonyl fluoride). 
Rabbit polyclonal antibody reactive to MDM2 (Santa Cruz Biotechnology, 
Santa Cruz, CA, U.S.) and protein G plus/protein A agarose beads (Oncogene 
Science, Boston, MA, U.S.) were used to immunoprecipitate MDM2 from 1 mg 
total lysate. Mouse monoclonal antibodies to total p53 were from Santa Cruz 
Biotechnology. 
 
4.3 Molecular Modeling methods  
The new version of the docking program AutoDock2 as implemented through 
the graphical user interface called AutoDockTools (ADT) was used to dock into 
the MDM2 structure 13n and the cocrystal ligand. The MDM2 structure was 
retrieved from the Protein Data Bank (PDB code 1LBL), and cocrystal waters 
and ligand were removed. 13n was built using the builder in the Maestro 
package of the Schroedinger Suite 2007, and optimization using a version of 
MacroModel was also included. The constructed compounds and the receptor 
structure were converted to AD4 format files using ADT, automatically 
generating all other atom values. The docking area was centered around the 
putative binding site. Grids of 60 Å × 60 Å × 60 Å with 0.375 Å spacing were 
calculated around the docking area for the ligand atom types using AutoGrid4. 
For each ligand, 100 separate docking calculations were performed. Each 
docking calculation consisted of 10 million energy evaluations using the 
Lamarckian genetic algorithm local search (GALS) method. The GALS method 
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evaluates a population of possible docking solutions and propagates the most 
successful individuals from each generation into the subsequent generation of 
possible solutions. A lowfrequency local search according to the method of 
Solis and Wets is applied to docking trials to ensure that the final solution 
represents a local minimum. All dockings described in this paper were 
performed with a population size of 250, and 300 rounds of Solis and Wets local 
search were applied with a probability of 0.06. A mutation rate of 0.02 and a 
crossover rate of 0.8 were used to generate new docking trials for subsequent 
generations, and the best individual from each generation was propagated over 
the next generation. The docking results from each of the 100 calculations were 
clustered on the basis of root-meansquare deviation (rmsd) (solutions differing 
by less than 2.0 Å) between the Cartesian coordinates of the atoms and were 
ranked on the basis of free energy of binding (ΔGAD4). Because AD4 does not 
perform any structural optimization and energy minimization of the complexes 
found, a molecular mechanics/energy minimization (MM/ EM) approach was 
applied to refine the AD4 output. The computational protocol applied consisted 
of the application of 100 000 steps of the Polak-Ribie re conjugate gradients 
(PRCG) or until the derivative convergence was 0.05 kJ/mol. The 13n/MDM2 
complex picture was rendered employing the UCSF Chimera software. 
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5.1 Background and design 
Starting from the results obtained from the previous series and from the 
molecular modeling studies, the aim of my second year of PhD was to identify 
a new lead compound starting from the structure of SM13. 
We designed and synthesized new derivatives bearing different and generally 
bulkier substituents, at the N-1 position for Series 3 and at the ester-group for 
Series 4, in order to explore the MDM2 wide pocket found to be partially 
occupied by in silico investigations. Similarly, the SM13 enantiomer was 
synthesized in order to investigate the influence of the stereochemistry on the 




Figure 27. Synthesized compounds of series 3 and 4 starting from SM13 
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5.2 Chemistry  
5.2.1 Chemistry 3rd series 
The designed (4’R) –ethyl 5-bromo-1-(substituted)-2-oxospiro [indoline-3,2’- 
thiazolidine] -4’-carboxylate derivatives (20a-c) were prepared applying the 
synthetic route shown in Scheme 4. 
 





The starting 1-substituted-5-bromo-indoline-2, 3-dione intermediates (18a-c) 
were obtained through microwave assisted reaction, between the N-1 of 5-
bromine isatin and 1-(bromomethyl)-4-chlorobenzene or 1-(2-bromoethyl)-4-
chlorobenzen for derivatives 18a and 18b, the reaction is conducted in strongly 
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basic conditions using DMF as solvent. While, for derivatives 18c, p-Cl 
phenylboronic acid was used as reactants and Cu(CH3COO)2 as catalyst. Then, 
all intermediates were transformed to the corresponding 
spirooxoindolethiazolidines (19a-c) by condensation with L-cysteine ethyl ester 
in EtOH. These derivatives were obtained with 80-90% yields, as (2’R) /(2’S) 
epimeric mixtures ranging from 60/40 to 40/60 ratios as previously described 
[Paragraph 3.2.1]. The 3’-acyl derivatives were obtained as single 
diasteroisomers, by reaction of compounds 19a-c with the corresponding 
cyclohexanecarbonyl chlorides in DCM using TEA as base. 
 
5.2.2 Chemistry 4th series 
For the synthesis of 22a-c and 23a-b an alternative synthetic strategy was 
adopted (Scheme 5). The SM13 compound, was subjected to hydrolysis of the 
ester group in alkaline conditions (21). The (2'S,4'R) -5-bromo-3'-
(cyclohexanecarbonyl)-1-methyl-2-oxo-N-substituted-spiro[indoline-3,2' 
thiazolidine]-4'carboxamide derivatives were obtained through a coupling 
reaction between the carboxyl group of the thiazolidine scaffold and several 
aliphatic and aromatic amines in DCM/DMF (9/1), using HOBt, HBTU as 
coupling agents and DIPEA as base. These derivatives were obtained with 33% 
yields, as single diastereoisomers. Differently, for compumnds 23a,b the 
carboxyl group in 4' was subjected to microwave assisted esterification , using 
p-toluenesulfonic acid as catalyst, methanol for compound 23a, and benzil alcol 
for 23b. Also these derivatives were obtained as single diastereoisomers with 
30% yields. Despite the different reaction conditions used racemization was 
always observed, as evidenced by NMR data. 
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Scheme 5. Synthesis of 22a-c and 23a-b derivatives 
 
 
The final products 25 and 26 were obtained using the same procedure adopted 
for SM13, in this case is used for, using the L-Penicillamine-OEt and the D-
Cysteine-OEt for the  the construction of the thiazolidine scaffold of (4'R)-ethyl 
5-bromo-3'-(cyclohexanecarbonyl)-1,5',5'-trimethyl-2-oxospiro [indoline-3,2' 
thiazolidine]-4'-carboxylate (25) and of (2'R,4'S)-ethyl 5-bromo-3'-
(cyclohexanecarbonyl)-1-methyl-2-oxospiro [indoline-3,2'-thiazolidine]-4' 
carboxylate (26), respectively. These derivatives were obtained with 20% and 
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Scheme 6. Synthesis of (4'R)-ethyl 5-bromo-3'-(cyclohexanecarbonyl)-1,5', 5'-
trimethyl-2-oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative (25) and 
(2'R,4'S)-ethyl 5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-oxospiro[indoline-3,2'-




5.3 Biological effects of the spirox-indole-thiazolidine synthesized  
5.3.1 Antiproliferative activity 
The synthesized compounds were examined, in the Department of Molecular 
and Cell Biology of the University of Naples “Federico II”, for their 
antiproliferative activity against two tumor cell lines: the human breast 
adenocarcinoma MCF-7 and human colon carcinoma HT-29 at 24 h. The IC50 
of the compounds was assessed both 24 and 48 hours, in order to verify if the 
mechanism of cytotoxicity was time dependent. The results are shown in Table 
3. 
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                                                aData represent mean values (+SD) of three independent determinations 
 
Despite the good results of cytotoxicity, by comparing the IC50 values than 
SM13 with all synthesized compounds, it is possible to observe a reduction of 
the biological activity. Despite the docking studies had indicated the existence 
of a large pocket on the surface of MDM2 corresponding to the binding region 
of the ester group of SM13, structural modification at this position did not lead 
to favorable biological activities. The compound 26, (designed as SM13 
enantiomer), did not show inoroved biological properties, showing that the 
configurational inversion does not represent a convenient strategy for 
interacting with MDM2. 
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6.1. Chemistry 
Reactions were carried out with magnetic stirring in round-bottomed flasks 
unless otherwise noted. Moisture-sensitive reactions were conducted in oven-
dried glassware under a positive pressure of dry nitrogen, using pre-dried, 
freshly distilled solvents. Microwave assisted reactions were performed in a 
Biotage Initiator+ reactor. All solvents and reagent were purchased by Sigma-
Aldrich. Analytical thin layer chromatography (TLC) was performed on pre-
coated glass silica gel plates 60 (F254, 0.25 mm, VWR International).  
Purifications were performed by flash column chromatography on silica gel 
(230-400 mesh, Merck Millipore). Large scale purifications were conducted on 
the flash purification system apparatus Biotage Isolera One.  NMR spectra were 
recorded on Varian Mercury-400 apparatus. 1H and 13C NMR spectra are 
reported in parts per million (ppm) referred to specific signals due to deuterated 
solvents as internal references. The following abbreviations are used to describe 
peaks: s (singlet), d (doublet), dd (double double), t (triplet), q (quadruplet) and 
m (multiplet). ESI-MS experiments were performed on an Applied Biosystem 
API 2000 triple-quadrupole spectrometer. Combustion microanalyses were 
performed on a Carlo Erba CNH 1106 analyzer, and were within 0.4% of 
calculated values. These elemental analysis results confirmed 95% purity for 
synthesized compounds. Unless otherwise specified, final products were 
converted to their chlorohydrate salts using HCl saturated diethyl ether, 
followed by filtration. 
 
General Procedure for the Synthesis of (4'R)-ethyl 5-bromo-1-(substituted)-
2-oxospiro[indoline-3,2'-thiazolidine]-4' carboxylate derivatives. (20a-c) 
To a solution of 5-Br indol-2, 3-dione derivatives (1 mmol) in DMF (15 mL) 
was added NaH (1.5 mmol), KI (1.5 mmol) and 1-(bromomethyl)-4-
chlorobenzene (1.5 mmol) or 1-(bromoethyl)-4-chlorobenzene (1.5 mmol) for 
obtained respectly 18a and 18b. While, for the 18c intermediated to a solution 
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of 5-Br of indol-2, 3-dione derivatives (1 mmol) in DMF (15 mL) was added 
Cu(CH3COO)2 (1.5 mmol), p-Cl phenylboronic acid (1.5 mmol) and  Pyridine 
(1.5 mmol). Microwave assisted reactions were performed at 160 °C for 20 
minutes. The solvent is evaporated in vacuo. The organic solution was dissolved 
in DCM and washed with water (3x 100 mL), dried over Na2SO4, and 
evaporated in vacuo. Flash chromatography on silica gel, using ethyl acetate/n-
hexane as eluent, overall yielded the correspondent derivatives 18a-c. The 
corresponding (4'R)-ethyl 5-bromo-1-(substituted)-2-oxospiro [indoline-3,2'-
thiazolidine]-4' carboxylate derivatives (20a-c) are obtained as described 
previously 101 [Paragraph 4.1.1].  
 
(4'R)-ethyl 5-bromo-1-(4-chlorobenzyl)-3'-(cyclohexanecarbonyl)-2-oxospiro 
[indoline-3,2'-thiazolidine]- 4'-carboxylate. (20a) 
yield  49%. 1H NMR (400 MHz,CDCl3) δ 1.16-1.24 (m, 4H, CH2); 1.44 (t, 3H, 
CH3); 1.62-1.77 (m, 6H, CH2); 2.21 (t, 1H, CH);  3.27 (d, 1H, J = 15.0 Hz, H-
5’a); 3.60 (d, 1H, H-5’b); 4.27 (q, 2H, CH2); 4.42 (d, 1H, J = 18.0 Hz, CH2); 
4.95 (d, 1H, CH2); 6.00 (s, 1H, H-4’); 6.33 (d, 1H, J = 9.0 Hz, Aryl); 6.61 (d, 
1H, J = 8.4 Hz, H-7); 6.79 (d, 1H, Aryl); 7.12 (d, 1H, J = 9.0 Hz, Aryl); 7.23 (d, 
1H, Aryl); 7.31 (d, 1H, H-6); 7.52 (s, 1H, H-4). ESIMS m/z calcd for 




yield  49%. 1H NMR (400 MHz,CDCl3) δ 1.16-1.23 (m, 4H, CH2); 1.46 (t, 3H, 
CH3); 1.65-1.78 (m, 6H, CH2); 2.16 (t, 1H, CH);  2.94 (t, 2H, CH2); 3.46 (d, 1H, 
, CH2 Hz, H-5’a); 3.79-3.97 (m, 3H, H-5’b and CH2); 4.40 (q, 2H, CH2); 5.11 
(d, 1H, J = 6.4 Hz, H-4’); 6.55 (d, 1H, J = 8.8 Hz, H-7); 7.22 (d, 2H, J = 9.0 Hz, 
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Aryl); 7.30 (d, 2H, Aryl); 7.33 (d, 1H, H-6); 7.57 (s, 1H, H-4). ESIMS m/z calcd 
for C28H30BrClN2O4S, 604.08; found, 604.16. 
(4'R)-ethyl 5-bromo-1-(4-chlorophenyl)-3'-(cyclohexanecarbonyl)-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate. (20c) 
yield 49%. (A) : 1H NMR (400 MHz,CDCl3) δ 1.16-1.24 (m, 4H, CH2); 1.44 (t, 
3H, CH3); 1.62-1.77 (m, 6H, CH2); 2.21 (t, 1H, CH);  3.53 (d, 1H, J = 12.0 Hz, 
H-5’a); 4.03 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.48 (q, 2H, CH2); 5.20 (d, 
1H, J = 5.6 Hz, H-4’); 6.64 (d, 1H, J = 8.4 Hz, H-7); 7.37 (d, 1H, H-6); 7.41 (d, 
2H, J = 8.0 Hz, Aryl); 7.44 (d, 2H, Aryl); 7.70 (s, 1H, H-4). (B) : 1H NMR (400 
MHz,CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.41 (t, 3H, CH3); 1.64-1.78 (m, 6H, 
CH2); 2.06 (t, 1H, CH);  3.34 (d, 1H, J = 12.0 Hz, H-5’a); 3.92 (dd, 1H, J’ = 6.0 
and 11.6 Hz, H-5’b,); 4.37 (q, 2H, CH2); 5.52 (d, 1H, J = 5.2 Hz, H-4’); 6.77 (d, 
1H, J = 8.4 Hz, H-7); 7.49 (d, 1H, H-6); 7.56 (s, 1H, H-4). ESIMS m/z calcd for 
C26H26BrClN2O4S, 576.05; found, 576.15. 
Synthesis of (2’S,4'R)-5-bromo-N-(4-chlorophenyl), N-(4-chlorobenzyl) e N-
(4-chlorophenethyl) -3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxamide derivatives. (22a-c) 
SM13101 [Paragraph 4.1.1] (1 mmol) was added to a H2O/CH3OH solution in 
9/1 ratio and 3 mmol of NaOH. The reaction is was stirring for 3 hours at room 
temperature and monitored by TLC (ethyl acetate / methanol, 9/1) 
Subsequently, the solvent is evaporated under reduced pressure and the crude 
of reaction dissolved in ethyl acetate and the organic solvent is washed with a 
bicarbonate solution (3x100mL). The acetate was dried with Na2SO4 and 
evaporated in vacuo, obtaining a quantitative yield. The intermediate 21 was 
presented as an orange oil. From 5 mmol of the derivative 21, dissolved in 
dichloromethane and DMF, (9/1) (50 mL) HOBt (6.0 mmol), DIC (6.0 mmol), 
DIPEA (12.0 mmol) and 4-Cl aniline, or 4-Cl benzylamine, or 4-Cl 
phenethylamine (6.0 mmol) were added. After 12 hours the reaction was 
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stopped; the dichloromethane was washed with water (3 x 150 mL). The organic 
solvent was then dried over anhydrous sodium sulfate and evaporated under 
vacuum. The final product were obtained by purification through column 
chromatography using silica gel as stationary phase and as eluent a suitable 
mixture of ethyl acetate / n-hexane. The product 22a-c were isolated as single 
diastereomers with a yield ranging between 32 and 44% and characterized by 




Overall yield 44%. (A) : 1H NMR (400 MHz, CDCl3) δ 1.15-1.18 (m, 4H, CH2); 
1.56-1.87 (m, 6H, CH2); 2.34 (t, 1H, CH);  3.24 (s, 3H, CH3); 3.62 (d, 1H, J = 
12.0 Hz, H-5’a); 4.18 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 5.21 (d, 1H, J = 
6.8 Hz, H-4’); 6.68 (d, 1H, J = 8.4 Hz, H-7); 7.27-7.70 (m, 6H, H-6, H-4 and 
aryl); (B) : 1H NMR (400 MHz,CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.64-1.78 (m, 
6H, CH2); 2.17 (t, 1H, CH);  3.26 (s, 3H, CH3); 3.64 (d, 1H, J = 12.0 Hz, H-
5’a); 4.24-4.27 (m, 1H, H-5’b,); 4.51-4.54 (m, 1H, CH2a); 4.74-4.76 (m, 1H, 
CH2b );  5.77 (d, 1H, J = 5.2 Hz, H-4’); 6.68 (d, 1H, J = 8.4 Hz, H-7); 7.26-7.35 





Overall yield  32%. (A). 1H NMR (400 MHz, CDCl3) δ 1.12-1.30 (m, 4H, CH2); 
1.57-1.82 (m, 6H, CH2); 2.22 (t, 1H, CH);  3.21 (s, 3H, CH3); 3.56 (d, 1H, J = 
12.0 Hz, H-5’a); 4.02 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.51 (dd, 1H, CH2a 
J’ = 6.8, J” = 14.8 Hz); 4.73 (dd, 1H, CH2b  J’ = 6.8, J” = 14.8 Hz);  5.04 (d, 
1H, J = 6.8 Hz, H-4’); 6.68 (d, 1H, J = 8.4 Hz, H-7); 6.76-6.79 (m, 2H, H-6 and 
aryl); 7.02 (s, 1H, H-4); 7.26-7.40 (m, 3H, aryl); (B): 1H NMR (400 MHz, 
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CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.64-1.78 (m, 6H, CH2); 2.17 (t, 1H, CH);  
3.25 (s, 3H, CH3); 3.64 (d, 1H, J = 12.0 Hz, H-5’a); 4.24-4.27 (m, 1H, H-5’b,); 
4.51-4.54 (m, 1H, CH2a); 4.74-4.76 (m, 1H, CH2b );  5.49 (d, 1H, J = 5.2 Hz, H-
4’); 6.68 (d, 1H, J = 8.4 Hz, H-7); 7.26-7.35 (m, 6H, H-6, H-4 and aryl).  ESIMS 
m/z calcd for C26H29BrClN3O2S, 561.09; found, 562.95. 
 
(2’S,4'R)-5-bromo-N-(4-chlorophenethyl)-3'-(cyclohexanecarbonyl)-1 
methyl -2-oxospiro [indoline-3,2'-thiazolidine]-4'-carboxamide. (22c) 
Overall yield 44%. (A) : 1H NMR (400 MHz ,CDCl3) δ 1.13-1.34 (m, 4H, CH2); 
1.56-1.84 (m, 6H, CH2); 2.11 (t, 1H, CH);  2.93-3.12 (m, 2H, CH2); 3,23 (s, 3H, 
CH3); 3.51 (d, 1H, J = 12.0 Hz, H-5’a); 3.72-3.79 (m, 2H, CH2); 4.01 (dd, 1H, 
J’ = 6.0 and 11.6 Hz, H-5’b,); 5.01 (d, 1H, J = 6.8 Hz, H-4’); 6.49 (s, 1H, NH); 
6.72 (d, 1H, J = 8.4 Hz, H-7); 7.24-7.69 (m, 5H, H-4, H-6 and aryl); 7.48 (d, 
1H, aryl); (B): 1H NMR (400 MHz, CDCl3) δ 1.13-1.19 (m, 7H, CH2 and CH3); 
1.62-1.75 (m, 6H, CH2); 2.16 (t, 1H, CH);  2.95-3.13 (m, 2H, CH2); 3.26 (s, 3H, 
CH3); 3.62 (d, 1H, J = 12.0 Hz, H-5’a); 3.74-3,77 (m, 2H, CH2); 4.23-4.25 (m, 
1H, H-5’b,); 5.49 (d, 1H, J = 5.2 Hz, H-4’); 6.67 (d, 1H, J = 8.4 Hz, H-7); 7.25-
7.59 (m, 6H, H-6, H-4 and aryl).  ESIMS m/z calcd for C27H29BrClN3O3S; 
589,08 found, 590.06. 
 
Synthesis of (2'S,4'R)-benzyl 5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative (23a) and 
(2'S,4'R)-methyl 5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate  derivative. (23b) 
The intermediate 21 (1 mmol), synthesized as described previously, was 
solubilized in a toluene and methyl alcohol solution (1/1) (for the compound 
23b) or toluene and benzyl alcohol (1/1) (for the compound 23a), (1 mmol) of 
p-toluene sulfonic acid was added. The reaction is stirring at reflux temperature 
for 16 h. Subsequently, the solvent was evaporated under reduced pressure and 
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the crude is solubilized in dichloromethane and extracted with water (3 x 100 
mL), the organic phase is dried on anhydrous sodium sulphate and evaporated 
in vacuo. The final products (23a,b) are obtained by purification through 
column chromatography using silica gel as stationary phase and as eluent a 
suitable mixture of ethyl acetate / n-hexane as single diastereoisomer. 
 
(2'S,4'R)-benzyl 5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative. (23a) 
Overall yield  38%. (A): 1H NMR (400 MHz, CDCl3) δ 1.14-1.75 (m, 10H, 
CH2); 2.19 (t, 1H, CH);  3.22 (s, 3H, CH3); 3.48 (d, 1H, J = 12.0 Hz, H-5’a); 
3.96-3.99 (m, 1H, H-5’b,); 5.15 (d, 1H, J = 8.0 Hz, H-4’); 5.37 (dd, 2H, CH2, 
J’= 8.0 Hz, J’’= 32.0 Hz); 6.66 (d, 1H, J = 8.4 Hz, H-7); 7.26-7.55 (m, 6H, H-
6 and aryl); 7.60 (s, 1H, H-4). (B): 1H NMR (400 MHz, CDCl3) δ 1.14-1.75 (m, 
10H, CH2); 2.18 (t, 1H, CH);  3.25 (s, 3H, CH3); 3.49 (d, 1H, J = 12.0 Hz, H-
5’a); 4.30 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 5.21-5.23 (d, 2H, CH2, J=8.0 
Hz); 5.58 (d, 1H, J = 5.2 Hz, H-4’); 6.79 (d, 1H, J = 8.0 Hz, H-7); 7.48 (d, 1H, 




oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative. (23b) 
Overall yield  41%. (A) : 1H NMR (400 MHz, CDCl3) δ 1.18-1.81 (m, 10H, 
CH2); 2.18 (t, 1H, CH);  3.23 (s, 3H, CH3); 3.49 (d, 1H, J = 12.0 Hz, H-5’a); 
3.98 (s, 3H, CH3); 4.02 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 5.18 (d, 1H, J = 
8.0 Hz, H-4’); 6.70 (d, 1H, J = 8.4 Hz, H-7); 7.43 (d, 1H, H-6); 7.60 (s, 1H, H-
4). (B) : 1H NMR (400 MHz,CDCl3) δ 1.14-1.80 (m, 10H, CH2); 2.16 (t, 1H, 
CH);  3.48 (s, 3H, CH3); 3.73 (d, 1H, J = 12.0 Hz, H-5’a); 3.90 (s, 3H, CH3); 
4.46 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 5.55 (d, 1H, J = 5.2 Hz, H-4’); 6.77 
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(d, 1H, J = 8.4 Hz, H-7); 7.49 (d, 1H, H-6); 7.56 (s, 1H, H-4). ESIMS m/z calcd 
for C20H23BrN2O4S, 466.06; found, 467.38. 
 
 Synthesis of (4'R)-ethyl 5-bromo-3'-(cyclohexanecarbonyl)-1,5',5'-trimethyl-
2-oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative (25) and 
(2'R,4'S)-ethyl 5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative. (26) 
NaHCO3 (1.0 g, 12 mmol) and 5-bromo-1-methyl isatin (6, 2.4 g, 10 mmol) were 
added to a solution of  L-Pen-OEt (2.3 g, 12 mmol) for compound 24a, or D-
Cys-OEt (2.3 g, 12 mmol) for compound 24b, in ethanol (100 mL), and the 
suspension was stirred at room temperature for 12 h. Then the suspension was 
filtered, and the filtrate was concentrated. Spiro(oxoindolethiazolidine) ethyl 
ester residue was dissolved in DCM and washed with water (3 × 50 mL). The 
combined organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated. A 5:1diastereoisomeric mixture of the title’s compound was 
obtained as an oil with 73% yield. The compound were used in the next reaction 
without further purification. To a solution of 24a and 24b derivatives ( 5 mmol) 
in  THF (50 mL) was added a solution of cyclohexanecarbonyl chlorides (5.5 
mmol) in THF (10 mL) and TEA (10 mmol). The reaction mixture was stirred 
at room temperature for 2 h, and water was then added. The organic solution 
was washed with water (3 × 100 mL), dried over Na2SO4, and evaporated in 
vacuo. Flash chromatography on silica gel, using ethyl acetate/n-hexane as 





oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative. (25) 
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Overall yield  37%. (A) : 1H NMR (400 MHz, CDCl3) δ 1.18-1.24 (m, 4H, CH2); 
1.40 (t, 3H, CH3); 1.60-1.71 (m, 6H, CH2); 1.77 (s, 6H, CH3);  2.15 (t, 1H, CH);  
3.24 (s, 3H, CH3); 4.41 (q, 2H, CH2); 5.03 (d, 1H, J = 4.2 Hz, H-4’); 6.74 (d, 
1H, J = 8.0 Hz, H-7); 7.35 (d, 1H, H-6); 7.59 (s, 1H, H-4). (B) : 1H NMR (400 
MHz,CDCl3) δ 1.18-1.24 (m, 4H, CH2); 1.40 (t, 3H, CH3); 1.60-1.73 (m, 6H, 
CH2); 1.80 (s, 6H, CH3); 2.21 (t, 1H, CH);  3.29 (s, 3H, CH3); 4.35 (q, 2H, CH2); 
5.12 (d, 1H, J = 5.2 Hz, H-4’); 6.69 (d, 1H, J = 8.4 Hz, H-7); 7.49 (d, 1H, H-6); 
7.55 (s, 1H, H-4). ESIMS m/z calcd for C23H29BrN2O4S, 508.10; found, 508.18. 
 
(2'R,4'S)-ethyl 5-bromo-3'-(cyclohexanecarbonyl)-1-methyl-2-
oxospiro[indoline-3,2'-thiazolidine]-4'-carboxylate derivative. (26) 
Overall yield 49%. []25 D +40.5° (c 0.8, MeOH). (A) : 
1H NMR (400 MHz, 
CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.41 (t, 3H, CH3); 1.64-1.78 (m, 6H, CH2); 
2.17 (t, 1H, CH);  3.20 (s, 3H, CH3); 3.47 (d, 1H, J = 12.0 Hz, H-5’a); 3.97 (dd, 
1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.41 (q, 2H, CH2); 5.13 (d, 1H, J = 5.6 Hz, 
H-4’); 6.67 (d, 1H, J = 8.4 Hz, H-7); 7.39 (d, 1H, H-6); 7.57 (s, 1H, H-4). (B) : 
1H NMR (400 MHz,CDCl3) δ 1.15-1.22 (m, 4H, CH2); 1.41 (t, 3H, CH3); 1.64-
1.78 (m, 6H, CH2); 2.17 (t, 1H, CH);  3.26 (s, 3H, CH3); 3.34 (d, 1H, J = 12.0 
Hz, H-5’a); 3.92 (dd, 1H, J’ = 6.0 and 11.6 Hz, H-5’b,); 4.37 (q, 2H, CH2); 5.52 
(d, 1H, J = 5.2 Hz, H-4’); 6.77 (d, 1H, J = 8.4 Hz, H-7); 7.49 (d, 1H, H-6); 7.56 
(s, 1H, H-4). ESIMS m/z calcd for C21H25BrN2O4S, 480.07; found, 480.15. 
 
6.2 Biology 
Dulbecco’s modified Eagle medium (DMEM), fetal bovine serum (FBS), 
trypsin−EDTA solution (1×), penicillin and streptomycin, and phosphate 
buffered saline (PBS) were from Cambrex Biosciences. 3 (4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT), propidium iodide (PI), Triton X-
100, sodium citrate, and formamide were purchased from Sigma (Milan, Italy). 
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6.2.1 Cell culture  
Human breast cancer (MCF-7) cell lines and human colorectal adenocarcinoma 
cell lines (HT-29) were grown at 37 °C in Dulbecco’s modified Eagle medium 
containing 10 mM glucose (DMEMHG) supplemented with 10% fetal calf 
serum and 100 units/mL each of penicillin and streptomycin and 2 mmol/L 
glutamine. In each experiment, cells were placed in fresh medium, cultured in 
the presence of synthesized compounds (from 0.1 to 25 mM), and followed for 
further analyses. 
 
6.2.2 Cell viability assay 
Cell viability was determined using the 3[4,5- dimethylthiazol-2,5-diphenyl-
2H-tetrazolium bromide (MTT) colorimetric assay. The test is based on the 
ability of mitochondrial dehydrogenase to convert, in viable cells, the yellow 
MTT reagent (Sigma Chemical Co., St. Louis, MO) into a soluble blue formazan 
dye. Cells were seeded into 96-well plates to a density of 105 cells/100 µL well. 
After 24 h of growth to allow attachment to the wells, compounds were added 
at various concentrations (from 0.1 to 25 M). After 24 or 48 h of growth and 
after removal of the culture medium, 100 µL/well medium containing 1 mg/mL 
MTT was added. Microplates were further incubated at 37 °C for 2 h in the dark. 
The solution was then gently aspirated from each well, and the formazan 
crystals within the cells were dissolved with 100 µL of DMSO. Optical densities 
were read at 550 nm using a Multiskan Spectrum Thermo Electron Corporation 
reader. Results were expressed as percentage relative to vehicle-treated control 
(0.5% DMSO was added to untreated cells). IC50 (concentration eliciting 50% 
inhibition) values were determined by linear and polynomial regression. 
Experiments were performed in triplicate. 
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7.1 Background 
Since the chemical modification on the structure of the lead compound SM13 
did not allow the identification of more potent derivatives, further investigations 
about the biochemical mechanism of action of SM13 were condicted using 
some focused biological assays. 
7.2 Effects of SM13 on KAT-4 cell proliferation in vitro  
The effectiveness of the spiro[indoline-3,2'-thiazolidine] derivate compound, 
SM13, in the regulation of apoptotic signalling in a several p53 WT tumour cells 
lines has already been demonstrated [Paragraph 3.3.1,Table 1 and Table 2]. 
Thus, in the Department of Advanced Biochemical Sciences, of the University 
of Naples, ‘Federico II’, the effect of SM13 in a p53 mutant cell line (KAT-4) 
was evaluated. It was found that SM13 reduces KAT-4 cell proliferation both 
at 24 and 48h after treatment (Figure 28A).121 
Giving the mutation of p53 gene in KAT-4 cells, which inhibits its 
transcriptional activity, we evaluated the effect of SM13 on mitochondrial-
dependent apoptotic signalling. Indeed, recent studies have shown that 
interactions of p53 with various members of the Bcl-2 family cause 
mitochondrial-mediated apoptosis in a transcription-independent manner.122 
Accordingly, our data showed that SM13 induced p53 levels, increased the 
expression of the proapoptotic protein Bax, leading to the release of 
cytochrome-c. This event leads to the activation of both Caspase 9 and Caspase 
3, thus, inducing cell death (Figure 28B).106 
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Figure 28. Effects of SM13 on tumour cell growth in vitro. (A) KAT-4 cells were treated 
with SM13 for 24 and 48 h, and cell proliferation was analyzed. (*Po0.05 vs control 
24H; **Po0.05 vs control 48H). Results are representative of five independent 
experiments and are presented as mean ± s.e.m. (B) To evaluate the mechanism of 
action of SM13, we analyzed its effect on mitochondrial-dependent apoptotic signalling 
by western blot. Images are the mean of three independent experiments 
 
Accordingly, also the levels of Cyt-c in cytosolic extracts were increased 
(Figure 29A). Morover SM13 does not modify gene expression of p53 (Figure 
29B), thus confirming that SM13 rather inhibits p53 degradation.  
 
 
Figure 29. (A) To confirm the pro-apoptotic effect of SM13 we evaluated cytochrome 
c release from mitochondria towards cytosol by western blot. In cytosolic extracts, Cyt 
c levels were increased in treated cells respect to control. Images are representative of 
3 independent experiments  (*p < 0.05 vs control). (B) To demonstrate the specificity 
of SM13 mechanism action to inhibit p53 degradation rather than regulate p53 gene 
expression, we performed a Real Time PCR to evaluate the effect of SM13 on p53 gene 
expression. Data show that there are no significant difference between control and 
treated cells. Results are the mean of 5 independent experiments  (*p < 0.05 vs control) 
 
Chapter VII: Biological bases for SM13 tumour growth inhibition 
- 106 - 
 
To confirm the apoptotic effect of SM13, we evaluated DNA fragmentation 
through a Tunel assay. Figure 30 shows that treatment with SM13 induced 
apoptotic events in tumour cells. All together, these data suggest that SM13 is 




Figure 30. TUNEL assay. Positive nuclei were counted and results were expressed in 
graph as mean ± s.d. SM13 is able to induce apoptotic events in tumour cells. Images 
are representative of three independent experiments 
 
Moreover, to confirm the p53 transcription independent effect of SM13, gene 
expression of p53 target genes, p21 and Gadd45, was assessed. In a p53 WT 
tumour cell line (MCF7) the treatment with SM13 induced p21 and Gadd45 
gene expression, whereas in p53-mutant cell type (KAT-4) such phenomenon 
was reduced. These data suggest that the effects of SM13 are strictly dependent 
on p53, and given the lack of transcriptional activity of p53 (Figure 31), they 
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Figure 31. To confirm the p53 transcription-independent effect of SM13, we evaluated 
gene expression of p53 target genes, p21 and Gadd45. In a p53 WT tumour cell line, 
MCF7, the treatment with SM13 induced p21 and Gadd45 gene expression, whereas in 
p53-mutant cell type, KAT-4, such phenomenon was reduced (*Po0.05 vs control). 
Results are the mean of five independent experiments and are presented as mean ± 
s.e.m. 
 
7.3 Effects of SM13 on FRO cell proliferation in vitro 
To assess the specificity of SM13 effectiveness in the regulation of p53-
dependent apoptosis, we evaluated its effects in FRO cells, a tumour cell line 
which does not express p53.123 Figure 32 shows that SM13 increased cleaved 
caspase 3 levels in KAT-4, but not in FRO cells; thus, suggesting that the ability 
of SM13 to induce apoptosis strictly depends on p53.106 
 
Chapter VII: Biological bases for SM13 tumour growth inhibition 
- 108 - 
 
 
Figure 32. The ability of SM13 to induce apoptosis was evaluated in FRO cells, a 
tumour cell line, which do not express p53. p53 and cleaved caspase 3 levels were 
evaluated by western blot. SM13 was not able to regulate cleaved caspase 3 levels in 
FRO cells with respect to KAT-4 cells. Results are representative of three independent 
experiments 
 
7.4 Effects of SM13 on KAT-4 cell growth in vivo  
To confirm in vitro data, we evaluated the effect of SM13 on tumour growth in 
vivo. Experiments were carried out, in 6-week-old BALB/c nude mice. For 
tumour formation, a suspension containing 2 *106 KAT-4 cells in 200 ml of 
DMEM were injected subcutaneously in the dorsal side of nude mice, as 
previously described by Sorriento’s research group.124 Mice were divided into 
four groups (5 mice per group) and administered twice a week for 2 weeks with 
intra-tumour or intraperitoneal injections (IP) of the specific treatment of SM13. 
In particular, two groups received intra-tumour injection of SM13 at low (low: 
1 mg kg–1) or high dosage (high: 3 mg kg–1); another group received IP of 5 mg 
kg-1 of the compound and; the control group received intra-tumour or IP of 
DMSO. The IP of DMSO did not modify tumour growth with respect to intra-
tumour injection.  Tumour growth was measured by caliper twice a week and 
expressed as tumour volumes in mm3. Data show that SM13 is a potent inhibitor 
of tumour growth in a dose-dependent manner. Indeed, the intra-tumour 
injection of SM13 inhibited tumour growth at low dosages and was more 
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efficient at high dosages. Also the intra-peritoneal treatment strongly delayed 
tumour growth. (Figure 33) 
 
 
Figure 33.  Effects of SM13 on tumour growth in vivo.To validate in vitro results, we 
studied the effects of SM13 in vivo in Balb/c nude mice. Tumour growth was measured 
twice a week by a caliper during all the treatment long (14 days of treatment). SM13 
retard tumour growth compared with controls. Results are the mean of measurements 
from five mice per group (*Po0.05 vs control). Figure also shows a representative 
image of tumours at the end of the treatment 
 
To confirm the mechanism by which SM13 induced apoptosis, we evaluated its 
effect on mitochondrial signalling in tumours from treated and control mice. 
According to in vitro data, intra-tumour injection of low and high doses of SM13 
significantly increased p53, Bax, Cit-C, active caspase 9 and active caspase 3 
levels in a dose-dependent manner. (Figure 34)106 
 
Chapter VII: Biological bases for SM13 tumour growth inhibition 
- 110 - 
 
 
Figure 34. Tumours were homogenized to confirm by western blot analysis the effect 
of SM13 on mitochondrial-dependent apoptotic signalling. In treated tumours, SM13 
increases protein levels of Bax and citochrome c, and activates both caspase 9 and 
caspase 3. Images are the mean of five independent experiments 
 
7.4.1 Evaluation of side effects after treatment with SM13  
Finally, we tested the safety of in vivo administration of our compound in 
healthy nude mice. There were no significant changes in body weight among 
treated and control groups of mice. No morphological differences were found 
in tissues from treated mice compared with controls (Figure 35). These data 
indicate that the treatments with SM13 had no effects on mice health at the doses 
and time of treatment that were used in this study. 
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Figure 35. We tested the safety of in vivo administration of our compounds in healthy 
nude mice. Internal organs (liver and kidney) from mice treated with intra-peritoneal 
injection (IP) of SM13 (5mg/kg) were analyzed by Masson trichrome staining. No 
morphological differences were found in treated mice compared to controls. Images 
are the mean of 5 independent experiments 
 
7.5 Discussion  
Examining in depth the biochemical properties of SM13, it has been 
demonstrated how this molecue, at low doses, is capable of inducing the 
accumulation of p53 protein, simultaneously inducing significant apoptotic cell 
death also. Moreover, SM13 proved to be a potent inhibitor of tumour growth 
in cells carrying a mutated p53 gene, being effective also at low dosages. It is 
known that p53 induces apoptotic events through the regulation of gene 
transcription in the nucleus. [Paragraph 1.6.1] Recently, it has been shown that 
p53 is also able to induce apoptosis in a transcription independent manner 
(Figure 36A) by the activation of the mitochondrial apoptotic signalling.125 
Indeed, it directly induces permeabilisation of the outer mitochondrial 
membrane by forming complexes with antiapoptotic proteins Bcl-x and Bcl-2, 
resulting in the release of cytochrome c in the cytosol. Moreover, it has been 
shown that p53 translocation to mitochondria occurs earlier after TPA 
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stimulation, leading to mitochondrial dysfunction.126 The specific signalling 
involved in this transcriptional-independent effect of p53 on apoptosis is still 
unclear. What is known is that the transcriptional blockade of p53 by -amanitin 
induces p53 mitochondrial localization and Bax accumulation, and activation in 
mitochondria. Accordingly, here we show that SM13 induces apoptosis of 
KAT-4 cells, which express a mutated p53 protein lacking the transcriptional 
activity, by targeting p53-dependent mitochondrial signalling (Figure 36B). 
Indeed, the SM13-dependent increase of p53 levels, in KAT-4 cells is associated 
with the increase of BAX, release of cytochrome c, increase of cleaved caspase 
3 levels and, finally, cell death. The confirmation that such mechanism strictly 
depends on p53, either WT or transcription activity deficient, derives from the 
finding that SM13 has no effect on FRO cells, a cell line that does not express 
p53. It could be a compensatory response in those conditions, like cancer, in 
which p53 cannot activate gene transcription, but must induce cell death to 
block a pathological increase of cell growth In conclusion, it has been evidenced 
that SM13 is an effective regulator of p53 in KAT-4 cells. It is well known  that 
the treatment of human tumours by a combination of selected drugs with 
different mechanisms of action decrease  toxicity in comparison with  
monotherapy. In this context, SM13 could be considered a good anticancer drug 
to be used in combination chemotherapy, as it is selective and does not generate 
side effects. SM13, in fact, has strong pro-apoptotic effects by regulating p53 
turnover within the cell and it could be used as a prototype small molecule for 
cancer therapy.  
In conclusion, during my PhD programme I contributed in the identification of 
SM13 as a feasible anticancer agents, which could be used alone or in 
combination with other drugs to ameliorate the response to chemotherapy in a 
wide set of tumour types characterised by elevated levels of MDM2 and low 
levels of p53.106 
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Figure 36. p53 transcription-dependent and -independent activation of apoptotic 
pathway. (A) p53 is activated in response to DNA damage and induces the apoptotic 
pathway through two alternative mechanisms, one dependent on transcriptional 
activity of p53 and one independent from transcriptional activity of p53. Indeed, 
activated p53 can move towards nucleus to activate the transcription of pro-apoptotic 
genes or movetowards mitochondria to induce the release of cytochrome c. (B) Under 
basal conditions, MDM2 binds p53, thus leading to the degradation of the protein. 
SM13 inhibits MDM2/p53 binding by competing with p53 for binding to MDM2. SM13 
therefore leads to the inhibition of MDM2dependent degradation of p53 and to the 
increase of p53 levels. p53 binds and inhibits antiapoptotic proteins (BclXL); thus, 
inducing Bax levels on mitochondrial membrane, which leads to the release of 
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8.1 Cell culture   
MCF7, which express a WT variant of p53, KAT-4, which bears a p53 variant 
mutated at codon 273 (CGT-CAT; Arg-His), BHT101, which expresses a p53 
mutant at codon 251 (ATC-ACC; Ile-Thr) and FRO cells, which do not express 
p53 at all, were cultured in Dulbecco’s minimal essential medium (DMEM) 




SM13 was dissolved in absolute DMSO. Intra-peritoneal and intra-tumour 
injections of absolute DMSO were used for the treatment of control mice. 
 
8.3 Immunoprecipitation and Western Blot 
Immunoprecipitation and western blot analysis were performed as described in 
REF 110. Anti-p53, MDM2, Bax, Citochrome c, Caspase 9 and Actin antibodies 
were from Santa Cruz Biotechnology, Inc. (Heidelberg, Germany); anti-cleaved 
caspase 3 antibody was from Cell Signalling (Danvers, MA, USA). 
 
8.4 Tunel assay 
Apoptosis was evaluated in KAT-4 cells after treatment with SM13, using the 
DeadEnd Colorimetric Tunel System from Promega (Madison, WI, USA), 
following the manufacturer’s instructions. Results are expressed as mean ± s.d. 
of apoptotic nuclei. 
 
8.5 In vivo study design 
Experiments were carried out, in accordance to NIH guidelines for Animal 
Investigation, in 6-week-old BALB/c nude mice (Charles River Italia, Calco, 
Italy), which had access to food and water ad libitum. For tumour formation, a 
suspension containing 2 106 KAT-4 cells in 200 ml of DMEM were injected 
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subcutaneously in the dorsal side of nude mice, as previously described.110 
Animals were anesthetised using isofluorane 2%. We used mice that developed 
tumours of B6 mm in diameter by 2 weeks. Mice were divided into four groups 
(5 mice per group) and administered twice a week for 2 weeks with intra-tumour 
or intraperitoneal injections (IP) of the specific treatment of SM13. In particular, 
two groups received intra-tumour injection of  SM13 at low (low: 1 mg kg–1) or 
high dosages (high: 3 mg kg–1 ); another group received IP of 5 mg kg 
compounds and; the control group received intra-tumour or IP of DMSO. The 
IP of DMSO did not modify tumour growth with respect to intra-tumour 
injection, thus in figures we include intratumour injection of DMSO as control 
for treated tumours.Tumour growth was measured by caliper twice a week and 
expressed as tumour volumes in mm3 according to the formula ‘Volume = ¼ 
(width)2 x length/2’. At the end of the treatment, mice were killed by cervical 
dislocation and tumours were processed for biochemical or histological analysis. 
The ‘Federico II’ University Ethical Committed for Animal Studies approved 
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9.1 Background and design 
In the search for structural modifications able in increasing the efficacy of SM13 
as p53 modulators, also different templates have been investigated during my 
Phd work. Considering the minimal structural requirements necessary to inhibit 
p53-MDM2 protein-protein interaction, evidenced in the previous chapters. two 
privileged scaffolds, namely thiazolidine and diketopiperazine nucleus were 
selected for the synthesis of new inhibitors. (Figure 37) 
 
 
Figure 37. Thiazolidine and diketopiperazine nucleus selected 
 
Both scaffolds, in fact, provide several derivatization groups. Moreover, the 
thiazolidine can be considered as a structural simplification of the previous 
libraries,99,100 maintaing unchanged the portion of thiazolidine and substituting 
the indole nucleus by an aryl group. This modification increase scaffold 
flexibility and, therefore, may allow an optimal orientation of the substituents 
to the binding site. Similarly, the diketopiperazine nucleus is obtainable from 
reactions between different amino acids, being a particularly suitable template 
for the spatial orientation of the substituents. Thus, the diketopiperazine 
derivatives were designed  using as aminoacidic building bloks the ones 
bringing the same substituents in the side chain of the amino acids involved in 
p53-MDM2 interaction. Hence, for my last year of PhD, I worked on the 
synthesis of two new libraries of thiazolidine and diketopiperazine based 
molecules designed as modulators of p53 activity. (Figure 38)  
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Figure 38. Synthesized compounds 
 
9.2 Chemistry  
9.2.1 Chemistry of Thiazolidine based derivatives 
The new (4R)-2-(4-chlorophenyl)-N-(substituted)-3-substituted-4-carboxamide 
derivatives (3-6) were obtained starting from the synthesis of the thiazolidine 1 
which was, subsequently, functionalized at the carboxyl using with different 
aromatic and alifatic amines as widely described previously.102 (Scheme 7). The 
isomeric mixture of intermediate 2a-c was then subjected to an acylation 
reaction of the N-3 by p-Cl benzoyl chloride in DCM with TEA used as  base. 
The derivatives (3, 4) were obtained with a yield of 30% and 60% and as a pure 
diastereoisomer. Countrarily, the compounds 5 and 6 were synthesized as N-3 
ureido  analogues of the previously described intermediates by reaction with 
triphosgene and various aliphatic amines. Also in this case the final compounds 
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Scheme 7. Synthesis of derivatives 3-6 
 
 
The (4R)-ethyl 2-(4-chlorophenyl)-3-(cyclohexanecarbonyl) thiazolidine-4-
carboxylate (8) and (4R)-ethyl 3-(4-chlorobenzoyl)-2-(4-chlorophenyl) 
thiazolidine-4-carboxylate (9) derivatives were prepared applying the synthetic 
route shown in Scheme 8. The thiazolidine ethyl ester derivative 7 was prepared 
as previously described and then derivatized at the N-3- thiazolidine by 
cyclohexanecarbonyl chloride or p-Cl benzoyl chloride in DCM and TEA as 
base leading to derivatives 8 and 9, resepctively. Final products were obtained 
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Scheme 8. Synthesis of (4R)-ethyl 2 -(4-chlorophenyl)-3-(cyclohexanecarbonyl) 
thiazolidine-4-carboxylate (8) and  (4R)-ethyl 3-(4-chlorobenzoyl)-2-(4-




9.2.2 Chemistry of diketopiperazine based derivatives 
The designed diketopiperazine derivatives (22-27) were prepared applying the 
general synthetic route shown in Scheme 9. All compounds were obtained by a 
reaction of reductive amination, between aldehydes properly selected amino 
acids. Followed by a coupling reaction with other aminoacids and 
intramolecular cyclization to the desired products. The final products 
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9.3 Biological effects 
All synthesized derivatives are current in the process of biological assays to test 
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yl)(piperazin-1-yl)methanone derivative (3) and (4-butylpiperazin-1-yl)((4R)-
3-(4-chlorobenzoyl)-2-(4-chlorophenyl)thiazolidin-4-yl)methanone 
derivatives. (4) 
2-(4-chlorophenyl) thiazolidine-4-carboxylic acid 102 (1, 1.0 g, 4.11 mmol, 1.0 
eq.)  was dissolved in 30 ml of DCM/DMF (1/1 v/v). Then, HOBT (0.72 g, 5.34 
mmol, 1.3 eq.), HBTU (2.02 g, 5.34 mmol, 1.3 eq.), DIPEA (1.86 ml, 10.7 
mmol, 2.6 eq.) and piperazine (0.65 ml, 5.34 mmol, 1.2 eq.) (2a) or 1-
butylpiperazine (0.65 ml, 5.34 mmol, 1.2 eq.) (2b) were added. The mixture was 
stirred at room temperature for 24h, then the organic phase was dried, crude 
product was dissolved in DCM, washed with water (2 x 30 mL), dried over 
Na2SO4 and concentrated. Derivative 2a,b were purified by Isolera One using a 
gradient from n-exhane to ethyl acetate/n-exane 2:1 (v:v) and obtained as a 
colourless oil in around 65% of yield. Both the intermediates (2a,b) were 
derivatized with p-Clbenzoyl chloride in conditions previously described for 
obtaining 3 and 4 derivatives. They were purified by Isolera One using a 




yl)methanone derivative. (3) 
Overall yield  67%. 1H NMR (400 MHz,CDCl3) δ 2.65 (t, 1H, CH2); 2.77-2.81 
(m, 4H, CH2) 2.99 (dd, 1H, CH2, J’=4.6, J”= 11.0 Hz); 3.40-3.44(m, 4H, CH2); 
4.87 (t, 1H, CH); 5.99 (s, 1H, CH); 7.27-7.33 (m, 6H, aryl) 7.66 (d, 2H, J= 8.2 
Hz).  ESIMS m/z calcd for C21H21N3Cl2O2S, 449.07; found 449.13.  
(4-butylpiperazin-1-yl)((4R)-3-(4-chlorobenzoyl)-2-(4-chlorophenyl) 
thiazolidin-4-yl)methanone derivatives. (4) 
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Overall yield  63%. 1H NMR (400 MHz,CDCl3) δ 0.95 (t, 3H, CH3,); 1.33-
1.39(m, 2H, CH2,); 1.50-1.61 (m, 2H, CH2); 3.11-3.17 (m, 2H, CH2); 2.55-2.68 
(m, 4H, CH2); 2.81-2.85 (m, 1H, CH); 3.30-3.39 (m, 1H, CH); 3.77-3.89 (m, 
4H, CH2); 5.19 (t, 1H, CH); 6.05 (s, 1H, CH); 7.18-7.39 (m, 6H, aryl) 7.92 (d, 
2H, J= 8.2 Hz).  ESIMS m/z calcd for C25H29N3ClO2S, 505.14; found 505.21.  
 
Synthesis of the tert-butyl 4-((4R)-2-(4-chlorophenyl)-4-((4-
chlorophenyl)carbamoyl)thiazolidine-3-carbonyl)piperazine-1-carboxylate (5 
)and (4R)-N,2-bis(4-chlorophenyl)-3-(piperazine-1-carbonyl)thiazolidine-4-
carboxamide derivatives. (6) 
2-(4-chlorophenyl) thiazolidine-4-carboxylic acid 102 (1, 1.0 g, 4.11 mmol, 1.0 
eq.)  was dissolved in 30 ml of DCM/DMF (1/1 v/v). Then, HOBT (0.72 g, 5.34 
mmol, 1.3 eq.), HBTU (2.02 g, 5.34 mmol, 1.3 eq.), DIPEA (1.86 ml, 10.7 
mmol, 2.6 eq.) p-Cl aniline (0.65 ml, 5.34 mmol, 1.2 eq.) were added. The 
mixture was stirred at room temperature for 24h, then the organic phase was 
dried, crude product was dissolved in DCM, washed with water (2 x 30 mL), 
dried over Na2SO4 and concentrated. Derivative 2c was purified by Isolera One 
using a gradient from n-exhane to ethyl acetate/n-exane 2:1 (v:v) and obtained 
as a colourless oil in 65%. Subsequently, A solution of 2c (1 mmol) in DCM 
(10 ml) was treated with triphosgene ( 0.4 eq.),TEA ( 1.2 eq.) and piperazine for 
obtained derivatives 5 and 1-butyl piperazine for derivatives 6.The reaction was 
stirred at room temperature for 10 minutes, then the organic phase was washed 
with distilled water (3x15 mL), dried over Na2SO4 and evaporated. Derivative 
5 and 6 were purified by Isolera One using a gradient from n-exhane to ethyl 
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Overall yield  62%. 1H NMR (400 MHz,CDCl3) δ 1.41(s, 9H, Boc); 3.11-3.22 
(m, 5H, CH2 and CH); 3.28-3.32 (m, 4H, CH2); 3.59 (t, 1H, CH2); 5.12(t, 1H, 
CH); 6.09 (s, 1H, CH); 7.26-7.30 (m, 4H, aryl); 7.39-7.44 (m, 4H, aryl); 9.02 
(s, 1NH).  ESIMS m/z calcd for C26H30N4Cl2O4S, 564.14; found 564.22.  
. 
(4R)-N,2-bis(4-chlorophenyl)-3-(piperazine-1-carbonyl)thiazolidine-4-
carboxamide derivatives. (6) 
Overall yield  59%. 1H NMR (400 MHz,CDCl3) δ 2.73-2.77 (m, 1H, CH2); 2.80-
2.88 (m, 5H, CH2 and CH); 3.39-3.45 (m, 4H, CH2); 4.51(t, 1H, CH); 5.48 (s, 
1H, CH); 7.22-7.29 (m, 6H, aryl) 7.54 (d, 2H, J= 8.2 Hz).  ESIMS m/z calcd for 
C21H22N4Cl2O2S, 464.08; found 464.12.  
 
Synthesis of the (4R)-ethyl 2-(4-chlorophenyl)-3-(cyclohexanecarbonyl) 
thiazolidine-4-carboxylate (8) derivative and (4R)-ethyl 3-(4-chlorobenzoyl)-
2-(4-chlorophenyl)thiazolidine-4-carboxylate derivative. (9) 
To a solution of (4R, 2S,R)-ethyl 2-(4-chlorophenyl)thiazolidine-4-carboxylate 
(7) (1 mmol) in DCM (10 ml) TEA (1.2 eq.) and cyclohexanecarbonyl chloride 
(1.2 eq) for derivatives 8 or pCl-benzoyl chloride for derivatives 9 were added. 
The reaction were stirred at room temperature for 10 minutes, then the organic 
phase was washed with distilled water (3x15 mL), dried over Na2SO4 and 
evaporated. Derivative 8 and 9 were purified by Isolera One using a gradient of 




Overall yield  66%. 1H NMR (400 MHz,CDCl3) δ 1.18-1.24 (m, 4H, CH2); 1.40 
(t, 3H, CH3); 1.66-1.79 (m, 6H, CH2); 2.15 (t, 1H, CH);  2.80 (d, 1H, CH, J = 
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12.0 Hz); 3.61 (dd, 1H, CH, J’ = 6.0 and 11.6 Hz); 4.38 (q, 2H, CH2); 5.41 (d, 
1H, CH, J = 5.6 Hz); 6.11 (s, 1H, CH); 7.28-7.35 (m, 4H, aryl); 7.42-7.50 (m, 




Overall yield 60%. 1H NMR (400 MHz, CDCl3) δ 1.38 (t, 3H, CH3); 2.85 (dd, 
1H, CH2, J’=6.2, J”= 11.4 Hz); 3.52-3.56 (m, 1H, CH), 4.93 (t, 1H, CH); 6.03 
(s, 1H, CH); 7.15-7.28 (m, 4H, aryl) 7.42-7.50 (m, 4H, aryl).  ESIMS m/z calcd 
for C19H17NCl2O3S, 409.03; found 409.12.  
 
General Procedure for the Synthesis of the diketopiperazine derivatives. (22-
27) 
Aldehyde derivatives 1 (500 l) was added to a solution of L-Trp-OMe or L-
Phe-OMe, or L-Leu-OMe (2) in dichlorometane/acetic acid in ratio 4:1 (20/5 
ml) at reflux temperature to obtaine compounds 3. After 2 hours to the solution 
were added 2,8 equivalents of sodium triacetoxyborohydride maintaining reflux 
temperature for 3 hours to obtain derivatives 4 (yeld 73%). Than the solution 
was brought to neutral pH and washed with water (3 x 20 mL). The combined 
organic layer was dried over anhydrous sodium sulfate, filtered, concentrated 
and purified with flash chromatography in 8:2 n-Exane/AcOEt. To a solution of 
Boc-Phe-COOH, or Boc-Trp-COOH, or Boc-Leu-COOH dissolved in 
DCM/DMF  in ratio 9:1 were added 1,2 eq of PyBop, 1,2 eq of HOAt and 2,4 
eq of Dipea (were added Boc-aminoacid) at room temperature over night, to 
obtain compounds 5. Than the solution was washed with neutral, acid and basic 
water (3 x 50 mL). The combined organic layer was dried over anhydrous 
sodium sulfate, filtered, concentrated and purified with flash chromatography in 
5:5 n-Exane/AcOEt (yeld: 65%). To obtain derivatives 6 was prepared a 
solution of DCM/TFA in ratio 3:1 (9:3 mL) to remove the protecting group Boc. 
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Trifluoroacetic acid was removed with diethyl ether under pression. Final 
compounds 7a-e were obtained with DCM/TEA under reflux temperature for 
30 minutes, washed with water, dried over anhydrous sodium sulfate, filtered, 
concentrated and purified with flash chromatography in 30:20 n-Exane/AcOEt 
(yield 41-50%). 
 
(36,6S)-3 -[(1H-indol-3-yl)methyl ]-6-benzyl-1-isobutylpiperazine -2,5-dione. 
(22) 
Overall yield  47%. 1H NMR (400 MHz,CDCl3) δ 0.95 (d, 3H, CH3, J= 4.0 Hz); 
1.01 (d, 3H, CH3, J= 4.0 Hz); 1.24 (t, 2H, CH2); 2.15 (m, 1H, CH); 2.68 (q, 1H, 
CH2); 3.18 (d, 1H, CH2 J=3.0 Hz); 3.53 (d, 1H, CH2 J=6.0 Hz); 4.10 (d, 1H, 
CH2 J=12.2 Hz); 4.18 (q, 1H, H-6); 4.25 (t, 1H, H-3); 6.78-7.42 (m, 10H, aryl).  
13C NMR (100 MHz, CDCl3) δ 20.6 (2CH3), 26.3 (CH); 30.9 (CH2), 37.2 (CH2), 
51.7 (CH2); 55.7 (C-6); 61.3 (C-3); 110.5, 111.7, 119.1, 120.2, 122.9, 123.8, 
126.8, 128.1, 129.3, 130.9.9, 135.5 and 136.9 (aryl); 166.4 and 166.5 (CO). 




Overall yield  41%. 1H NMR (400 MHz,CDCl3) δ 0.97 (d, 3H, CH3 J= 6.0 Hz); 
1.02 (d, 3H, CH3 J= 6.0 Hz); 2.17 (m, 1H, CH); 2.81 (m, 2H, CH2); 3.33 (dd, 
1H, CH2, J’=6.2, J’’=12.4 Hz); 3.65 (dd, 1H, CH2 J’=3.6, J’’=6.4 Hz);  3.75 (d, 
1H, CH2 J=6.2 Hz); 4.25 (q, 1H, CH2); 4.32 (t, 1H, H-3); 5.35 (d, 1H, H-6 J=18.0 
Hz); 6.11-7.79 (m, 10H, aryl).  13C NMR (100 MHz, CDCl3) δ 20.31 (1CH3); 
20.74 (1CH3); 26.3 (CH); 27.1 (CH2), 40.42 (CH2), 51.42 (CH2); 57.46 (C-3); 
61.04 (C-6); 109.07, 111.90, 119.90, 120.83, 123.04, 127.06, 129.05, 129.39, 
135.96 and 135.97 (aryl); 166.45 and 167.43 (CO). ESIMS m/z calcd for 
C24H27N3O2, 389,21; found 390.21.  
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Overall yield  45%. 1H NMR (400 MHz,CDCl3) δ 0.97 (d, 3H, CH3, J= 6.2 Hz); 
1.03 (d, 3H, CH3, J= 6.2 Hz); 2.17 (m, 1H, CH); 2.8 (m, 2H, CH2); 3.33 (dd, 1H, 
CH2, J’=6.4, J’’=12.2 Hz); 3.65 (dd, 1H, CH2, J’=3.6, J’’=6.4 Hz);  3.75 (d, 1H, 
CH2 J=6.2 Hz); 4.25 (q, 1H, CH2); 4.32 (t, 1H, H-3); 5.35 (d, 1H, H-6, J=17.8 
Hz); 6.11-7.67 (m, 10H, aryl).  13C NMR (100 MHz, CDCl3) δ 20.31 (1CH3); 
20.74 (1CH3); 26.3 (CH); 27.1 (CH2), 40.42 (CH2), 51.42 (CH2); 57.46 (C-3); 
61.04 (C-6); 109.07, 111.90, 119.90, 120.83, 123.04, 127.06, 129.05, 129.39, 
135.96 and 135.97 (aryl); 166.45 and 167.43 (CO). ESIMS m/z calcd for 




Overall yield 50%. 1H NMR (400 MHz,CDCl3) δ 0.96 (d, 3H, CH3, J= 4.4 Hz); 
0.97 (d, 3H, CH3,J= 4.2 Hz); 1.03 (m, 3H, CH ,CH2); 3.37 (dd, 1H, CH2) J’=4, 
J’’=8.2 Hz);  3.52 (dd, 1H, CH.2 J’=4.4, J’’=8.0 Hz); 3.80 (m, 1H, H-6); 3.95 (d, 
1H, CH2, J=16.0 Hz); 4.15 (t, 1H, H-3); 5.62 (d, 1H, CH2, J=16.0 Hz); 6.78 (s, 
1H, NH); 6.92 (s, 1H, H-2’);  7.03 (t, 1H, H-6’); 7.20 (t, 1H, H-5’); 7.22-7.36 
(m, 6H, H-7’ and aryl); 7.58 (d, 1H, H-4’ J=8.2 Hz).  13C NMR (100 MHz, 
CDCl3) δ 22.5 (2CH3), 24.4 (CH); 33.9 (CH2), 41.2 (CH2), 50.4 (CH2); 57.3 (C-
6); 72.2 (C-3); 109.7, 111.1, 118.8, 119.8, 121.7, 123.0, 127.0, 127.9, 128.5, 
136.4 and 136.5 (aryl); 165.0 and 165.3 (CO). ESIMS m/z calcd for 
C24H27N3O2, 389,21; found 390.21.  
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Overall yield  43%. 1H NMR (400 MHz,CDCl3) δ 0.88 (d, 3H, CH3, J= 4.0 Hz); 
0.98 (d, 3H, CH3,J= 4.2 Hz); 1.54 (m, 3H, CH ,CH2); 3.41 (dd, 1H, CH2 J’=4.6, 
J’’=8.2 Hz);  3.63 (dd, 1H, CH.2 J’=4.4, J’’=8.0 Hz); 3.95 (m, 1H, H-6); 4.02 (d, 
1H, CH2, J=16.0 Hz); 4.17 (t, 1H, H-3); 5.40 (d, 1H, CH2, J=16.4 Hz); 6.83 (s, 
1H, NH); 6.95 (s, 1H, H-2’);  7.09 (t, 1H, H-6’); 7.24 (t, 1H, H-5’); 7.28-7.39 
(m, 6H, H-7’ and aryl); 7.66 (d, 1H, H-4’ J=8 Hz).  13C NMR (100 MHz, CDCl3) 
δ 22.8 (2CH3), 24.6 (CH); 33.7 (CH2), 41.5 (CH2), 50.2 (CH2); 57.6 (C-6); 71.2 
(C-3); 109.4, 111.3, 118.5, 119.7, 121.1, 123.3, 127.2, 127.9, 128.4, 136.3 and 
136.8 (aryl); 165.5 and 165.9 (CO). ESIMS m/z calcd for C24H27N3O2, 389,21; 
found 390.21.  
(3S,6S)-1-((1H-indol-3-yl)methyl)-3-benzyl-6-isobutylpiperazine-2,5-dione 
(27). 
Overall yield 45%. 1H NMR (400 MHz,CDCl3) δ 0.98 (d, 3H, CH3, J= 6.2 Hz); 
1.06 (d, 3H, CH3, J= 6.2 Hz); 2.18 (m, 1H, CH); 2.85 (m, 2H, CH2); 3.36 (dd, 
1H, CH2, J’=6.4, J’’=12.2 Hz); 3.71 (dd, 1H, CH2, J’=3.6, J’’=6.4 Hz);  3.78 (d, 
1H, CH2 J=6.2 Hz); 4.24 (q, 1H, CH2); 4.39 (t, 1H, H-3); 5.50 (d, 1H, H-6, 
J=17.8 Hz); 6.13-7.41 (m, 10H, aryl).  13C NMR (100 MHz, CDCl3) δ 20.4 
(1CH3); 20.5 (1CH3); 26.7 (CH); 27.2 (CH2), 40.4 (CH2), 51.6 (CH2); 57.4 (C-
3); 61.0 (C-6); 109.2, 112.5, 119. 0, 120.6, 123.0, 127.1, 129.3, 129.5, 136.3 
and 136.9 (aryl); 166.5 and 168.0 (CO). ESIMS m/z calcd for C24H27N3O2, 
389,21; found 390.21.
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11.1 Introduction 
Quinones are a widely diffused group of natural products with wide-ranging 
properties that are involved in many biological processes.127 The most intensely 
investigated biological property of this class of compounds is cytotoxicity 
against tumour cells. Several quinone-based compounds, particularly those 
belonging to the anthracycline group, are widely used to treat liquid tumours 
(leukaemia and lymphomas), and, in combination with chemotherapy, they are 
also used in the treatment of solid tumours.128,129 Given the rapid onset of drug 
resistance mechanisms130,131 and such severe side-effects as myelosuppression 
and cardiotoxicity,132,133 the clinical use of quinone-based anti-cancer drugs is 
much debated. Nevertheless, scientific interest in this class of compounds has 
not abated thanks to their positive risk-benefit ratio, especially when combined 
with anti-tumour therapies, and to their recently demonstrated synergy with 
biotechnological drugs.134,135 Indeed, interest in the quinone-based scaffold and 
its derivatives, either as modulators or as pharmacological tools, has even 
increased consequent to their involvement in such metabolic pathways as 
purinergic signalling,136 inhibition of human monoamine oxidase,137 telomerase 
138 and vasorelaxation.139 
 
11.2 Background and design 
In the last part of my PhD work I focused my research work in the design and 
synthesis of dihydrithieno [2,3-b] naphto-4,9-dione analogues as anticancer 
agents. In the last years, the research group in wich I spend my PhD programme 
has deeply investigate the potential use of the dihydrithieno[2,3-b] naphto-4,9-
dione scaffold (DTNQ) and its derivatives as anti-tumour agents.140 Five 
different series of compounds have been synthesized and investigated (Figure 
39, series A-E), and their structure-activity relationship studied. The 
cytotoxicity of synthesized derivatives against several tumour cell lines was 
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comparable to that of leading reference compounds, in both wild type and 
resistant cell lines. Moreover, biological studies revealed mechanisms of action 
other than typical ROS and NO production, namely, modulation of heat shock 
protein140b and, particularly for the most planar chromophores (Figure 39, series 
E), topoisomerase-II inhibition.140a 
 
 
Figure 39. Molecular structures of the previously synthesized derivatives (A-E)  
 
DTNQ-Pro (Figure 40) resulted as the most potent derivative towards the 
different series, with an IC50 in the nanomolar range in different solid and liquid 
tumors.140d Hence, starting from this lead-compound (DTNQ-Pro) and in the 
attempt to shed further light on the structure-activity relationship of this class of 
compounds, I’ve been involved in the design and synthesis of DTNQ derivatives 
bearing modifications of the ester group at position 3. The first modification 
consisted in the reduction of the ethyl carboxylate leading to more hydrophilic 
derivatives (Figure 40, series F). Derivatization of the same carboxylic group to 
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amide was performed to obtain highly functionalized compounds (Figure 40, 
series G), designed as open analogues of the diketopiperazine series previousòy 
described (series C and D, figure 39). The main biochemical events correlated 
to the activity of these compounds was also explored using a range of cell-based 
approaches.141 
 
Figure 40. Molecular structures of the proposed analogues (F and G) 
 
11.3 Chemistry  
11.3.1. Chemistry of series F  
The first series of compounds was prepared starting from DTNQ, according to 
the pathway depicted in Scheme 10.141 Acylation of the starting compound with 
a slight excess of 4-chlorobenzoyl chloride or 2-chloroacetyl chloride led to the 
corresponding 4chlorobenzamido (2) and (2’-chloro) acetamide (4) 
intermediates with 65% and 95% yields, respectively. Reduction of the ester 
group at position 3 of derivatives 2 and 4 was achieved with sodium borohydride 
(3 eq.) in methanol. Fast and almost quantitative conversion to hydroxymethyl 
derivatives 3 and 5 was obtained after minimal work-up of crude products. 
Finally, nucleophilic displacement of the chlorine atom of 5 using the 
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appropriate aromatic or aliphatic amines in dichloromethane and triethylamine 
at reflux readily provided the corresponding acetamide analogues (6-8, 52-57% 
yield). 
 





11.3.2 Chemistry of series G  
The products of series G were synthesized by replacing the 3- ester group with 
an amide group followed by functionalization of the 3-amino group of the 
DTNQ system.141 Initially, direct amidation using the Curtius rearrangement 
upon derivatization of the ester to acylazide and sodium methoxide catalyzed 
transamidation142 was unsuccessful. On the other hand, hydrolysis of the ester 
prior to amidation was not feasible due to rapid decarboxylation in both acidic 
and alkaline media, as previously described.143 Consequently, we used a 
different synthetic route given the feasibility of a solid phase catalysed double 
Michael addition to quinone systems, previously reported.144 Our synthetic 
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strategy implies the condensation of naphthoquinone with an appropriately 4 
modified thiazolidine derivative. As shown in Scheme 11, the starting 
thiazolidine derivative 10 was obtained by reaction of 2-phenyl-1,3-
thiazolidine-4-carboxylic acid with 4-chlorobenzylamine using HOBt/HBTU as 
coupling agent in a dichloromethane/dimethylformamide mixture with 57% 
yield. Condensation of compound 10 with naphthoquinone, in MeOH, over 
Al2O3, gave, after acid hydrolysis of Schiff base intermediate (10a), the 3-(N-
4-chlorophenyl)-carboxamide DTNQ derivative 11 in a 44% yield. Acylation of 
the 3-amino group of 11 with the same reagents and under the conditions 
described above for the N-acylated DTNQ derivatives, yielded the 3-(4-
chlorobenzamido)-3-N-(4chlorophenyl) carboxamide derivative 12 as final 
product and the 3-(2-chloro) acetamide intermediate 13 with yields of 64 and 
78%, respectively. Reacting compound 13 with piperidine under the conditions 
previously described led to the final compound 14 (yield 53%). 
 
Scheme 11. Synthesis of N-3-disubstituted 4,9-dioxo-2,3,4,9-tetrahydronaphtho[2,3-
b]thiophene-3-carboxamide derivatives (12 and 14). 
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11.4 Biological effects  
11.4.1 In vitro cytotoxicity 
The synthesized compounds were examined, in the Department of Molecular 
and Cell Biology of the Second University of Naples “Sun”, for their 
antiproliferative activity against the HuH7 (human hepatocarcinoma), MCF7 
(human breast adenocarcinoma), LN229 (glioblastoma) andBxPC3 (human 
pancreas adenocarcinoma) cell lines, some of which are characterized by a 
reduced response to doxorubicin.145 Cell viability was assessed 48 h after 
treatment with the tested compounds using the MTT assay. The IC50 values are 
summarized in Table 4. For comparative purposes, doxorubicin was included in 
the assay. Doxorubicin exerted marked cytotoxicity against the breast cancer 
cell line; it was less effective against the glioblastoma, liver and pancreatic cell 
lines. DTNQ analogues 6 and 7, which belong to the F series, retained 
micromolar activity against all tested cell lines, whereas derivative 8 was the 
most potent analogue; indeed, its cytotoxic effect was 4.4-fold higher versus 
doxorubicin in LN229 cells.126 
 
Table 4. Cytotoxic activity of DTNQ derivatives on selected tumour cell lines. Values 
were calculated 48 h after compound administration and are expressed as mean ± SEM 
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The most interesting results were obtained with derivatives 12 and 14, which 
belong to the G series and were designed as open analogues of previously 
synthesized spirodiketopiperazine derivatives. The cytotoxicity of these 
compounds was higher than that of doxorubicin in all tested cells, except breast 
cancer cells. 
 
11.4.2 Cardiotoxicity  
It is well known that the clinical use of anthracyclines, especially doxorubicin, 
in the treatment of many neoplastic diseases is limited by cumulative 
cardiotoxicity.116,117 This effect has been attributed to the redox process 
involving the quinone system that results in the formation of reactive oxygen 
species and ultimately in myocyte death. Thus, we evaluated the cardiotoxicity 
of the most potent synthesized compounds by means of proliferation and lipid 
peroxidation (TBARS) assays in cardiac-derived H9C2 myocytes. The H9C2 
cells were treated for 48 h with 2.5 M of compounds 8, 12, 14, and 
doxorubicin. This concentration was selected because it was the highest IC50 
value found in MTT assays of LN299 cells. As shown in Figure 41A, treatment 
with compound 14 did not affect H9C2 proliferation, whereas cardiomyocyte 
proliferation was significantly lower in cells treated with compounds 8, 12 and 
doxorubicin (83, 61, and 53%, respectively) than in untreated cells. 
Concomitantly, lipid peroxidation was significantly higher after administration 
of these compounds, as evidenced by the values of the lipid peroxidation marker 
TBARS (Figure 41B). Compound 14 did not affect TBARS values in treated 
cells, which explains at least one of the reasons for its lack of toxicity in the cell 
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Figure 41.  Effects of the treatment of H9C2 cells with 2,5 M of compounds 8, 12, 14, 
and doxorubicin for 48 h on cell growth and lipid peroxidation. Proliferation is 
expressed as percentage with respect to the untreated cells (control). Cell growth was 
evaluated by the MTT assay as described in the Experimental section. In the panel B is 
reported the TBARS value in treated and untreated (control) H9C2 cells. The bars 
represent means ± SEM of three independent experiments. * p < 0.05, **p < 0.01 
values significantly different from doxorubicin # p < 0.05, ## p < 0.01 values 
significantly different from control 
 
11.4.3 Biological effects of compound 14 on LN299 cells 
The preliminary results regarding the cytotoxicity and cardiotoxicity after 
treatment with compound 14 prompted us to study the mechanism of action of 
this compound on the LN299 glioblastoma cell line. To this aim, we first verified 
the effect of the stereochemistry of the chiral centre at C-3 on the activity of 14. 
The two enantiomerically pure compounds, 14(+R) and 14(-S) were prepared 
as reported elsewhere 125c-g by the method of Evans (Scheme 12).  
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Scheme 12. Resolution of enantiomers by Evans’ method 
 
 
Treatment of LN299 cells with 0.6 M of 14, 14(+) and 14(-) induced a 
cytotoxic effect resulting in 50, 48, 50% cell death, respectively.126 These data 
suggest that the stereochemistry of C-3 in these derivatives does not influence 
the cytotoxic activity, as previously observed for other DTNQ analogues.125c-g 
In the attempt to explain the differences observed in the behaviour of compound 
14 and doxorubicin against glioblastoma cells [Table 4], we verified the site of 
action of both compounds. Accordingly, the intracellular localization of the 
molecules was investigated by confocal microscopy of LN229 cells treated with 
0.6 M of compound 14 and doxorubicin (Figure 42). Compound 14 clearly 
induced cell differentiation by vimentin remodelling and was prevalently 
located in the cytoplasm.146 Doxorubicin was mainly located in the nucleus of 
the survived undifferentiated cells, which suggests its mechanism of action 
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Figure 42.  Subcellular localization of compound 14 and doxorubicin in LN229 cells. 
LN229 cells were cultured as described in Methods, and treated for 48 h with and 
without 0.6 M of compound 14 and doxorubicin (red) and visualized by confocal 
microscopy. The cells were fixed in paraformaldehyde and vimentin and nuclei were 
stained with anti-vimentin antibody (green) and DAPI (blue), respectively. The 
merged images show the localization of the tested compound (red), vimentin filaments 
(green) and nuclei (blue) 
 
Human glioblastoma tissues display metabolic abnormality as reflected by 
increased uptake of glucose compared with normal brain tissue.147 Consistent 
with the importance of glucose for tumour growth, many studies have shown 
that tumour suppressors and oncogenes influence the metabolism of this 
nutrient. The phosphatidylinositol 3-kinase/AKT pathway, which is activated in 
a large fraction of human tumours, positively regulates glucose uptake and 
glycolysis.148 Therefore, we analysed the effects of compound 14 on glucose 
uptake and serine/threonine kinase AKT expression. Incubation of LN299 cells 
with 0.6 M of compound 14 for 48 h (Table 5) induced a strong increase of 
glucose content in the medium of LN229 cells (about 2.2-fold versus untreated 
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cells). This effect was negligible after treatment with the same concentration of 
doxorubicin.  
 
Table 5. Glucose concentration in the medium of LN299 cells after incubation for 48 
h with 0.6 M of compound 14 and doxorubicin. Values are expressed as glucose 
concentration per mg of protein ± SEM. 
 
 
Moreover, as shown in the western blot of Figure 43, AKT expression was 2-
fold lower in treated than in untreated LN299 cells. Concomitantly, a decrease 
in the expression of full length caspase 9 was observed.149 
 
Figure 43. Western blot analysis of cytoplasmatic AKT and inactive caspase-9 levels 
in LN229 cells untreated (ctr) and treated with 0.6 M of compound 14 for 48 h 
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 A decrease of glucose concentration and AKT expression in LN299 cells could 
switch energy metabolism towards fatty acid degradation and thus increase 
membrane lipid peroxidation.150 To determine if one of the cytotoxic effects of 
compound 14 was to induce apoptosis by lipid peroxidation we evaluated 
TBARS production and caspase 3 activity in these cells (Figure 43). After 48 h 
treatment with 0.6 M 14, there was a dramatic increase (five-fold) in membrane 
lipid peroxidation evaluated by TBARS assay (Figure 44A). Moreover, caspase-
3 activity was three fold higher in treated cells (Figure 44B), which indicates 
that cell death was induced via an apoptotic pathway.151 
 
 
Figure 44. (A) TBARS levels in LN299 cells after 48 h of incubation with 0.6 M 14. 
(B) LN229 cells were treated with 0.6 M for 48 h and then evaluated for cell-free 
caspase3 activity as described in the Experimental protocols. Data are expressed as 
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12.1. Chemistry 
Reactions were carried out with magnetic stirring in round-bottomed flasks 
unless otherwise noted. Moisture-sensitive reactions were conducted in oven-
dried glassware under a positive pressure of dry nitrogen, using pre-dried, 
freshly distilled solvents. Microwave assisted reactions were performed in a 
Biotage Initiator+ reactor. All solvents and reagent were purchased by Sigma-
Aldrich. Analytical thin layer chromatography (TLC) was performed on pre-
coated glass silica gel plates 60 (F254, 0.25 mm, VWR International).  
Purifications were performed by flash column chromatography on silica gel 
(230-400 mesh, Merck Millipore). Large scale purifications were conducted on 
the flash purification system apparatus Biotage Isolera One.  NMR spectra were 
recorded on Varian Mercury-400 apparatus. 1H and 13C NMR spectra are 
reported in parts per million (ppm) referred to specific signals due to deuterated 
solvents as internal references. The following abbreviations are used to describe 
peaks: s (singlet), d (doublet), dd (double double), t (triplet), q (quadruplet) and 
m (multiplet). ESI-MS experiments were performed on an Applied Biosystem 
API 2000 triple-quadrupole spectrometer. Combustion microanalyses were 
performed on a Carlo Erba CNH 1106 analyzer, and were within 0.4% of 
calculated values. These elemental analysis results confirmed 95% purity for 
synthesized compounds. Unless otherwise specified, final products were 
converted to their chlorohydrate salts using HCl saturated diethyl ether, 




4-chlorobenzoyl chloride (0.073 ml, 0.57 mmol, 1.2 eq.) and triethylamine (0.08 
ml, 0.57 mmol, 1.2 eq.) were added to a solution of DTNQ (0.48 mmol, 0.14 g, 
1.0 eq.) in 10 ml of dichloromethane and the mixture was stirred at room 
temperature during 30 minutes. The solution was treated with distilled water (3 
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x 20 mL), and the organic phase was extracted, dried over Na2SO4 and 
evaporated in vacuo. Crude product was purified by flash chromatography using 
diethyl ether: n-exane 3:2 (v:v) as eluent. Intermediate 6 was isolated as a 
yellowish solid with 65% yield. 1H NMR (400 MHz, CDCl3) δ   1.23 (t, 3H, 
CH3); 3.84 (d, 1H, J = 12.8 Hz, H-2’); 3.97 (d, 1H, H-2”); 4.35 (q, 2H, CH2); 
7.44 (d, 2H, J = 8.6 Hz, aryl); 7.72-7.77 (m, 2H, H-6 and H-7); 7.80 (d, 2H,); 
8.04 (s, 1H, NH); 8.06-8.11 (m, 2H, H-8 and H-5). ESI-MS m/z calcd for 




Intermediate 2 (0.1 g, 0.23 mmol) was dissolved in methanol (10 mL), and the 
resulting solution was cooled to 0°C in an ice bath. After addition of NaBH4 
(26.1 mg, 0.69 mmol, 3 eq.) the reaction was allowed to warm at room 
temperature and was stirred for 3h. After quenching with citric acid (10% w/w), 
resulting solution was concentrated in vacuo and extracted in DCM (2x15 ml). 
The organic solvent was dried over Na2SO4, evaporated and the crude product 
purified by flash chromatography using diethyl ether: n-exane 3:1 (v:v) as 
eluent. The final compound 7 was obtained as yellow solid (yield 87%). 1H 
NMR (400 MHz, CDCl3) δ   3.71 (d, 1H, J = 14.2 Hz, CH2’); 3.80 (d, 1H, CH2′′); 
3.92 (d, 1H, J = 12.8 Hz, H-2’); 4.14 (d, 1H, H-2”); 7.09 (d, 2H,  J = 8.8 Hz, 
aryl); 7.42 (d, 2H, aryl); 7.73-7.77 (m, 2 H, aryl); 7.95-7.99 (m, 2H, H-6 and H-
7); 8.05-8.10 (m, 3H, H-8, H-5, NH). 13C NMR (100 MHz, CDCl3) δ 39.2 (C-
2); 66.5 (CH2OH); 72.9 (C-3); 126.9; 127.2; 127.4; 128.9; 129.2; 129.5; 132.3; 
133.4; 133.8; 134.8; 137.2; 138.6. (aryl); 159.6, 166.6, 180.6, (C=O).  (C=O).  
(C=O).  ESI-MS m/z calcd for C20H14ClNO4S  399.03, found 399.11.  
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A solution of DTNQ (0.1 g, 0.33 mmol) in DCM (10 ml) was treated with 
chloroacetyl chloride (0.031 ml, 0.40 mmol, 1.2 eq.) and TEA (0.56 ml, 0.40 
mmol, 1.2 eq.). The reaction was stirred at room temperature for 30 minutes, 
then the organic phase was washed with distilled water (15 mL), saturated 
NaHCO3 (15 ml) and HCl 2N (15 ml), dried over Na2SO4 and evaporated. Crude 
product was characterized by high purity, as evidenced by NMR spectra, hence 
was used in the following step without further purification. Spectral data were 




Reduction of the ester 4 to its hydroxymethyl derivative was achieved as 
previously described for the synthesis of compound 3. Product was obtained as 
a yellowish solid in 78% yield. 1H NMR (400 MHz, CDCl3) δ   3.61-3.70 (m, 
2H, CH2); 3.91 (d, 1H, J = 11.6 Hz, H-2’); 4.08 (s, 2H, CH2); 4.12 (d, 1H, H-
2”); 7.63-7.72 (m, 2H, H-6 and H-7); 8.07-8.18 (m, 3H, H-8, H-5 and NH). ESI-
MS m/z calcd for C15H12ClNO4S 337.02, found 337.08. 
 
General procedure for the synthesis of compounds 6-8 
Intermediate 5 (0.12 g, 0.35 mmol, 1.0 eq.) was dissolved in 12 ml of DCM 
together with TEA (0.059 ml, 0.42 mmol, 1.2 eq.) and catalytic amount of NaI. 
Then, 1.2 equivalents of 4-chloroaniline, 4-chlorobenzylamine or piperidine 
were added to the solution, refluxing at 80°C for 4h. Hence, the organic solvent 
was washed with HCl 2N (10  ml) and brine (2 x 15 mL), dried over Na2SO4 
and concentrated. Compounds 6-8 were isolated by flash chromatography using 
DCM:MeOH 9:1 (v:v) as eluent.   
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Orange solid (53% yield) 1H NMR (400 MHz, CD3OD) δ   3.60-3.65 (m, 2H, 
CH2); 3.72 (s, 2H, CH2); 3.82 (d, 1H, J = 12.8 Hz, H-2′); 3.89 (d, 1H, H-2′′); 
6.61 (d, 2H, J = 8.8 Hz, aryl); 7.09 (d, 2H, aryl); 7.68-7.83 (m, 2H, H-6 and H-
7); 8.02 (d, 2H, J = 7.2 Hz; H-8 and H-5). 13C NMR (100 MHz, CD3OD) δ  37.1 
(C-2); 49.5 (CH2);  62.7 (CH2); 72.3 (C-3); 118.5; 125.9; 126.3; 130.1; 132.2; 
138.9; 139.7; 140.0, 142.5 (aryl); 161.3, 175.1 (C=O).  ESI-MS m/z calcd for 




Yellowish solid (57% yield). 1H NMR (400 MHz, CD3OD) δ 3.35 s, 2H, CH2); 
3.62-3.69 (m, 2H, CH2 ); 3.84 (d, 1H, J = 10.8 Hz,  H-2’); 3.99 (m, 3H H-2”, 
CH2); 6.97 (d, 2H, J= 7.5, aryl)  7.24 (d, 2H, aryl); 7.65-7.80 (m, 2H, H-6 and 
H-7); 7.98-8.06 (m, 2H, H-8 and H-5). 13C NMR (100 MHz, CD3OD) δ  38.4 
(C-2); 48.4 (CH2); 49.9 (CH2); 62.8 (CH2); 72.6 (C-3); 125.7; 126.2; 129.3; 
131.8; 133.5; 134.7; 136.0; 138.8; 139.5 (aryl); 161.1, 175.8, 180.3 (C=O).  ESI-




Yellow solid (52% yield).1H NMR (400 MHz, CDCl3) δ  1.43-1.47 (m, 2H, 
piperidine); 1.60-1.65 (m, 4H, piperidine); 2.42-2.49 (m, 4H, piperidine); 2.88-
3.00 (m, 2H, CH2OH); 3.66 (s, 2H, CH2); 3.86 (d, 1H, J = 11.2 Hz, H-2′); 4.13 
(d, 1H, H-2′′); 7.69-7.84 (m, 2 H, H-6 and H-7); 8.06-8.09 (m, 2H, H-8 and H-
5); 8.64 (s, 1H, NH). 13C NMR (100 MHz, CDCl3) δ 23.9 (CH2); 26.3 (CH2); 
39.2 (C-2); 55.1 (CH2); 62.6 (CH2); 66.7 (CH2); 72.6 (C-3); 126.8; 127.1; 132.3; 
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133.5; 133.6; 134.7; 137.9 (aryl); 159.2, 171.9, 181.0 (C=O).  ESI-MS m/z calcd 
for C20H22N2O4S 386.13, found 386.19. 
 
(2R,4R) and (2S,4R) -N-(4-chlorobenzyl)-2-(4-chlorophenyl)thiazolidine-4-
carboxamide. (10) 
2-(4-chlorophenyl) thiazolidine-4-carboxylic acid (9, 1.0 g, 4.11 mmol, 1.0 eq.)  
was dissolved in 30 ml of DCM/DMF (1/1 v/v). Then, HOBT (0.72 g, 5.34 
mmol, 1.3 eq.), HBTU (2.02 g, 5.34 mmol, 1.3 eq.), DIPEA (1.86 ml, 10.7 
mmol, 2.6 eq.) and 4-chlorobenzylamine (0.65 ml, 5.34 mmol, 1.2 eq.) were 
added. The mixture was stirred at room temperature for 24h, then the organic 
phase was dried, crude product was dissolved in DCM, washed with water (2 x 
30 mL), dried over Na2SO4 and concentrated. Derivative 10 was purified by 
Isolera One using a gradient from n-exhane to ethyl acetate/n-exane 2:1 (v:v) 
and obtained as a colourless oil in 57% yield. 1H NMR (400 MHz, CDCl3) δ  
3.09-3.14 (dd, 1H, J = 6.0 and 3.0 Hz, H-5b) 3.24-3.30 (m, 2H, H-5b and H-6a); 
3.33-3.41 (dd, 1H, J = 6.0  = 3.0 Hz, H-5a); 3.89 (t, 1H, H-4b);  4.26-4.30 (dd, 
1H, J’ = 6.0 and  3.0 Hz, H-4a); 4.32-4.35 (m, 2H, CH2); 5.45 (s, 1H, H-2a); 5.49 
(s, 1H, H-2b); 7.18-7.29 (m, 6H, Aryl); 7.41-7.47 (t, 2H, Aryl). ESI-MS m/z 




Compound 11 was synthesized using the synthetic procedure elsewhere 
described starting from 0.5 g of 10 (1.37 mmol). Purification was achieved in 
purification system apparatus Biotage Isolera One using a gradient elution from 
n-exane to diethyl ether/n-exane 2/1. The desired compound was obtained in 
44% yield as an orange solid. 1H NMR (400 MHz, CDCl3) δ 3.17 (d, 1H, J = 
12.0 Hz, H-2′); 3.95 (d, 1H, H-2′′); 4.41-4.48 (dd, 1H, J = 5.8 and  14.6 Hz, 
CH2); 4.64-4.71 (dd, 1H, CH2’’);  7.38-7.42 (m, 4H, aryl); 7.70-7.79 (m, 2H, H-
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6 and H-7); 7.90 (s, 1H, NH); 8.07-8.13 (m, 2H, H-8 and H-5). ESI-MS m/z 




Derivative 12 was obtained from 11 using the same protocol previously 
described for 2. Final product was isolated as a yellowish solid by flash 
chromatography using diethyl ether:n-exane 1:1. Yield 64%. 1H NMR (400 
MHz, CDCl3) δ 3.91 (d, 1H, J = 12.4 Hz, H-2′); 4.21 (d, 1H, H-2′′); 4.38-4.42 
(dd, 1H, J = 5.6 and 15.2 Hz, CH2’); 4.48-4.52 (dd, 1H, CH2’’); 6.87 (s, 1H, 
NH); 7.11 (d, 2H, J = 7.6 Hz, aryl); 7.22 (d, 2H, aryl); 7.43 (d, 2H; J = 7.6 Hz, 
aryl); 7.69-7.76 (m, 4 H, H-6, H-7, and aryl); 8.00-8.05 (m, 2H, H-8 and H-5); 
8.37 (s, 1H, NH). 13C NMR (100 MHz, CDCl3) δ 42.9 (C-2); 44.5 (CH2); 82.7 
(C-3); 125.9; 128.2; 128.5; 131.8; 132.1; 134.0; 134.3; 134.4; 136.2; 159.9 
(aryl); 160.3, 162.9, 172.0, 180.0 (C=O). ESI-MS m/z calcd for 




Intermediate 13 was obtained from 11 using the protocol described above for 4. 
Crude product was purified by flash chromatography using diethyl ethe:n-exane 
3:1 (v:v) as eluent. A yellowish solid was obtained in 78% yield. 1H NMR (400 
MHz, CDCl3) δ 3.50 (d, 1H, J = 12.6 Hz, H-2′); 4.02-4.12 (dd, 2H, J’ < 1 and 
15.2 Hz, CH2); 4.24 (d, 1H, H-2′′); 4.37-4.44 (dd, 1H, J = 6.0 and 15.2 Hz, CH2); 
4.49-4.56 (dd, 1H, CH2); 6.68 (s, 1H, NH); 7.15 (d, 2H, J = 8.8 Hz, aryl); 7.27 
(d, 2H, aryl); 7.71-7.78 (m, 2H, H-6 and H-7); 7.92 (s, 1H, NH); 8.05 (t, 2H, H-
8 and H-5). ESI-MS m/z calcd for C22H16Cl2N2O4S 474.02, found 474.09.  
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Compound 14 was obtained from 13 as described for 8. Purification by flash 
chromatography, using diethyl ether as eluent, led to a yellow solid in 53% 
yield. 1H NMR (400 MHz, CDCl3) δ 1.43-1.46 (m, 2H, piperidine); 1.54-1.63 
(m, 4H, piperidine); 2.41-2.47 (m, 4H, piperidine); 2.86-2.98 (d, 2H, J = 4.8 Hz, 
CH2); 3.76 (d, 1H, J = 12.4 Hz, H-2′); 4.35-4.39 (m, 2H, H-2′′ and CH2’); 4.45-
4.51 (dd, 1H, CH2’’, J = 5.6 and 15.2 Hz); 6.80 (s, 1H, NH); 7.13 (d, 2H, J = 
7.6 Hz, aryl); 7.24 (d, 2H, aryl); 7.69-7.77 (m, 2 H, H-6 and H-7); 8.05-8.09 (m, 
2H, H-8 and H-5); 8.97 (s, 1H, NH). 13C NMR (100 MHz, CDCl3) δ 23.8 (CH2); 
26.3 (CH2); 40.8 (C-2); 43.6 (CH2); 55.2 (CH2); 62.5 (CH2); 74.2 (C-3); 126.9; 
127.2; 129.1; 129.2; 132.4; 133.4; 133.6; 133.7; 134.8; 136.0; 136.5 (Aryl); 
160.3, 169.4, 173.2, 179.8 (C=O).  ESI-MS m/z calcd for C27H26ClN3O4S 
523,13, found 523.20. 
 
12.2 Biology 
12.2.1 Cell cultures 
Human hepatocarcinoma cell line HuH7, human glioblastoma cell line LN299, 
human cardiac derived myocytes H9C2, human pancreatic adenocarcinoma cell 
line BxPC-3 and human breast adenocarcinoma cell line MCF7 were obtained 
from the American Type Culture Collection (Manassas, VA, USA) and cultured 
in DMEM medium (Dulbecco's modified Eagle's medium for HUH7, LN229 e 
H9C2 cells) and in RPMI-1640 medium (for BxPC-3 and MCF7 cells) 
supplemented with 10% (v/v) fetal bovine serum (InvitrogenTM Life 
Technologies, Carlsbad, CA, USA), 100 U·mL−1 of penicillin and 100 µg·mL−1 
of streptomycin  at 37°C in a humidified atmosphere of 5% CO2 in air.  
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12.2.2 Cell viability assay 
Cell viability for all cell lines was determined using the 3-[4,5-demethylthiazol-
2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay. The test is 
based on the ability of mitochondrial dehydrogenase to convert, in viable cells, 
the yellow MTT reagent (Sigma Chemical Co., St. Louis, MO) into a soluble 
blue formazan dye. Cells were seeded into 96-well plates to a density of 105 
cells/100 μL well. After 24 h of growth to allow attachment to the wells, 
compounds were added at various concentrations (from 0.1 to 25 mM). After 
24 or 48 h of growth and after removal of the culture medium, 100 μL/well 
medium containing 1 mg/mL MTT was added. Cell cultures were further 
incubated at 37 °C for 2 h in the dark. The solution was then gently aspirated 
from each well, and the formazan crystals within the cells were dissolved with 
100 μL of DMSO. Optical densities were read at 570 nm using a Multiskan 
Spectrum Thermo Electron Corporation reader. Results were expressed as 
percentage relative to vehicle-treated control (0.5% DMSO was added to 
untreated cells). IC50 (concentration eliciting 50% inhibition) values were 
determined by linear and polynomial regression. Experiments were performed 
in triplicate. 
 
12.2.3 Thiobarbituric acid-reactive species (TBARS) levels  
Lipid peroxidation was evaluated using an analytical quantitative methodology. 
It relies upon the formation of a colored adduct produced by the stoichiometric 
reaction of aldehydes with thiobarbituric acid (TBA). The TBARs assay was 
performed on membranes extracted from cells treated with 8, 12, 14, and 
doxorubicin, and from untreated, control cells, using an ice-cold lysis buffer (50 
mM Tris, 150 mM NaCl, 10 mM EDTA, 1% Triton) supplemented with a 
mixture of protease inhibitors. The homogenate was centrifuged at 1200 g for 
10 min in order to separate cytosol (supernatants) from membranes (pellet). The 
pellet was dissolved in 50 mMTris, 150 mM NaCl and 10 mM EDTA, and the 
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protein content of the samples was determined by Bio-Rad assay (Bio-Rad 
Laboratories, San Diego, CA, USA). Aliquots (10 mL) of the menbrane 
preparation were added to 2 mL of TBA–trichloroacetic acid (TCA) (15% TCA, 
0.3% TBA in 0.12 N HCl) solution at 100°C for 30 min. The reaction was 
stopped by cooling the sample in cold water, and, after a centrifugation at 15 
000 g for 10 min, the chromogen (TBARs) was quantified by spectrophotometry 
at a wavelength of 532 nm. The amount of TBARs was expressed as µM•µg-1 
proteins. All data are the mean± SEM of three experiments. 
 
12.2.4 Glucose uptake  
Cells were washed twice with 2 ml of HEPES buffer solution A (HEPES, 20 
mM; NaCl, 137 mM; KCl, 4.7 mM; MgSO4, 1.2 mM; CaCl2, 1.8 mM; pH 7.4) 
in both upper and lower compartments. After washing, 1 ml of HEPES buffer 
containing D-[U–14C] glucose 0.5 mCi/ml and 1 mM total glucose (solution B) 
was added to the upper compartment. Cells were then incubated for 30 min at 
37 C, the electrical resistance measured, and buffer from the upper and lower 
compartments removed. Glucose uptake was stopped by washing each 
membrane twice with ice-cold PBS. After that, 1 ml of NaOH solution (0.1 
mol/l) was added to lyse the cells, and aliquots were removed for scintillation 
counting and protein measurement. Scintillation solution (5 ml, Ecoscint XR 
scintillation solution, National Diagnostics) and 0.5 ml of the different test 
solutions were mixed and analysed by scintillation counting using a Packard 
Liquid Scintillation Analyzer 1600TR. 
 
12.2.5 Immunostaining and confocal microscopy 
LN299 cells grown were fixed in PBS 4% paraformaldehyde then permeabilized 
5 min with PBS 1% Triton. Immunostaining was carried out by incubation with 
anti-vimentin antibodies 1:1000 followed by revelation using Cy3-conjugated 
anti-rabbit immunoglobulin (Ig) G antibodies (Jackson Immunoresearch 
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Laboratories, West Grove, PA) at a dilution of 1/200 for 45 minutes. The cells 
were analyzed by an LSM-410 Zeiss confocal microscope. 
 
12.2.6 Western Blot analysis 
The effects of 14 on expression of AKT and caspase-9, were determined by 
Western blots. For cell extract preparation, cells were washed twice with ice-
cold PBS/BSA, scraped and centrifuged for 30 min at 4°C in 1 ml of lysis buffer 
(1% Triton, 0.5% sodium deoxycholate, 0.1 M NaCl, 1 mM EDTA, pH 7.5, 10 
mM Na2HPO4, pH 7.4, 10 mM PMSF, 25 mM benzamidin, 1 mM leupeptin, 
0.025 U/ml aprotinin). Equal amounts of cell proteins were separated by SDS-
PAGE. The proteins on the gels were electrotransferred to nitrocellulose 
membranes. The membranes were  incubated over night with primary antibodies 
(anti-AKT, anti-caspase 9, anti-tubulin antibodies) in 1% buffer solution (Tris 
buffered saline solution containing 1% nonfat dry milk and 0.05% Tween 20), 
washed 3 times with 1% buffer solution and incubated with a horseradish 
peroxidase-labeled secondary antibody for 1 hr at room temperature. The 
immune complexes were visualized using the ECL system. 
 
12.4 Statistical analysis 
All analyses were conducted using Graph-Pad Prism (GraphPad Software Inc., 
San Diego, CA). The significance of differences between groups was 
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The ability of p53 to respond to stress signals by triggering cell-cycle arrest and 
cell death by apoptosis is crucial to inhibit tumor development and for the 
response to anticancer therapy. Inactivation of p53 by mutation occurs in about 
half of all human tumors. Tumors that retain wild-type p53 often acquire an 
alternative mechanism for its inactivation, largely through deregulation of 
MDM2 (murin double minute-2) protein. Negative regulation of p53 activity 
and stability is enhanced in many human tumors and effectively impairs the 
activities of the p53 pathway. Therefore, recovery of p53 activity in cancer cells 
by antagonizing MDM2 has been proposed as a novel approach for treating 
cancer and validated in vitro by macromolecular studies. More recently, genetic 
and biochemical analysis of the p53-MDM2 interaction have revealed structural 
features suggesting that it might be targetable by small molecules. The 
interaction of MDM2 and p53 was shown to be mediated by a deep well-defined 
hydrophobic cavity on the surface of MDM2. This cleft is filled only by three 
side chains of the helical region of p53, making this site an attractive target to 
design a small molecule able to mimic the contacts and the orientations of these 
key amino acids, thereby disrupting p53-MDM2 interaction. Several low 
molecular weight inhibitors, including bicyclic derivatives sulfonamides, 
oxindole and benzodiazepinediones have been identified and reported.  
This PhD thesis presents the results obtained in the searching for small-
molecules able to “reactive” the p53 transcriptional activity. The research was 
based on the identification of both DNA-damaging agents and p53-MDM2 
interaction modulating compounds ,. Initially, the synthesis of a new 2-
oxospiro [indoline-3,2'-thiazolidine] derivatives, designed as cellular cycle 
modulators and p53-MDM2 interaction inhibitors, was carried on, followed by 
in depth characterization of the biochemical events at the basis of their 
pharmacological activities. A second part of this PhD research project  was 
dedicated to the design and synthesis of DTNQ derivatives as DNA- damaging 
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agents and then, to assess their involvement in the p53-MDM2 interaction. The 
first part of project led to design, synthesis and biological evaluation of a four 
series of new 2-oxospiro [indoline-3,2'-thiazolidine] derivatives, as inhibitors 
of p53-MDM2 protein-protein interaction. In particular, compound 13n 
(SM13) was identified as a high efficacy compound in several tumour cell lines 
with great selectivity against the normal cell line. The well-known p53-MDM2 
inhibitor, nutlin-3, was considerably less efficient in all tested cell lines and 
also in the in vitro p53-MDM2 binding inhibition assay. SM13 reduces cell 
proliferation and induces apoptosis in vitro in cells carrying either p53 WT or 
mutated gene, suggesting that its effect is independent from p53 transcriptional 
activity. On the contrary, SM13 has no effect in a p53 null cell line. In vivo, 
SM13 induces cancer cell death in a dose-dependent manner through the 
activation of the mitochondrial-dependent death signalling in p53-mutated 
cells, also reducingtumour growth. Thus, SM13 can be considered as a 
potential anticancer agents to be used for the treatment of p53-dependent 
tumours, even in the absence of p53 transcriptional activity. 
In the second part of this PhD research project the synthetic procedures to obtain 
new highly functionalized DTNQ derivatives were provided. The derivatives 
thus obtained were biologically evaluated, These compounds exhibit cytotoxic 
activity against various solid tumour cell lines. In particular, compound 14 is 
more effective than doxorubicin against the LN229 (glioblastoma), and BxPC3 
(pancreas) human cell lines, and is significantly less cytotoxic in the H9C2 
cardiomyocytes. In LN299 cells, compound 14 strongly inhibits glucose uptake 
in LN229 cells, in comparison with doxorubicin. Concomitantly, compound 14 
decreases serine/ threonine kinase AKT expression, which confirms the 
modulatory activity of this kinase on cellular glucose uptake. The results 
obtained confirm once again that chemical modifications of the DTNQ system 
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